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Abstract 
 
The aim of the work in this thesis was to investigate the effects of gap junction modulation 
during acute myocardial infarction (MI) on ventricular arrhythmogenesis in the settings of 
acute reperfusion and chronic post-myocardial infarction. Ventricular arrhythmias can 
occur during reperfusion because of abrupt changes in electrophysiology, whilst 
arrhythmias occur post-MI because the healed infarct scar forms a substrate for re-entry, 
with increased inhomogeneity of scarring being associated with greater arrhythmia 
susceptibility. 
 
The effects gap junction modulation on reperfusion arrhythmogenesis were studied in an 
ex vivo rat model of acute ischaemia-reperfusion. Gap junction modulators were 
administered to hearts subjected to left anterior descending artery occlusion followed by 
reperfusion. The electrophysiological changes that accompany ischaemia-reperfusion were 
studied using optical mapping. Gap junction modulators, AAP10 and carbenoxolone, 
reduced the incidence of reperfusion arrhythmias. This was associated with the attenuation 
of the abrupt recovery of conduction during reperfusion, which may underlie their anti-
arrhythmic effects. 
 
A four-week rat chronic myocardial infarction model was developed to study the effects 
of acute gap junction modulation on late post-MI arrhythmias. Gap junction modulators, 
rotigaptide and carbenoxolone, were administered acutely for 7 days from the time of 
surgical MI, and rats were studied at 4 weeks post-MI with ECG-telemetry, programmed 
electrical stimulation, optical mapping, histomorphometry and connexin43 
immunohistochemistry. Enhancing gap junction coupling with rotigaptide acutely during 
	   7 
MI reduced heterogeneities in infarct border zone scarring and reduced susceptibility to 
ventricular arrhythmias on programmed electrical stimulation. Histomorphometric studies 
support a possible mechanism whereby homogenisation of the acute ischaemic insult and 
the cell death process may result in more homogeneous scarring and a less arrhythmic 
healed substrate. 
 
Gap junction modulation was anti-arrhythmic in the acute reperfusion setting, and the 
enhancement of coupling during acute MI may represent a novel therapeutic strategy to 
modify the morphology of the healed infarct and alter post-infarction arrhythmia 
susceptibility. 
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1.1 Overview 
The work in this thesis addressed the effects of gap junction modulation on myocardial 
structure and function. Specifically, the effects of gap junction modulation on ventricular 
arrhythmogenesis in the acute reperfusion setting and the chronic post-myocardial 
infarction (MI) setting were studied.  
 
In this chapter, an introduction to ventricular arrhythmias will be provided followed by a 
general description of the mechanisms that underlie them in acute reperfusion and in the 
chronic post-MI setting. An introduction to gap junctions will then be provided, followed 
by a discussion of their role in ventricular arrhythmogenesis. Finally, the concept of 
pharmacological gap junction modulation and their potential effects on arrhythmogenesis 
will be introduced. 
 
1.2 Ventricular arrhythmias 
Ventricular arrhythmias, sometimes referred to as ventricular dysrhythmias, are cardiac 
rhythm disturbances that arise from the cardiac ventricles. This term is commonly used to 
describe the two main ventricular tachyarrhythmias, which are ventricular tachycardia and 
ventricular fibrillation, but also encompasses arrhythmias in the form of isolated 
premature ventricular beats, couplets and bigeminy. 
 
Ventricular tachycardia (VT) is clinically defined in humans as three or more beats in a 
row that originate from the ventricles at a rate of greater than 100 beats per minute (bpm). 
Ventricular tachycardias can be classified by morphology and divided into monomorphic 
VT, in which the ECG complexes have a consistent QRS morphology, and polymorphic 
VT, where there are beat-to-beat variations in the morphology of the QRS complexes 
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(Zipes et al., 2006). Ventricular tachycardias are also often classified clinically based on 
duration, with VTs that self-terminate within 30 seconds classified as non-sustained, and 
VTs of greater than 30 seconds classified as sustained. A third way of classifying clinical 
VTs is based on its haemodynamic effects. This classification divides VTs into 
haemodynamically stable VTs and haemodynamically unstable VTs. 
 
Ventricular fibrillation (VF) is defined as a rapid (usually more than 300 bpm), irregular 
ventricular rhythm with marked variability in QRS cycle length, morphology, and 
amplitude (Zipes et al., 2006). Ventricular fibrillation often occurs as a result of 
ventricular tachycardia degenerating into fibrillation, and is a cardiac rhythm that is 
invariably haemodynamically unstable and associated with a cessation of cardiac output.   
 
Ventricular arrhythmias are life-threatening and are responsible for the majority of the 
100,000 and 300,000 sudden deaths per year in the UK and USA respectively (Zheng et 
al., 2001; Morgan et al., 2006). There are multiple clinical pathologies that can cause these 
potentially lethal arrhythmias, amongst them dilated cardiomyopathy, hypertrophic 
cardiomyopathy, inherited cardiac arrhythmia syndromes and congenital heart disease. 
However, ventricular arrhythmias occur most commonly in the context of chronic 
coronary artery disease (Huikuri et al., 2001; Zipes & Wellens, 1998), and these 
ventricular arrhythmias associated with coronary artery disease are the focus of the studies 
described in this thesis. 
 
Individuals with coronary artery disease, who develop myocardial ischaemia and 
infarction, are susceptible to ventricular tachyarrhythmias at three distinct phases over the 
natural history of the disease (i.e. during acute ischaemia-infarction, at coronary 
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reperfusion, and late post-myocardial infarction). The mechanisms of arrhythmogenesis 
that account for acute ischaemic arrhythmias, reperfusion arrhythmias and late post-
infarction arrhythmias are distinct. The next section provides a general overview of 
arrhythmia mechanisms, and the following two sections describe the process of 
arrhythmogenesis specific to acute reperfusion arrhythmias and chronic post-infarction 
arrhythmias. 
 
1.3 Arrhythmia mechanisms 
There are three main mechanisms responsible for cardiac tachyarrhythmias (Antzelevitch 
2001; Shah et al., 2005; Wolf & Berul, 2008): 
(1) Re-entry 
(2) Triggered activity 
(3) Enhanced automaticity 
 
The first of these mechanisms is a result of abnormal cardiac impulse propagation or 
conduction, whilst the latter two are the result of abnormal impulse generation. Re-entrant 
arrhythmias are often further sub-classified into anatomical re-entry and functional re-
entry. 
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Figure 1-1: The three mechanisms responsible for cardiac tachyarrhythmias: enhanced 
automaticity, triggered activity and re-entry. Acute myocardial ischaemia, coronary 
reperfusion and myocardial infarction, which are focus of this thesis, can result in 
arrhythmias of all 3 mechanisms (HCM: hypertrophic cardiomyopathy, DCM: Dilated 
cardiomyopathy, LQT: Long QT, CPVT: Catecholaminergic polymorphic ventricular 
tachycardia) (Reproduced from Wolf and Berul, 2008).  
 
1.3.1 Re-entrant arrhythmias 
Re-entry describes the phenomenon whereby the propagating cardiac impulse fails to 
terminate and instead persists to re-excite cardiomyocytes that have recovered from their 
previous refractory states. This re-excitation sets up a perpetual re-entrant circuit through 
which cardiac excitation can continue to propagate. Re-entrant arrhythmias are often 
subdivided into anatomical re-entry around a fixed anatomical obstacle, and functional re-
entry without anatomical block. 
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1.3.1.1 Anatomical re-entry 
The role of re-entry as a cause of cardiac arrhythmias was first established by Mines and 
Garrey, working independently, in the early 20th century (Mines, 1913; Garrey, 1914). 
Their work built on that of Mayer, who first showed in 1906 that contraction waves could 
be induced to circulate continuously around ring-like structures cut from the muscular 
tissue of the jellyfish following a single stimulus (Mayer, 1906). Mayer described that in 
one specimen, the pulsation persisted for 11 days during which it travelled an equivalent 
of 457 miles (Mayer, 1908). Although his experiments provided important insight into 
conditions required for re-entry, he did not propose this as a mechanism for cardiac 
arrhythmias. 
 
It was not until 1913, when Mines adapted and repeated Mayer’s initial experiments on 
ring-like structures from hearts from different species that it became evident that 
anatomical re-entry was responsible for some arrhythmias (Mines, 1913). Mines was able 
to initiate re-entry in these rings of cardiac tissue and made the important observation that 
uni-directional block is a pre-condition for re-entry to occur. If excitation occurred in both 
directions around a ring, the two wavefronts would eventually collide, encounter 
refractory tissue and terminate. He also made the observation that slowing of conduction 
can predispose to re-entry, as shown in Figure 1-2. Finally, Mines showed that a critically 
timed premature stimulus can terminate the circulating excitation, a principle now used in 
modern anti-tachycardia pacing protocols in Implantable Cardioverter Defibrillators 
(ICDs). These important insights were gleaned without access to electrical or mechanical 
recordings, and provided the first descriptions of anatomical re-entry around a fixed 
obstacle. They accurately described the nature of many anatomically re-entrant 
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arrhythmias encountered clinically, including atrial flutter, atrio-ventricular re-entrant 
tachycardia (AVRT) and atrio-ventricular nodal re-entrant tachycardia (AVNRT). 
 
Figure 1-2: Anatomical re-entry. Original figure reproduced from Mines’ seminal paper 
showing the principle of re-entrant excitation in the form of circus movement around an 
anatomical obstacle (Mines, 1913). Mines described the important relationship between 
conduction velocity and refractory period, and the “wavelength concept”. In example (a), 
the impulse propagates clockwise, leaving behind it an area of absolute refractory tissue 
(black) and relatively refractory tissue (stippled). If conduction is fast or if the refractory 
period is long, the front of the wave will eventually encounter refractory tissue and the 
impulse will terminate. However, if conduction is slow or if the refractory period is short, 
as in example (b), the originally excited tissue will have recovered excitability by the time 
the head of the excitation wave returns to its origin, thus permitting re-excitation and 
allowing for the excitation to perpetuate. 
 
1.3.1.2 Functional re-entry 
Garrey described functional re-entry as a cause for cardiac arrhythmias based on his 
studies of fibrillating canine ventricles at around the same time as Mines’ seminal work 
(Garrey, 1914). Garrey, using observations made solely with the naked eye, described 
functional re-entry by demonstrating that re-entry could occur without a fixed anatomical 
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obstacle. He described the occurrence of blocks to conduction “of transitory character and 
shifting location” during ventricular fibrillation. Functional re-entrant arrhythmias are now 
known to occur because of impulse propagation around areas of refractory tissue, often 
referred to as lines or areas of “functional block”.  
 
The leading circle concept was formulated by Allessie et al to explain the occurrence of 
functional re-entry. This was based on experiments on isolated rabbit preparations (Figure 
1-3) and describes an impulse circulating around a core of permanently refractory tissue 
(Allessie et al., 1977). In a “leading circle” re-entrant circuit, there is no excitable gap and 
the circuit is just large enough so that the circulating wavefront can excite the relatively 
refractory tissue ahead of it. In this concept, the centripetal wavelets from the leading 
circle keep the core in a state of permanent refractoriness.  
 
Figure 1-3: Functional re-entry. A figure adapted from Allessie et al, 1977, showing the 
concept of “leading circle” functional re-entry. Left: activation map showing clockwise 
activation of functional re-entrant circuit. Right: the leading circle with the converging 
wavelets in the center, rendering the core refractory. Block is indicated by double bars.  
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A second form of functional re-entry is that of the spiral wave. Spiral waves (or rotors or 
vortices) differ from leading circle re-entry because its core is excitable but not excited, 
whereas the core in leading circle re-entry is permanently refractory. They were initially 
described for a specific chemical reaction (Müller et al., 1985), but have since been 
implicated in the genesis of both tachycardia and fibrillation (Davidenko et al., 1992; 
Kleber & Rudy, 2004). 
 
1.3.2 Triggered arrhythmias 
Triggered arrhythmias are the result of abnormal impulse generation. This abnormal 
impulse generation is due to afterdepolarisations, which as the name suggests, are extra 
depolarisations that occur following the initial depolarisation of a propagated action 
potential. If the afterdepolarisations are of sufficient magnitude, they may reach threshold 
and initiate further action potentials. These triggered arrhythmias can be isolated single 
action potentials or may be a repetitive series. 
 
Afterdepolarisations are broadly divided into early afterdepolarisations (EADs) and 
delayed afterdepolarisations (DADs) based on the timing of the abnormal depolarisation. 
Early afterdepolarisations (EADs) occur with abnormal depolarisation during phase 2 or 
phase 3 of the action potential. EADs occur in the context of action potential prolongation 
or slowing of repolarisation, for example during bradycardia or in pathological conditions 
such as Long QT syndrome or Brugada syndrome. The prolongation of action potential is 
thought to be a crucial part of the initiation of EADs. In the case of Phase 2 EADs, AP 
prolongation allows for the time- and voltage-dependent recovery of the L-type calcium 
channels, which are inactivated following the initial depolarisation of the action potential 
(January & Riddle, 1989). This recovery of the L-type channels allows a small number to 
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reopen, which leads to further inward currents that create the oscillations in membrane 
potential that are seen in Phase 2 EADs. It has been suggested that Phase 2 and Phase 3 
EADs may have different underlying mechanisms, and there is evidence that the Na-Ca 
exchanger may play a role in Phase 3 EADs (Szabo et al., 1994). 
 
Delayed afterdepolarisations (DADs) begin during phase 4, after repolarisation is 
completed, but before another action potential would normally occur. They tend to occur 
in situations where there is cytosolic calcium overload, such as in heart failure, during 
acute reperfusion following ischaemia, during exposure to catecholamines or during 
digitalis intoxication. The increased cytosolic Ca2+ concentration increases the forward 
mode activity of the sarcolemmal sodium-calcium exchanger (NCX), extruding one Ca2+ 
ion in exchange for three Na+ moving into the cell. The NCX action is electrogenic, with a 
net transfer of one positive charge into the cell, and leads to a depolarising current, called 
the transient inward (ITI) current, which is responsible for Phase 4 DADs (Boller & Pott, 
1989). 
 
Although the mechanisms by which afterdepolarisations can trigger an action potential are 
understood, it remains unclear how these triggered action potentials can overcome current 
source-sink mismatches to allow them to propagate across the myocardium. It has been 
demonstrated that action potential impulse propagation can fail when the current source is 
insufficient to excite a large mass of myocardium coupled to the source (Rohr et al., 
1997). Computational modelling studies have suggested that the numbers of contiguous 
susceptible myocytes required for an EAD and a barely suprathreshold DAD to trigger a 
propagating action potential were 70 and 80, respectively in 1-dimensional tissue. In 2D 
tissue, these numbers increased to 6940 and 7854, and in 3D tissue to 696,910 and 
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817,280 (Xie et al., 2010). Although these numbers were decreased by reduced gap 
junction conductance, simulated fibrosis, reduced repolarisation reserve and heart failure 
electrical remodelling, significant numbers of cells are still required, suggesting that 
synchronisation mechanisms exist for EADs and DADs to overcome the robust protective 
effects of source-sink mismatch. 
 
1.3.3 Enhanced automaticity 
A third mechanism of tachyarrhythmia is enhanced automaticity. Automaticity is a normal 
property of cardiomyocytes in the sinus node, the AV node and the His-Purkinkje system. 
The basis of this automaticity is a spontaneous, gradual fall in the resting membrane 
potential during Phase 4 of the action potential, which is the result of an interplay of 
several ionic currents, including the If  current (Brown et al., 1979). Alterations in the 
activity of these currents, for example during sympathetic activation, can enhance the 
automaticity of cells and increase the rate of action potential generation. 
 
1.4 Reperfusion ventricular arrhythmias 
Ventricular arrhythmias, both ventricular tachycardia (VT) and ventricular fibrillation 
(VF), can occur within seconds of restoration of blood flow to previously-ischaemic 
myocardium. This observation was first made by Cohnheim and Von Schulthess-
Rechberg (Cohnheim & Schulthess-Rechberg, 1881), and later confirmed by Tennant and 
Wiggers in 1935 (Tennant & Wiggers, 1935). Tennant and Wiggers were studying the 
effects of ischaemia and reperfusion on myocardial contractility, but noticed that a 
significant majority of canine hearts that were reperfused developed ventricular 
fibrillation. These early observations, made without electrical measurements or 
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recordings, suggested that the process of reperfusion creates an insult that is extremely 
arrhythmogenic. 
 
1.4.1 Clinical relevance 
In the clinical setting, reperfusion after brief periods of ischaemia, lasting seconds to 
minutes, occurs in the context of coronary artery vasospasm or Printzmetal/variant angina 
(Prinzmetal et al., 1959). These brief periods of reperfusion have been reported to be 
associated with the occurrence of ventricular arrhythmias (Tzivoni et al., 1983). In a study 
following 114 patients with variant angina over a mean period of 26 months, Miller et al 
found that VT or VF, attributed to reperfusion, was documented on ECG in ~25% of 
patients (Miller et al., 1982).  
 
Another example of coronary reperfusion encountered clinically is during acute 
reperfusion therapy for myocardial infarction. Reperfusion after longer periods of 
ischaemia lasting several hours occurs during fibrinolytic therapy or percutaneous 
coronary intervention (PCI) (FTT-Group, 1994; Keeley et al., 2003). Restoration of 
coronary blood flow to ischaemic myocardium in this setting is also associated with 
reperfusion arrhythmias, as shown by a study of over 3,000 patients undergoing primary 
PCI, which revealed that reperfusion VT/VF occurred in excess of 4% of such cases 
(Mehta et al., 2004). 
 
1.4.2 Mechanisms of reperfusion arrhythmias 
The arrhythmogenic mechanisms that underlie reperfusion VT and VF, although 
incompletely understood, are thought to be distinct from those for acute ischaemic 
arrhythmias. There is consensus that reperfusion arrhythmias are the result of abrupt 
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electrophysiological and biochemical changes brought about by the restoration of blood 
flow (Manning et al., 1984; Wit & Janse, 2001), although the relative importance of each 
variable is still unclear.  
 
1.4.2.1 Re-entrant reperfusion arrhythmias 
It has been suggested that the inhomogeneities of action potentials in and around the 
previously ischaemic myocardium may contribute to the occurrence of reperfusion 
arrhythmias by supporting re-entry (Manning et al., 1984; Wit & Janse, 2001). Ischaemia 
results in rapid depolarisation of the resting membrane potential, and a suppression of 
myocyte excitablility by voltage-dependent inactivation of the fast sodium inward current 
(INa), resulting in slowing of action potential (AP) upstroke, shortening of AP duration, 
and reduction of AP amplitude (Fozzard & Makielski, 1985; Akar & Akar, 2007). Acute 
ischaemia also results in gap junction uncoupling (de Groot & Coronel, 2004). Subsequent 
reperfusion of ischaemic myocardium triggers rapid restoration of action potentials 
towards that of pre-ischaemic levels (Murdock et al., 1980; Kaplinsky et al., 1981). The 
abrupt recovery of action potentials is not equally rapid in the first few seconds, and there 
is marked spatial heterogeneity in action potentials immediately following reperfusion 
(Downar et al., 1977), which may contribute to the occurrence of reperfusion arrhythmias 
by predisposing to re-entry (Corr & Witkowski, 1983; Wit & Janse, 2001). 
 
There are several experimental studies which suggest that electrophysiological 
inhomogeneities are indeed important in the process of arrhythmogenesis in acute 
reperfusion following regional ischaemia (Downar et al., 1977). Downar et al recorded 
subepicardial transmembrane potentials from intact pig hearts to document changes 
induced by acute ischaemia and reperfusion. Ischaemia shortened action potential 
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duration, and decreased its amplitude, upstroke velocity, and resting potential, and cells 
became unresponsive after 12 to 15 minutes of coronary artery occlusion. However near 
normal action potentials could be restored by flushing the occluded artery with saline as 
late as 40 minutes after occlusion. In these studies, reperfusion was associated with 
marked inhomogeneity of cellular responses, both in action potential duration and 
amplitude as well as refractory periods and electrogram fractionation, and was often 
associated with reperfusion VF. The inhomogeneities led the authors to conclude that “re-
entry within ischaemic myocardium was the most likely mechanism for arrhythmias” 
during reperfusion.  
 
Similarly, Cox et al and Kaplinsky et al (Cox et al., 1973; Kaplinsky et al., 1981), in two 
separate studies, both recorded bipolar electrograms in dog hearts subjected to coronary 
artery ligation and reperfusion. In both these studies, the investigators noticed the 
progressive reduction in amplitudes and fractionation of bipolar electrograms recorded 
from the ischaemic zone. In both studies, they also noticed that reperfusion of the 
ischaemic myocardium resulted in inhomogeneous recovery of the ischaemic myocardium 
in the first few minutes following reperfusion. Some areas recovered nearly 
instantaneously with large amplitude, non-fractionated electrograms, whilst other areas 
continued to have low-amplitude fractionated electrograms in the first few minutes after 
the onset of reperfusion. These marked inhomogeneities would be expected to predispose 
to re-entry. Recovery of gap junction coupling after reperfusion and the associated 
inhomogeneities in coupling may also predispose to re-entry, and the role of gap junctions 
in reperfusion arrhythmogenesis is discussed in detail below in Section 1.8.2. 
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Although there is plenty of experimental evidence to suggest that inhomogeneous 
recovery of action potentials exists in the first few seconds to minutes following 
reperfusion, it is unlikely that these electrophysiological inhomogeneities are the sole 
causes of reperfusion ventricular arrhythmias (Manning et al., 1984). Indeed, in the study 
by Kaplinsky et al described above, the authors noticed two time windows of arrhythmic 
risk following reperfusion and proposed different arrhythmic mechanisms for these two 
phases (Kaplinsky et al., 1981). The first time window in the first 60 seconds after 
reperfusion, associated with marked inhomogeneities in cellular electrical responses, often 
resulted in VF and was presumed to be due to re-entrant arrhythmias. They also noticed a 
second time window of arrhythmia vulnerability at 2 to 7 minutes after reperfusion. By 2-
3 minutes after reperfusion, the electrical activity in the previously ischaemic zone had 
fully recovered and was by then homogeneous, thus the authors proposed that the later-
phase reperfusion arrhythmias were due to non-reentrant mechanisms, either due to 
enhanced automaticity or triggered arrhythmias. This second phase of reperfusion 
arrhythmias was usually in the form of isolated or short runs of ventricular beats, and 
seldom developed into sustained VT or VF. 
 
1.4.2.2 Non-reentrant reperfusion arrhythmias 
There is evidence to support the assertion that non-reentrant mechanisms do play a role in 
reperfusion arrhythmogenesis. Sheridan et al proposed a role for enhanced automaticity in 
reperfusion arrhythmogenesis based on their data on ischaemia-reperfusion experiments in 
anaesthetised cats (Sheridan et al., 1980). They reported striking increases in 
idioventricular rate in cat hearts during reperfusion and that these changes may predispose 
to ventricular arrhythmias. They attributed these rate increases to alpha-adrenergic 
stimulation, and showed that alpha-receptor blockade with either phentolamine or prazosin 
	   49 
significantly reduced the number of premature ventricular complexes during coronary 
reperfusion, abolished early ventricular fibrillation from 25% in controls to 0%, and 
prevented the increase in idioventricular rate seen with coronary reperfusion. 
 
There are also data to support the role of abnormal calcium cycling and triggered 
arrhythmias in reperfusion arrhythmogenesis. Shen and Jennings reported increased 
myocardial calcium levels during reperfusion in dog hearts subjected to 40 minutes of 
ischaemia (Shen & Jennings, 1972), which could predispose to afterdepolarisations and 
triggered arrhythmias. Lakireddy et al performed optical mapping in guinea pig hearts 
subjected to ischaemia and reperfusion, and found that, out of a total of 135 episodes of 
ventricular arrhythmias, 23 were linked to calcium oscillations (Lakireddy et al., 2006).  
 
The “calcium paradox” represents a paradigm for the pathophysiological changes that 
accompany the changes in cytosolic calcium levels during acute ischaemia-reperfusion 
(Piper, 2000). The calcium paradox was first described by Ariaen Zimmerman and Willem 
Hülsmann in the 1960s, when they made the observation that perfusion of an isolated 
heart with Ca2+ free Krebs-Henseleit buffer for 2 minutes followed by buffer containing 
physiological Ca2+ caused rapid deterioration of the heart, accompanied by dramatic 
alterations in myocardial ultrastructure (Zimmerman & Hülsmann, 1966). The sequence of 
calcium depletion during ischaemia, followed by the reestablishment of an unlimited Ca2+ 
supply with the restoration of blood flow to previously-ischaemic myocardium is 
comparable to Zimmerman and Hülsmann’s calcium paradox. 
 
The calcium paradox has been shown not just to lead to acute reperfusion injury, by 
disrupting the cell membrane and causing myofibrillar hypercontracture and mitochondrial 
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damage, but may also contribute to reperfusion arrhythmogenesis. Van Gilst and Koomen 
simulated the changes in calcium concentrations during ischaemia-reperfusion by 
perfusing isolated, rat hearts with calcium-free perfusate for durations between 30 and 480 
seconds, followed by perfusion with perfusate containing physiological calcium 
concentrations (van Gilst & Koomen, 1987). The calcium repletion phases in these 
experiments were accompanied by the occurrence of short periods of VT, with the 
incidence and duration of the reperfusion VTs increasing with the duration of calcium-free 
perfusion. These data suggest that the process of calcium washout and subsequent calcium 
overloading may play a role as a trigger for reperfusion VT.  
 
The overloading of intracellular calcium during reperfusion is further exacerbated by the 
effects of lactate accumulation and acidosis on calcium homeostasis during the preceding 
ischaemic phase. Terracciano and MacLeod showed that both lactate accumulation and 
acidosis, which occur during ischaemia, can cause the slowing of Ca2+ extrusion from 
cardiomyocytes, thus contributing to calcium overloading during subsequent reperfusion 
(Terracciano & MacLeod, 1994; Terracciano & MacLeod, 1997). The calcium 
overloading in reperfusion can increase the forward mode activity of the sarcolemmal 
sodium-calcium exchanger (NCX), extruding one Ca2+ ion in exchange for 3 Na+ moving 
into the cell. This NCX action is electrogenic, with a net transfer of one positive charge 
into the cell, and can cause Phase 4 delayed afterdepolarisations and triggered action 
potentials (Boller & Pott, 1989). Another possible mechanism involves the rapid cellular 
uptake of calcium following calcium repletion enhancing the heterogeneity in cellular 
injury, thus enhancing the electrical heterogeneities present during early reperfusion and 
predisposing to arrhythmias (van Gilst & Koomen, 1987). 
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1.4.3 Determinants of reperfusion arrhythmias 
Although the underlying arrhythmic mechanisms are multifactorial and complex, multiple 
determinants of reperfusion arrhythmias have been reported based on studies on 
experimental models. One factor that determines reperfusion arrhythmia susceptibility is 
the size of the ischaemic zone (Curtis & Hearse, 1989b). Curtis et al found that the size of 
the occluded zone in an ex vivo rat model of regional ischaemia-reperfusion positively 
correlated with reperfusion arrhythmia incidence.  
 
Another factor determining reperfusion arrhythmia susceptibility is the duration of 
regional ischaemia prior to reperfusion (Manning & Hearse, 1984). This relationship 
between ischaemia duration and reperfusion arrhythmia incidence has been shown to be 
bell-shaped for multiple animal species. Studies have shown that this time window of 
vulnerability varies from species to species. Peak susceptibility occurs at 7 minutes for in 
vivo experiments in the rat, and around 9 to 10 minutes for ex vivo experiments, whilst 
peak susceptibility for reperfusion arrhythmias is approximately 40 minutes after onset of 
ischaemia for dogs (Manning & Hearse, 1984). How these bell-shaped relationships found 
in animal species translate to humans is unknown. 
 
A third factor shown to alter susceptibility to reperfusion arrhythmias is heart rate (Bernier 
et al., 1989). Bernier et al showed that hearts paced at faster heart rates during regional 
ischaemia-reperfusion had increased incidences of both ischaemia- and reperfusion-
induced ventricular arrhythmias. They performed left atrial pacing at different rates during 
ex vivo ischaemia-reperfusion experiments on Wistar rat hearts and showed that pacing led 
to a rate-dependent increase in the incidence of reperfusion-induced VF from 25% in 
unpaced hearts to greater than 90% when the rate was 420 bpm or higher. 
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1.5 Post-myocardial infarction ventricular arrhythmias 
Individuals who survive myocardial infarction are known to be at greater risk of 
ventricular tachyarrhythmias and sudden cardiac death (SCD) compared to the general 
population. This increased risk of SCD is partly because the infarct scar forms a substrate 
that supports and increases the risk of re-entrant VT, but also partly because this subset of 
the population is at greater risk of further acute coronary events. 
 
1.5.1 Incidence of post-MI ventricular arrhythmias and sudden cardiac death 
This increased risk in sudden cardiac death has been well documented in community 
epidemiology studies, and was first established in the 1970s and 1980s. Analysis of data 
from the Framingham Study in 1979 showed that 1 in 5 patients who had a myocardial 
infarction died within a year of that event (Kannel et al., 1979). Although those initial 
studies helped to highlight the increased SCD risk post-MI, they were performed in the era 
before acute reperfusion therapy and before the routine use of ACE inhibitors and beta-
blockers. In a recent study looking into the incidence of SCD post-MI in the age of 
modern therapies, Adabag et al followed 2,997 individuals in Minnesota who had 
previous MI (Adabag et al., 2008). They reported that although the incidence of SCDs 
post-MI has declined in the past 30 years, there is still a significant risk of SCD in this 
population with a 6.9% cumulative incidence over 5 years, and with the greatest incidence 
over the first 30 days (1.2% incidence over first 30 days). The incidence of arrhythmic or 
sudden cardiac death is even higher if considering only high-risk patients with 
LVEF<40%. Yap et al looked at data pooled from the placebo arms of 5 trials and found a 
12.6% mortality over 2 years in this cohort, of which the majority (7.1%) was attributed to 
arrhythmic death (Yap et al., 2005). 
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The above studies highlight the increased risk of arrhythmic or sudden cardiac death post-
MI, but do not specifically determine the cause of death. Sudden cardiac deaths can be due 
to a variety of bradyarrhythmias as well as VT and VF. Documentation of arrhythmia 
incidence in the post-MI population is logistically difficult, and there were little data on 
this subject until the recent CARISMA trial. In this trial, just under 300 post-MI patients 
had implantable loop recorders inserted to document the nature and frequency of 
arrhythmias post-myocardial infarction, with a mean follow-up period of 1.9 years (Bloch 
Thomsen et al., 2010). Over this follow-up period, 13.1% of patients had non-sustained 
VT, 3.0% had sustained VT and 2.7% had VF, showing that ventricular arrhythmias are 
not infrequent in this population, and could account for a proportion of the sudden cardiac 
deaths seen in the epidemiological studies described above. 
 
1.5.2 Mechanisms of ventricular tachycardia in chronic stable infarcts 
Re-entry is thought to be the commonest mechanism for ventricular tachycardias that 
occur in post-MI patients. Studies using programmed stimulation protocols and 
endocardial recordings by Wellens and colleagues in the 1970s showed that the majority 
of VTs in stable, post-MI patients were re-entrant in nature (Wellens et al., 1972). 
Similarly, in a more recent study, Das et al reported that 91% of post-MI patients with VT 
referred for catheter ablation had macro-reentrant VT (Das et al., 2010). 
 
The underlying pathological and electrophysiological substrates that support these re-
entrant ventricular arrhythmias in the mature, healed infarct has been well-characterised. It 
is known that these arrhythmias arise from the infarct border zone, where fibrotic scar 
connects and interfaces with surviving myocardium (Delacretaz & Stevenson, 2001; 
SippensGroenewegen et al., 1993). Heterogeneous scarring with varying degrees of 
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fibrosis and varying subendocardial myocardial tissue preservation produces the 
anatomical substrate that supports re-entrant arrhythmias (de Bakker et al., 1993; Fenoglio 
et al., 1983). 
 
Work by de Bakker and colleagues in the 1980s was instrumental in elucidating the 
anatomical substrate that supports re-entrant VTs in infarcted hearts (de Bakker et al., 
1988). In a key study, they performed intra-operative mapping of endocardial activity in 
72 patients undergoing surgery for refractory ventricular tachycardia (VT). In these 
patients, 98% of tachycardias were found to spread centrifugally on the endocardial 
surface. Importantly, they were also able to record small electrograms of low amplitude 
preceding the main activation at the endocardial site of origin, which they termed 
“presystolic activity”. Histological analysis revealed that viable myocardial fibres located 
subendocardially and intramurally were responsible for the presystolic activity that was 
recorded. These studies provided the first correlation between electrophysiological and 
histological data in humans showing that the majority of VTs in post-infarction patients 
were anatomically re-entrant, and these VT circuits involved bundles of surviving 
myocardium within areas of dense scar. In a further study, they showed that this complex 
network of surviving myocardial fibres caused “zigzag” and tortuous activation across the 
infarcted area, with this increased pathlength contributing to macroscopic conduction 
slowing (de Bakker et al., 1993). Abnormalities in gap junctions also play a role in post-
MI re-entrant VT circuits, and this is discussed in detail below in Section 1.8.3. 
 
Although multiple studies have shown that re-entry is the predominant mechanism of VTs 
in stable, chronic MI hearts, some VTs are due to focal, non-reentrant mechanisms. In 
their series of post-MI patients referred for VT ablation because of intractable VT, Das et 
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al reported that 9% were due to non-reentrant VT (Das et al., 2010), where endocardial 
mapping showed a focal source with centrifugal activation of impulse from the focal 
source during the VT, and where there was a failure to entrain the tachycardia. These focal 
VTs were presumably due a combination of triggered activity and enhanced automaticity. 
However, the estimates of the proportion of VTs that are non-reentrant in origin varies 
from study to study, with increased proportions in patients with heart failure. In a small 
study of 13 patients with reduced LVEF and refractory VT by Pogwizd et al, 
intraoperative mapping with plunge electrodes was performed and revealed that 50% of 
VTs were focal in this cohort with a mean LVEF of 33% (Pogwizd et al., 1992). 
 
1.5.3 Role of the infarct border zone in post-MI VT 
The infarct border zone is thought to be a critical part of re-entrant VT circuits in post-MI 
hearts, as results of ventricular mapping studies have indicated that re-entrant VTs often 
arise from these areas adjacent to dense scar (Josephson et al., 1978; Josephson et al., 
1980; Fenoglio et al., 1983). This is supported by data from substrate ablation studies 
showing that ablation at exit sites of VT circuits at the infarct border zone can successfully 
abolish previously inducible VTs (Marchlinski et al., 2000; Soejima et al., 2001). 
Experimental studies on animal models of chronic MI have also demonstrated the 
importance of infarct border zone remodelling at the molecular level in contributing to the 
arrhythmogenic substrate (Baba et al., 2005). For example, redistribution of connexins and 
gap junctions (Peters et al., 1997), reduction in action potential amplitude and upstoke 
(Lue & Boyden, 1992), reduction in the inward sodium current (INa) and altered INa 
kinetics (Pu & Boyden, 1997), reduced Ca2+ currents (Aggarwal & Boyden, 1995) and a 
reduction in delayed rectifier currents IKr and IKs (Jiang et al., 2000), have all been shown 
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to occur at the infarct border zone of a 5-day canine post-infarction model and are all 
thought to contribute to post-MI arrhythmogenesis. 
 
1.5.4 Prevention of sudden cardiac death in post-MI patients 
Anti-arrhythmic drugs have been shown to be ineffective in preventing late post-infarction 
ventricular arrhythmias and sudden cardiac death, and were indeed associated with 
increased mortality in patients with structural or ischaemic heart disease in the CAST and 
SWORD trials (Echt et al., 1991; Waldo et al., 1996). The current strategy to prevent 
sudden cardiac death resulting from late post-infarction arrhythmias involves the use of 
Implantable Cardioverter Defibrillators (ICDs) (Epstein et al., 2008), or radiofrequency 
ablation of the arrhythmic substrate (Aliot et al., 2009). High-risk patients, with reduced 
left ventricular ejection fraction, are selected for implantation of Implantable Cardioverter 
Defibrillators (ICDs), with the selection criteria based on the entry criteria of the ICD 
clinical trials (Goldenberg et al., 2010; AVID, 1997; Moss et al., 1996; Moss et al., 2002). 
However, this approach to prevent SCD in the post-MI population is unsatisfactory for 
two reasons. Firstly, it does not address the cause of the arrhythmia and is merely a 
treatment of last resort. The other significant disadvantage of using ICDs to prevent 
sudden cardiac death is the poor patient selection for implantation of these devices due to 
our inability to accurately identify the patients at high risk of arrhythmic events. 
 
1.5.5 Poor risk stratification of post-MI patients 
Several reasons account for the poor risk stratification of post-MI patients for ICD 
therapy. Firstly, clinical tests currently used to risk stratify patients into high- and low-risk 
groups such as left ventricular ejection fraction (LVEF) and programmed electrical 
stimulation (PES) have poor specificities and sensitivities (Goldberger, 2010). As a result, 
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only approximately 20% of patients who receive an ICD for primary prevention 
indications ever receive appropriate therapies from their ICDs over their lifetimes 
(Mishkin et al., 2009), which raises cost effectiveness questions for this therapy (Tung et 
al., 2008). Approximately another 20% of these individuals receive inappropriate shocks 
from their ICDs, which can have significantly detrimental effects on quality of life 
(Groeneveld et al., 2006). A better understanding of the mechanisms that underlie 
ventricular arrhythmogenesis in the post-MI population may give rise to better tests to risk 
stratify patients. 
 
Secondly, the strategy of dichotomising patients into high- and low-risk groups based on 
an LVEF cut-off (for example 30% in MADIT-II) (Moss et al., 2002) is unsatisfactory 
because it fails to identify the majority of SCDs, which in terms of absolute numbers, 
occur more frequently in the so-called “low-risk” group (Buxton et al., 2007). 
Epidemiological data from the Maastricht Registry and Oregon Sudden Death Study have 
shown that the majority of coronary artery disease patients with prior MI who die 
suddenly have LVEF>30% (Stecker et al., 2006; Gorgels et al., 2003). Analysis of data 
from the MUSTT study revealed that coronary artery disease patients with LVEF of 30%-
40% may have SCD risks that exceed those of conventional “high-risk” patients (i.e. 
LVEF<30%) depending on presence of other risk factors (Buxton et al., 2007). The 
dichotomisation of risk may be inappropriate, as multiple complex factors interact to 
influence SCD risk, and risk stratification may be better served by composite risk score 
that take into account competing risks (Goldberger et al., 2011). 
 
Another factor that has complicated the task of accurately identifying post-MI patients 
susceptible to arrhythmias is the evolution of therapy for acute myocardial infarction 
	   58 
(AMI) over the past two decades. Acute coronary reperfusion, first thrombolysis (FTT-
Group, 1994) then percutaneous coronary intervention (PCI) (Keeley et al., 2003), has 
transformed outcomes for patients with AMI by improving LV ejection fraction and 
improving survival (van Domburg et al., 2005), with increasing numbers of patients in the 
UK and USA with AMI now receiving reperfusion therapy within the first few hours of 
AMI. This has effectively created two distinct groups of post-MI patients (reperfused and 
non-reperfused), with very different arrhythmogenic substrates (Callans, 2010). Because 
of increased myocardial salvage and therefore significantly improved LVEF with 
reperfusion (van Domburg et al., 2005), traditional methods of risk stratification using 
LVEF may be ineffective.  
 
1.5.6 Morphological determinants of post-MI arrhythmias 
The identification of high-risk patients at greater risk of ventricular tachyarrhythmias and 
SCD in the post-MI patients may be improved through the identification of novel 
determinants of arrhythmia and SCD susceptibility in this population. There has been 
some interest of late in using the morphology of the infarct scar to identify high-risk 
patients. It is known that larger infarcts are more susceptible to post-MI arrhythmias 
(Bello et al., 2005). Recently, it has also been shown that heterogeneity of infarct scarring 
is also a determinant of late post-MI arrhythmias, with increased heterogeneity of fibrosis 
being associated with increased arrhythmic risk (Schmidt et al., 2007).  
 
Schmidt and colleagues quantified the heterogeneity of the infarct periphery using 
delayed-enhanced MRI imaging in post-infarction patients, and found that increased 
heterogeneity strongly correlated with inducibilty of monomorphic ventricular 
tachycardias (Schmidt et al., 2007). Similarly, Yan et al demonstrated using cardiac MRI 
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that, in patients with prior MI, the extent of the heterogeneous peri-infarct zone provided 
incremental prognostic value beyond left ventricular systolic volume index or ejection 
fraction for predicting post-MI mortality (Yan et al., 2006). These preliminary studies 
suggest that infarct morphology may be an important determinant of arrhythmias, and 
improved imaging with delayed-enhanced MRI may be another tool to risk stratify post-
MI patients for ICD therapy. 
 
1.6 Gap junctions 
Gap junctions are clusters of transmembrane channels that mediate cell-to-cell coupling 
and allow the transfer of ions and small molecules of up to 1kDa in molecular mass 
between cells by directly linking the cytoplasmic components of adjacent cells (Kanno & 
Saffitz, 2001; Severs et al., 2008; Severs et al., 2004). Gap junctions are areas of near 
contact between adjacent cardiomyocytes (Figure 1-4), with a gap of 2-3nm between cells 
as seen on electron microscopy, thus the term “gap junctions”. 
 
In the heart, gap junctions play an important role in mediating electrical coupling between 
cells, and thus have a major role in allowing the orderly spread of electrical excitation 
across the myocardium. Another important electrophysiological function of gap junctions 
is to reduce repolarisation heterogeneities by allowing the passive flow of charge between 
adjacent cardiomyocytes (Strom et al., 2010). Alterations in gap junction function and 
distribution are known to affect cardiac impulse propagation, and are associated with a 
variety of cardiac pathologies and with cardiac arrhythmias (Severs et al., 2004; Severs et 
al., 2008). 
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Figure 1-4: Electron micrograph showing a gap junction at the area of contact between 
two adjacent cardiomyocytes. The desmosome and fascia adherens are also shown. 
(Reproduced from Severs, Bioessays 2000).  
  
1.6.1 Connexins 
Each gap junction channel consists of two connexon hemichannels, and each connexon is 
in turn made up of six connexin subunits (Figure 1-5A). Connexins are membrane-
spanning proteins, with four transmembrane domains, two extracellular loops and one 
intracellular loop (Figure 1-5B). The carboxy-terminus (C-terminus) is of variable length 
depending on the type of connexin protein, and the phosphorylation states of various 
amino acid residues in the C-terminus are important in regulating channel gating and 
function (Solan & Lampe, 2009; Solan & Lampe, 2007). 
 
Connexins are named by their molecular weight (in kiloDaltons), and 21 different 
connexin proteins have been identified in man (Sohl & Willecke, 2004). The principal 
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connexins expressed in the heart are connexin43 (Cx43), Cx40 and Cx45. Cx43 is the 
predominant connexin in cardiac ventricles. Figure 1-6 shows the typical connexin 
expression patterns in the different structures in the mammalian heart. 
Figure 1-5: (A) Schematic drawing of gap junction channels. Each cell contributes a 
connexon (or hemichannel) to form a gap junction channel. Each connexon consists of 6 
connexin protein subunits. The channels can open or close by altering the configuration of 
connexin subunits as shown. (B) A schematic diagram of a single connexin protein. Each 
connexin contains 4 transmembrane domains (M1 to M4), two extracellular loops (E1 and 
E2), one cytoplasmic loop, and the C- and N-terminus within the cytoplasm. (Reproduced 
and adapted from Sohl and Willecke, 2004).  
 
Each connexon can be composed of combinations of six Cx43, Cx40 or Cx45 subunits 
and each gap junction channel may be composed of combinations of two connexons. A 
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connexon can be homomeric (all six subunits are the same) or heteromeric (two or more 
different subunits). This can give rise to a variety of gap junction channels, which can be 
homotypic (all 12 subunits are identical), heterotypic (each of the two connexons contain 
identical subunits), monoheteromeric (a homomeric connexon docks with a heteromeric 
connexon) or bi-heteromeric (two heteromeric connexons dock together) (Moreno, 2004). 
 
Figure 1-6: Typical connexin expression patterns in the mammalian heart. Cx40, Cx43 
and Cx45 are the predominant cardiac connexins. (Reproduced from Severs et al, 2008).  
 
1.6.2 Regulation of gap junction coupling 
The degree of gap junction coupling between cells can be modulated through a number of 
processes. Individual gap junction channels can occur in three states (open, where there is 
maximal conductance, residual, or closed), and the state of a gap junction channel can be 
altered by chemical or voltage gating. Alterations in connexin protein expression can also 
alter the degree of gap junction coupling. 
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1.6.2.1 Chemical gating 
The biophysical properties of gap junction channels can be biochemically modulated 
through chemical gating, which then leads to altered gap junction coupling between cells. 
Intracellular pH is known to alter gap junction conductance, with reductions in pH leading 
to gap junction uncoupling. The sensitivity to low pH has been found to be connexin 
specific, indicating that the mechanism of action is related to molecular structure. The 
carboxy-terminus of the connexin protein is thought to play a role in pH sensitivity, and 
truncation or modification of the carboxy-terminus can reduce sensitivity to pH 
(Anyukhovsky et al., 2010). It has been suggested that the mechanism by which a 
reduction in pH uncouples gap junctions is through intramolecular interactions in which 
the carboxy-terminus acts as an independent domain that binds to a separate region of the 
protein and closes the channel, similar to the “ball-and-chain” mechanism of voltage-
dependent gating of potassium channels (Morley et al., 1996). Duffy et al demonstrated 
using nuclear magnetic resonance (NMR), that a reduction in pH caused binding of 
Cx43CT (carboxy-terminus of Cx43) to region 119-144 of Cx43 (Cx43L2), which they 
proposed is the intramolecular receptor for Cx43CT (Duffy et al., 2002). 
 
Another mechanism for chemical gating of gap junction channels is through alterations in 
the phosphorylation status of the connexin protein. The connexin protein has multiple 
serine residues on the carboxy-terminus that can be phosphorylated, and to date, 19 
phosphorylation sites have been described (Procida et al., 2009). For Cx43, at least three 
distinct bands can be resolved on Western blotting. These bands represent different 
isoforms with different amounts of phosphorylation. The fastest migrating band (P0) is the 
non-phosphorylated band, the middle band is P1 and the slowest migrating band is P2 
(Solan & Lampe, 2009). Solan and Lampe have shown that the P1 isoform is due to 
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phosphorylation of S365 (Solan et al., 2007), whilst the P2 isoform is due to 
phosphorylation at S325/328 and S330 (Lampe et al., 2006). The functional significance 
of phosphorylation or dephosphorylation at specific sites is still incompletely understood. 
Serine 368 is the most widely studied site, and has been shown to be dephosphorylated 
during ischaemia, and may play a role in gap junction uncoupling (Beardslee et al., 2000; 
Axelsen et al., 2006). Procida et al recently showed that Serine 306 is also functionally 
important, and loss of phosphorylation at this site can lead to reductions in single channel 
conductance (Procida et al., 2009). 
 
Several compounds have also been reported in the literature to alter gap junction coupling 
through chemical gating. N-alkyl octanols, such as heptanol and octanol, have been shown 
to reduce gap junction coupling, probably through a mechanism that reduces the open 
probabililty of channels without affecting unitary channel conductance (Bastiaanse et al., 
1993). Glycyrrhetinic acids are another class of compounds that have also been shown to 
uncouple gap junctions, though the exact mechanism of gap junction uncoupling is 
unknown. Carbenoxolone is a synthetic derivative of glycyrrhetinic acid with gap junction 
uncoupling effects, and is discussed in more detail later in this chapter. Other compounds 
or ions known to modulate gap junction conductance include lipophosphgycerides (Wu et 
al., 1993), arachidonic acid metabolites (Massey et al., 1992), and intracellular calcium 
(White et al., 1990). 
 
1.6.2.2 Voltage gating 
Gap junction channels are also regulated by voltage gating. Voltage gating involves rapid 
voltage-sensitive transitions between a primary open state and one or more 
subconductance states, but not to a fully closed state. The process of voltage gating is 
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significantly more rapid than chemical gating, and changes in gap junction channel 
conductance can occur over milliseconds (Moreno, 2004). Spray et al demonstrated in cell 
pairs of amphibian embryos that junctional conductance and permeability to the dye 
Lucifer Yellow are markedly and reversibly decreased by moderate transjunctional 
polarisation in either direction (Spray et al., 1979). It is thought that there are distinct 
voltage-sensitive and voltage-insensitive components to gap junction conductance 
(Moreno et al., 1994), thus leading to multiple sub-conductance states rather than an all-
or-none phenomenon. The residual conductance may represent incomplete closure of a 
pore by the connexin carboxy-terminus (Moreno, 2004). 
 
1.6.2.3 Connexin biosynthesis, gap junction assembly and turnover 
A slower temporal level of regulation of gap junction coupling involves connexin 
biosynthesis and junctional plaque assembly and turnover (Segretain & Falk, 2004). 
Connexins have a short half-life, and Laird et al showed that the half-life of Cx43 is only 
1.5 to 2 hours in primary cultures of neonatal myocytes (Laird et al., 1991). Similarly, 
studies in Langendorff hearts have shown a half-life for Cx43 in rat hearts of 1.3 hours 
(Beardslee et al., 1998). The rapid turnover of connexin proteins is a complex process 
involving biosynthesis of the connexin subunit proteins on endoplasmic reticulum 
membranes, oligomerisation of compatible subunits into connexons, delivery of the 
connexons to the plasma membrane, docking of compatible connexons in the extracellular 
space, arrangement of channels into organised gap junction plaques, and coordinated 
removal of channels into the cytoplasm followed by their degradation (Segretain & Falk, 
2004). Alterations or disruption to any stage of this process can alter the amount of 
functional gap junction channels and modify gap junction coupling. For example, acute 
ischaemia and metabolic stress have been shown to limit forward trafficking of connexins, 
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thus reducing the membrane localisation of connexin and reducing gap junction coupling 
(Smyth et al., 2010). 
 
1.7 Electrophysiological role of gap junctions 
Gap junctions play a key role in the propagation of action potentials across the 
myocardium by connecting the cytoplasmic compartments of adjacent cells. The 
discovery of the presence of low resistance pathways between cells was first made just 
under half a century ago in pioneering work by Weidmann (Weidmann, 1966). Up until 50 
years ago, it was unclear how cardiac muscle, known to be made up of multiple cells with 
each cell surrounded by a cell membrane, could function as an electrical syncytium. In 
experiments using radiopotassium, Weidmann demonstrated the presence of low 
resistance pathways between adjacent cardiomyocytes, which were later shown to be gap 
junction channels. 
 
We now know that these channels have a key role in impulse propagation with both 
experimental and computational studies showing that a reduction in coupling can reduce 
conduction velocity between cells (Rohr, 2004; Kleber & Rudy, 2004). Gutstein et al 
optically mapped of the epicardial electrical activation pattern in Cx43 conditional 
knockout mice and revealed that ventricular conduction velocity was significantly slowed 
by up to 55% in the transverse direction and 42% in the longitudinal direction in these 
mice, showing the importance of connexins and gap junction coupling in determining 
conduction velocity (Gutstein et al., 2001). The importance of gap junction coupling for 
myocardial conduction was also demonstrated in connexin knockdown studies, where 
transfection of cells with siRNA against Cx43, Cx40 and Cx45 significantly reduced 
conduction velocities in cell culture monolayers (Dias, 2010). It has also been shown that 
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carbenoxolone, a gap junction uncoupler, can reduce conduction velocity by about a 
quarter (Kojodjojo et al., 2006). Modelling studies have also shown that gap junction 
uncoupling can reduce conduction velocity (Shaw & Rudy, 1997c). 
 
Another important electrophysiological function of gap junctions is to reduce 
repolarisation heterogeneities between adjacent cardiomyocytes and between different 
regions of the myocardium. Gap junction channels allow the passive exchange of charge 
and ions between cells, thus reducing the dispersion of action potential durations. 
Computer simulations have shown that uncoupling of gap junctions can accentuate and 
unmask regional heterogeneities in APD (Lesh et al., 1989). Similarly, experimental 
studies have also shown that reduced gap junction coupling, such as in heart failure, is 
associated with increased APD dispersion (Poelzing & Rosenbaum, 2004). The 
consequent increase in APD dispersion would be expected to predispose to re-entry and be 
pro-arrhythmic. 
 
1.8 Alterations to gap junctions in cardiac pathology 
Changes to gap junction function or remodelling of gap junctions are known to occur in 
almost all arrhythmogenic cardiac pathologies, including in acute ischaemia (de Groot & 
Coronel, 2004; Beardslee et al., 2000), in the mature, healed infarct (Peters et al., 1997), in 
the failing myocardium (Severs, 1994), and in cardiomyopathies (Severs et al., 2006). As 
discussed above, these alterations in gap junctions can lead to conduction slowing and 
increased dispersion of APDs, both of which increase the likelihood of arrhythmias. In 
this section, the alterations in gap junction function in acute ischaemia, acute reperfusion 
and in the chronic healed infarct, and their relationship to ventricular arrhythmogenesis, 
are discussed. 
	   68 
1.8.1 Gap junctions and arrhythmias during acute myocardial ischaemia  
In addition to the well-documented changes in action potentials during acute ischaemia, 
there are also significant changes to gap junction coupling, which may contribute to 
arrhythmogenesis (de Groot & Coronel, 2004). Kleber et al showed that there is a 10-25% 
immediate rise in tissue impedance immediately following coronary occlusion, attributed 
to collapse of the vasculature (Kléber et al., 1987). However, there is then a second rise in 
tissue impedance after approximately 15 minutes, attributed to closure of gap junctions. 
This gap junction uncoupling has been attributed to multiple factors, including the 
accumulation of intracellular Ca2+, H+ and lysophosphoglycerides and arachidonic acid 
metabolites (Burt, 1987; Massey et al., 1992; Wu et al., 1993), whilst dephosphorylation 
and redistribution of Cx43 have also been shown to play a role (Beardslee et al., 2000).  
 
This rise in tissue impedance and gap junction uncoupling coincides temporally with the 
occurence of Phase 1b arrhythmias (Smith et al., 1995). This temporal association 
between gap junction uncoupling and phase 1b arrhythmias has led to suggestions that 
there is a causal relationship, but there are no direct experimental data to support this 
(Cinca et al., 1997). 
 
1.8.2 Gap junctions and arrhythmias during coronary reperfusion 
Heterogeneities in action potentials in the reperfused, previously ischaemic myocardium, 
are thought to be the main factor supporting re-entrant arrhythmias immediately after 
reperfusion (Wit & Janse, 2001). However, recent data also suggest a possible role for gap 
junction uncoupling in arrhythmogenesis during reperfusion. It was previously thought 
that gap junction uncoupling, once established during acute ischaemia, is irreversible. 
However, Cascio et al demonstrated that the gap junction uncoupling that occurs during 
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ischaemia is reversible and returns to pre-ischaemic levels approximately 30 minutes after 
reperfusion (Cascio et al., 2001). This reversibility of gap junction uncoupling with 
reperfusion gives rise to the possibility that they may also pay a role in reperfusion 
arrhythmogenesis. Cascio et al demonstrated that this restoration of gap juncion coupling 
was relatively slow in their experimental preparation, with relative uncoupling being 
present during the first few minutes after reperfusion. This persistence of uncoupling, in 
the face of concomitant recovery of excitability and restoration of action potential 
immediately after reperfusion, is expected to enhance electrical heterogeneities, slow 
conduction and thus increase the likelihood of arrhythmias. 
 
Anyukhovsy et al studied at the effects of preserving gap junctions during ischaemia-
reperfusion on reperfusion arrhythmogenesis (Anyukhovsky et al., 2010). Using mice 
expressing Cx32, a liver connexin that is less sensitive to pH-induced uncoupling, they 
showed that preservation of gap junction coupling during acute ischaemia-reperfusion can 
suppress reperfusion arrhythmias. These data provide further support to the view that 
abnormalities in gap junction coupling during reperfusion play a role in reperfusion 
arrhythmogenesis, as normalising coupling may suppress these arrhythmias. 
 
It has been suggested that heterogeneities in conduction velocities may be another possible 
mechanism by which abnormal gap junction coupling contributes to reperfusion 
arrhythmogenesis. Murdock et al recorded electrograms from plunge and epicardial 
electrodes during acute ischaemia-reperfusion in dogs and found that conduction slowed 
progressively during ischaemia, associated with progressive loss if electrograms from the 
plunge electrodes (Murdock et al., 1980). Upon reperfusion, they noted heterogeneous 
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improvements in conduction velocity, which could increase the likelihood or re-entry, and 
this was postulated as a possible mechanism for reperfusion arrhythmogenesis. 
 
1.8.3 Gap junctions and arrhythmias in the healed infarct 
Abnormalities of gap junctions are also well-documented in the healed infarct and are 
associated with late post-infarction ventricular arrhythmias (Peters et al., 1997; Peters et 
al., 1998). It has been shown that there is significant maldistribution of Cx43 at the infarct 
border zone. Cx43 is normally found at the ends of the cardiomyocytes at the intercalated 
disks, but at the infarct border zone, they are often maldistributed to the lateral 
membranes, a process referred to as “lateralisation” of Cx43, as shown in Figure 1-7 
(Peters, 1995; Peters & Wit, 1998). 
 
The maldistribution and lateralisation of Cx43 have been shown to have functional effects 
and have been correlated with post-MI ventricular tachycardia. Peters et al demonstrated 
that areas of full-thickness Cx43 maldistribution at the epicardial border zone of the 
healing canine infarct correlated spatially with the location of the common central 
pathways of figure-of-8 re-entrant ventricular tachycardia circuits (Peters et al., 1997). 
This suggests that gap junction remodelling post-infarction may be a determinant of 
susceptibility to ventricular tachycardias in the healed infarct and may play a role in late 
post-infarction arrhythmogenesis. 
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Figure 1-7: Confocal micrographs showing lateralisation of Cx43 at the infarct border 
zone (IBZ) of human ventricular myocardium from border of healed infarct. (A) At lower 
power, showing infarct scar with no labelling, highly disrupted gap junction distribution at 
the IBZ and normal appearances more distant from scar. (B) At high power, showing 
lateralised Cx43 in myocytes traversing densely fibrotic scar. Bar = 100 µm. (Reproduced 
from Peters et al, 1995).  
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Figure 1-8: Maldistribution of Cx43 correlates spatially with re-entrant VT circuits. Top: 
Activation map of a stable re-entrant circuit during ventricular tachycardia. Bottom: The 
central common pathway mapped correlated with areas of full-thickness gap-junction 
disturbance, denoted by open circles. Crosses denote areas of partial-thickness disturbance 
(Reproduced from Peters et al, 1997).  
 
Cabo et al studied the effects of Cx43 lateralisation on conduction properties in the central 
common pathway of the re-entrant VT circuits in the healing canine infarct. Measurements 
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of conduction velocities showed reductions in both longitudinal and transverse conduction 
in the central common pathway where there was significant Cx43 lateralisation, 
demonstrating the functional consequences associated with connexin maldistribution 
(Cabo et al., 2006). In a separate study, Cabo et al also showed using computational 
modelling that the heterogeneous remodelling of Cx43 observed at the infarct border zone 
can stabilise re-entrant VT circuits (Cabo & Boyden, 2006). 
 
1.9 Gap junctions and the spread of myocardial infarction 
Gap junctions are involved in the transfer of ions and small molecules of up to 1 kDa in 
molecular mass between cells. In addition to their roles in regulating conduction velocity 
and attenuating repolarisation heterogeneities, gap junctions also have the potential to 
modulate the spread of myocardial infarction. This can occur via the passage of necrotic, 
apoptotic or anti-apoptotic signals between cells through gap junction channels.  
 
The specific mediators of cell death and cell survival that pass through gap junction 
channels during infarction are still unclear, though it has been shown in in vitro studies 
that the process of cell death can indeed spread from cell to cell. It has been proposed that 
both necrotic and apoptotic factors that promote cell death and anti-apoptotic factors that 
promote cell survival can pass through gap junctions channels, leading to two competing 
hypotheses: the “kiss-of-death” and the “kiss-of-life” hypotheses (Decrock, Vinken, et al., 
2009b; Andrade-Rozental et al., 2000).  
 
The so-called “kiss-of-death” or bystander effect has been observed in in vitro studies on 
the effects of ganciclovir (GCV) on neoplastic cells. Cell transfected with herpes simplex 
virus-thymydine kinase (tk+) are sensitive to ganciclovir and can be killed by the antiviral 
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agent. When tk+ cells are co-cultured with tk- cells and exposed to ganciclovir, as shown 
in Figure 1-9, the process of cell death can spread from GCV-sensitive tk+ cells to GCV-
insensitive tk- cells cells through gap junction channels (Elshami et al., 1996).  
 
 
Figure 1-9: “Kiss of death” hypothesis. A cell transfected with herpes simplex virus-
thymidine kinase (tk+) co-cultured with untransfected cells (tk-). When exposed to 
ganciclovir, the tk+ cell undergoes apoptosis (red). The ganciclovir-insensitive tk- cells 
also undergo cell death, a process that is presumed to have spread from the tk+ cell 
through gap junctions. (Reproduced from Andrade-Rozental et al, 2000).  
 
However, the opposite “kiss-of-life” or “metabolic cooperation” effect has also been 
observed in in vitro studies. Wygoda et al demonstrated that adequate gap junctional 
communication to neighbouring cells could protect a GCV-sensitive tk+ cell from GCV-
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mediated apoptosis (Wygoda et al., 1997). Two possible explanations have been proposed 
for the observed “metabolic cooperation effect” (Pitts, 1998). One possibility is that the 
neighbouring healthy cells act as a sink for apoptotic/necrotic factors, which diffuse out of 
the at-risk tk+ cells through gap junction channels into neighbouring cells, thus protecting 
it from cell death. Another possibility is that the healthy tk- cells actively furnish the at-
risk tk+ cells with anti-apoptotic factors that promote cell survival. 
 
There are also several lines of in vivo evidence to suggest that altering gap junction 
coupling can modify the spread of myocardial infarction.  Garcia-Dorado et al first 
demonstrated that gap junction uncoupling with heptanol could limit the spread of 
necrosis during in reperfused myocardial infarction (Garcia-Dorado et al., 1997). Kanno et 
al subsequently showed that Cx43 heterozygous knockout mice, which had reduced levels 
of gap junction coupling, had smaller infarcts compared to wild-type (Kanno et al., 2003). 
Recently, gap junction uncoupling with carbenoxolone was shown to reduce reperfusion 
injury following transient cerebral ischaemia (Vakili et al., 2009). In line with these data, 
Prestia et al showed that enhancing gap junction coupling during myocardial infarction, in 
a mouse expressing Cx32, can lead to increased infarct size (Prestia et al., 2011), 
supporting the “kiss-of-death” hypothesis. 
 
However, there is also evidence to suggest the contrary. Studies using rotigaptide during 
myocardial infarction have also shown that enhancing coupling can lead to a reduction in 
infarct size, both in a rodent model (Haugan, et al., 2006b), and a canine model of 
myocardial infarction (Hennan et al., 2006). These conflicting data suggest that a 
combination of both the “bystander effect” and the “metabolic co-operation effect” may 
be at play during myocardial infarction, and that both pro-apoptotic and anti-apoptotic 
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factors may pass through gap junction channels during myocardial infarction to alter 
infarct spread and infarct size. 
 
1.10 Gap junction modulators 
Given the near-ubiquitous presence of gap junction abnormalities in arrhythmogenic 
cardiac pathologies, as described above, there has been significant attention surrounding 
gap junction modulators as a potentially novel class of anti-arrhythmic agents (Wit & 
Duffy, 2008). Most of these efforts have centred on developing agents to normalise or 
enhance gap junction coupling, though gap junction uncouplers have also been thought of 
as potential anti-arrhythmic agents (de Groot et al., 2003). AAP10 and rotigaptide are 
examples of agents that improve gap junction coupling, whilst carbenoxolone is a gap 
junction uncoupler, and the actions of these gap junction modulators are discussed below. 
 
1.10.1 Gap junction modulators that enhance coupling 
Gap junction modifying peptides were first described in the early 1980s when a naturally-
occurring peptide that improved rhythmicity in cultured cells was discovered (Aonuma et 
al., 1980). Although the specific mechanisms of action were not known then, this peptide 
was given the name “anti-arrhythmic peptide” (AAP). Over the next decade, attempts 
were made to synthesise derivatives of AAP. Dhein and colleagues succeeded in 
synthesizing several stable derivatives, of which AAP10 (H-Gly-Ala-Gly- 4Hyp-Pro-Tyr-
NH2) was the most stable and most widely studied (Dhein et al., 1994).  
 
The mechanism of action of these AAP molecules was later found to be through the 
enhancement of gap junctional intercellular communication without any significant effects 
on ion channels and cardiac action potential (Dhein et al., 1994; Dhein & Tudyka, 1995; 
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Muller, et al., 1997a; Muller, et al., 1997b). Muller et al performed double-cell voltage-
clamp experiments in isolated pairs of guinea-pig myocytes in which gap junction 
conductance was measured directly and showed that AAP10 enhanced gap junction 
coupling (Muller, 1997b). They also showed that all parameters of the action potential 
remain unchanged, thus concluding a lack of action on active membrane ionic currents. 
 
Figure 1-10: Schematic representation of rotigaptide illustrating its design by rotation-
inversion of AAP10 (Reproduced from Kjolbye et al, 2007).  
 
The main disadvantage of AAP10 was its instability in plasma with a half-life of 12 
minutes (Kjolbye et al., 2003), and thus its lack of suitability for in vivo administration. 
Subsequently, Zealand Pharma developed rotigaptide (previously ZP123), a more stable 
analog of AAP10, which has a half-life 1,700 times that of AAP10 (Kjolbye et al., 2003). 
Rotigaptide (Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2) has a very similar amino acid 
sequence to AAP10, but is a rotation-inversion of AAP10 that incorporates the unnatural 
D-configuration of the amino acids to provide improved proteolytic stability (Kjolbye et 
al., 2007) (Figure 1-10). The increased stability of rotigaptide has led to its use in a 
number of in vivo animal studies (Haugan, et al., 2006b; Hennan et al., 2006), and has 
been administered safely in humans (Lang et al., 2008). Like AAP10, rotigaptide has also 
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been shown to increase gap junction coupling without significant effects on the action 
potential (Eloff et al., 2003). 
 
Both AAP10 and rotigaptide are thought to enhance gap junction coupling by altering the 
phosphorylation status of Cx43. AAP10 has been shown to improve gap junctional 
communication by preventing ischaemia-induced dephosphorylation of the Serine 368 
residue of Cx43 (Jozwiak & Dhein, 2008), and shown to act via a Protein Kinase C 
dependent pathway in cell culture (Easton et al., 2009). Similarly, rotigaptide, has been 
shown to maintain gap junction coupling by preventing ischaemia-induced 
dephosphorylation of Serine 297 and Serine 368 (Axelsen et al., 2006). 
   
1.10.2 Gap junction modulators that reduce coupling 
Carbenoxolone is a drug that was first used as a treatment for dyspepsia and peptic ulcer 
disease in the 1970s and 1980s, and a derivative of glycyrrhetinic acid (Downer et al., 
1970; Iveson et al., 1971; Sircus, 1972), In addition to its gastroprotective effects, 
carbenoxolone has since been shown to reversibly inhibit gap junctional intercellular 
communication (Davidson et al., 1986; Davidson & Baumgarten, 1988), producing an 
approximately 25% reduction in conduction velocity in both longitudinal and transverse 
directions in cardiac tissue (de Groot et al., 2003). 
  
It been shown that carbenoxolone uncouples gap junctions without any significant actions 
on active membrane ionic currents. Kojodjodo et al showed that carbenoxolone did not 
affect effective refractory periods in humans (Kojodjojo et al., 2006), whilst de Groot and 
colleagues demonstrated no action on sodium, potassium and calcium currents in patch-
clamp experiments of isolated myocytes. 
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1.10.3 Gap junction modulators as anti-arrhythmic agents 
Several preclinical studies have shown that gap junction modulators may have anti-
arrhythmic effects both in the atrium and the ventricle (Kjolbye et al., 2007). Hennan et al 
subjected dogs to 60 minutes of coronary artery occlusion and 4 hours of reperfusion, and 
showed that rotigaptide reduced the incidence of premature ventricular complexes and 
ventricular tachycardia (Hennan et al., 2006). Shiroshita-Takeshita et al studied the effects 
of rotigaptide on a number of AF models in canine, and demonstrated that rotigaptide 
improved conduction in various AF models and supressed AF in the ischaemic AF model 
(Shiroshita-Takeshita et al., 2007). Although most efforts have focused on enhancing gap 
junction coupling, there is also evidence to suggest transient gap junction uncoupling prior 
to ischaemia may be anti-arrhythmic (Lascano & Negroni, 2007). Transient uncoupling 
with carbenoxolone prior to ischaemia reduced the number of arrhythmic events during 
subsequent ischaemia in a canine model of acute regional myocardial ischaemia, 
suggesting a possible role for gap junction uncoupling in the protective effects of 
preconditioning (Papp et al., 2007).  
 
1.10.4 Gap junction modulators as agents to modify infarct morphology 
In addition to being potential anti-arrhythmic agents, gap junction modulators may also be 
used to modulate the spread of infarction during acute MI, based on the preliminary 
evidence showing the effects of gap junction modulation on infarct size described above. 
By modifying the spread of infarction acutely, gap junction modulators may also have the 
potential to modify the morphology of the healed infarct scar. As it is known that the 
healed scar morphology is a determinant of post-infarction arrhythmia susceptibility 
(Schmidt et al., 2007), acute modulation of gap junction coupling during acute MI may 
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have significant effects on late post-MI arrhythmic susceptibility, as a result of its effects 
on modifying infarct morphology. 
 
1.11 Scope of thesis 
The main aim of the work in this thesis was to investigate the effects of gap junction 
modulation on myocardial structure and function, specifically in relation to their effects on 
ventricular arrhythmogenesis in the acute reperfusion and post-myocardial infarction 
settings. 
 
The main hypotheses addressed were: 
1. Gap junction modulation during acute ischaemia-reperfusion can, by altering the 
magnitudes of change in conduction velocity during reperfusion, modify 
susceptibility to reperfusion ventricular arrhythmias. 
2. Gap junction modulation during acute myocardial infarction can, by modifying the 
process of infarct spread and healing, alter the morphology of the healed infarct 
and the arrhythmic substrate, thus modifying post-infarction ventricular arrhythmia 
susceptibility. 
 
In order to address the main aim and hypotheses, there were a number of specific aims to 
the work described in this thesis: 
 
1. Selection and characterisation of a suitable model of acute ischaemia-reperfusion. 
2. Assessment of the determinants of reperfusion arrhythmias in this model of acute 
ischaemia-reperfusion and the electrophysiological changes during acute 
ischaemia-reperfusion. 
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3. Selection and characterisation of a suitable chronic, stable post-myocardial 
infarction model. 
4. Assessment of the arrhythmia susceptibility, both spontaneously and on arrhythmia 
provocation, of the chronic myocardial infarction model. 
5. Assessment of the determinants of arrhythmia susceptibility in the chronic, stable 
myocardial infarction model, and the electrophysiology of the healed infarct. 
6. Characterisation of the effects of pharmacological gap junction modulators in 
intact myocardium. 
7. Administration of gap junction modulators during acute ischaemia-reperfusion, 
with assessment of their effects on the electrophysiological changes during 
ischaemia-reperfusion and on reperfusion arrhythmia incidence. 
8. Administration of gap junction modulators acutely during myocardial infarction, 
with assessment of their effects on infarct morphology, arrhythmia susceptibility 
and electrophysiology of the healed infarct at the chronic, stable post-myocardial 
infarction phase. 
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Chapter 2 
Materials & Methods 
 
	   83 
2.1 Introduction 
This chapter provides a general description of the materials and methods used in the work 
in this thesis. Techniques covered in this chapter include in vivo myocardial infarction 
surgery, in vivo telemetry implantation, ex vivo Langendorff ischaemia-reperfusion 
experiments, ex vivo optical mapping of transmembrane voltage (Vm), arrhythmia 
provocation protocols, immunohistochemistry, Western blotting and histological staining. 
Further specific details on methodology will be provided in the relevant chapters. 
 
2.2 Materials 
2.2.1 Animals 
The studies described in this thesis were performed using male Sprague-Dawley rats, 
sourced from Harlan Laboratories UK (Bicester, UK). Rats that weighed between 250g 
and 300g (equivalent of 9 to 12 weeks old) were used. All animal studies were performed 
in accordance with the standards set out in the UK Animals (Scientific Procedures) Act 
1986 (Parliament, 1986). The work described in this thesis was approved by the Imperial 
College London Ethical Review Board and carried out under Project License PPL 
70/7033. All experiments were performed at least one week after arrival of animals to the 
Central Biomedical Services (CBS) Facility at St. Mary’s Campus, Imperial College 
London, to allow the animals to fully acclimatise to their new environment. 
 
The Sprague-Dawley rat is an outbred albino strain of the Rattus norvegicus species. This 
outbred rat was originated by the Sprague-Dawley Company, Madison, Wisconsin in 1925 
through a series of crosses that started with a single-hooded male rat and six albino 
females. The direct descendents of this original colony are now used widely in 
cardiovascular research, including in studies on acute myocardial ischaemia and infarction 
	   84 
(Sun et al., 2000; Loot et al., 2002). Sprague-Dawley rats have an average life-span of 2.5 
to 3.5 years. There are multiple advantages to using this strain in biomedical research, 
including its stability and reproducibility in physiological studies, its calmness and ease of 
handling, and its reproductive efficiency. 
 
2.2.2 Gap junction modulators 
In the experiments described in this thesis, pharmacological gap junction modulators were 
used to modify gap junction coupling. To enhance coupling, three related peptide 
molecules, AAP10 (Anti-Arrhythmic Peptide 10), rotigaptide (previously ZP123) and 
ZP1210, were used. AAP10 (chemical structure: H2N-Gly-Ala-Gly-Hyp-Pro-Tyr-
CONH2) was custom-synthesized by Bachem (Bubbendorf, Switzerland), whilst 
rotigaptide (chemical structure: Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2) was 
custom-synthesized by the Imperial College London Drug Discovery Centre (London, 
UK), with the assistance of Dr Albert Jaxa-Chamiec. ZP1210 is a peptide related to ZP123 
and was provided by Zealand Pharma (Copenhagen, Denmark). To reduce gap junction 
coupling, carbenoxolone was used. This was obtained from Sigma-Aldrich (Dorset, UK) 
in the form of Carbenoxolone Disodium salt (Catalogue number C4790). Gap junction 
modulators were discussed in detail in Section 1.6. 
 
2.3 Rat myocardial infarction model 
2.3.1 Background 
A surgical rat myocardial infarction model was used in these studies. The technique of 
creating myocardial infarction by surgical ligation of coronary arteries in rat was first 
described in 1954 by Johns and Olson (Johns & Olson, 1954). Coronary occlusion models 
were developed in small animals because the early coronary occlusion experiments, which 
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were performed in dogs, produced significant variations in outcomes as a result of the 
underlying variations in coronary anatomy in that species (Gross et al., 1937). Johns and 
Olson described a technique of placing a suture around the left coronary artery in rats via a 
left thoracotomy, which produced a high rate of myocardial infarction in rats (83%) and 
produced infarctions that were more consistent in size than in dogs.  
 
This technique was subsequently modified and established by Pfeffer et al in the 1970s 
and 1980s to study the effects of myocardial infarction on ventricular function and to 
characterise the post-infarction ventricular remodelling processes (Pfeffer et al., 1979; 
Pfeffer et al., 1985; Pfeffer & Braunwald, 1990). A surgical protocol similar to that 
described by Pfeffer et al was used for experiments in this thesis, details of which are 
provided below (Pfeffer et al., 1979). 
 
2.3.2 Anaesthesia and Pre-operative management 
Studies were performed on male Sprague-Dawley rats (250-300g, 9-12 weeks old). Each 
rat was first placed inside an induction chamber and anaesthetised with a mixture of 5% 
isoflurane and 95% oxygen. The rat was then weighed and transferred to a Bain coaxial 
circuit and maintained with the above anaesthetic mixture. At this stage, pre-operative 
antibiotics (5mg/kg enrofloxacin), analgesia (0-05-0.1mg/kg buprenorphine) and warmed 
fluids (2ml of 0.9% saline) were administered subcutaneous (all drugs from Centaur 
Services, Somerset, UK). The left anterior chest wall was shaved in preparation for 
surgery. 
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The rat was then transferred and secured to an anaesthetic board. Intubation was achieved 
using the “hanging teeth” technique. A modified 16G intravenous cannula with blunted 
stillete (Becton Dickinson, UK) was used as the endotracheal tube and passed into the 
trachea across the vocal cords under direct vision, with the trachea transillumination. The 
cannula was then connected to a Harvard Rodent Ventilator (DC1 55-0000 Small Animal 
Ventilator 683, Harvard Apparatus, MA, USA) and appropriate positioning of the 
endotracheal tube was confirmed by inspecting for periodic bilateral lung inflation. The rat 
was ventilated using volume-controlled ventilation at a cycle rate of 100 cycles per minute 
and a tidal volume of 2.0-2.5ml, giving a minute volume of 200-250ml/min. Maintenance 
anaesthesia was with a mixture of 2% isoflurane/98% oxygen. The shaved area on the left 
anterior chest wall was then sterilised with 1% Chlorhexidine (AstraZeneca, UK). In gap 
junction modulator studies, a bolus of gap junction modulator or control phosphate-
buffered saline (PBS) was given intraperitoneally at this stage immediately before skin 
incision. Administration of gap junction modulators at this stage has been shown to 
produce therapeutic plasma levels at the time of coronary artery ligation (Haugan, et al., 
2006b). 
 
2.3.3 Rat myocardial infarction surgery protocol 
Following the anaesthesia and pre-operative care described above, the rat was draped and 
a left parasternal incision was made. Division of tissue planes was performed and the 
pectoralis major and pectoralis minor muscles were visualised and retracted to allow 
access to the intercostal muscles. A left thoracotomy was created through the 4th 
intercostal space, which then exposed the pericardial cavity (Figure 2-1). The 4th and 5th 
ribs were retracted to allow access to the heart through the thoracotomy. The thymus gland 
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was then mobilised and fixed into position with clamps to stabilise the heart within the 
pericardial cavity. The pericardial sac was divided by gentle dissection. 
 
With the heart exposed and the anterolateral aspect of the left ventricle in clear view, a 7-0 
Prolene suture was placed around the left anterior descending (LAD) artery at a point 1-
2mm distal to the inferior border of the left atrium, as shown in Figure 2-1. Halpern first 
described the coronary artery anatomy of the rat in a series of dissection studies in 1957 
(Halpern, 1957). The left coronary artery, after arising from the aorta, courses around the 
left side of the pulmonary trunk. This artery then becomes intramyocardial as it descends 
to the apex of the heart, taking a course that is parallel to the anterior longitudinal sulcus. 
The artery gives off branches to the conus region of the right ventricle and also gives off 
branches to supply the left ventricle, including the circumflex artery, the septal and the 
diagonal branches of the left anterior descending artery.  
 
Because of the intramyocardial course of the coronary artery, the suture was placed at a 
depth of approximately 1mm into the myocardium. Successful ligation of the artery was 
confirmed by direct visualisation of the immediate blanching and cyanosis of the 
myocardium supplied by the artery, followed by marked regional wall motion 
abnormalities in the left ventricle and akinesis of the anterior left ventricular wall supplied 
by the artery, in addition to dilatation of the left atrial appendage resulting from the acute 
rise in left ventricular end-diastolic pressure (LVEDP). If the initial ligation failed to 
induce a large enough area of ischaemia, additional ligatures were placed medial or lateral 
to the first ligature until a significant area of the anterior left ventricle was rendered 
ischaemic. 
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Figure 2-1: Myocardial infarction surgery (A) The heart is exposed through a left-sided 
thoracotomy through the 4th intercostal space. (B) To generate anterior myocardial 
infarction, a suture was placed and tightened around the LAD artery along the red line 
between the open circles. (Modified from Halpern, 1957).  
 
Successful ligation of the left anterior descending artery resulted in Phase 1 ischaemia-
induced ventricular fibrillation in a substantial minority of cases (Curtis & Hearse, 1989a), 
which typically occurred 5-8 minutes after successful coronary artery ligation. In the event 
of witnessed ventricular tachyarrhythmia, attempts were made to defibrillate the heart by 
flicking the heart and to maintain cardiac output by periodically compressing the heart 
between two tweezer handles or by chest compressions. In some cases, ventricular 
fibrillation could not be terminated, and these acute ischaemia-induced ventricular 
arrhythmias were responsible for the majority of deaths from this procedure. Estimates of 
acute mortality from this surgical procedure are in the region of 30-40% (Klocke et al., 
2007; Pfeffer et al., 1979), although the mortality rate appears to be strain-dependent as 
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the Lewis inbred strain has been shown to have lower acute mortality compared to the 
Sprague-Dawley outbred strain (16% vs 36%) (Liu et al., 1997). 
 
Upon successful ligation of the left anterior descending coronary artery, a chest drain was 
placed in the thoracic cavity to aid successful reinflation of the lungs following removal 
from the ventilator and to prevent the formation of a pneumo- or haemo-thorax. A 22G 
Abbocath® catheter (Bunzl Healthcare, UK) was modified by creating side-holes and 
used as the chest drain. The chest was then closed using a 4-0 Ethicon polyester non-
absorbable suture (Ethibond Excel suture, Johnson & Johnson Ethicon, UK). Firstly, the 
thoracotomy was closed using a continuous suture that brought together the 4th and 5th 
ribs. The muscle layer was then closed using a continuous suture to bring together the 
pectoralis major and minor muscles, before the skin incision was closed with a series of 
interrupted sutures. The isoflurane concentration was reduced to 1% during chest closure. 
 
2.3.4 Post-operative management 
On completion of cardiac surgery and after chest closure, the residual air and blood within 
the thoracic cavity was aspirated through the previously-inserted chest drain and several 
cycles of continuous positive airways pressure (CPAP) delivered to optimise lung re-
expansion. Animals were weaned on 100% oxygen, and the endotracheal tube was then 
disconnected from the ventilator before the animal was transferred onto the Bain coaxial 
circuit. The chest drain and endotracheal tube were removed once the animal was 
breathing comfortably on room air and when it regained consciousness. 
 
Upon regaining consciousness, the animal was returned to its cage and surviving animals 
were single-housed in individually-ventilated cages (IVCs) in a stable environment, and 
	   90 
maintained with standard rat chow and water ad libitum. Animals were checked on a daily 
basis for signs of distress and for signs of wound infection or dehiscence. Additional top-
up analgesia was provided in the event of distress. 
 
2.4 In vivo ECG-telemetry 
2.4.1 Background 
An ECG-radiotelemetry system was used to monitor ECG in vivo in rats and to document 
the incidence of ventricular arrhythmias. Telemetry refers broadly to a technology that 
allows remote measuring and reporting of information. Biotelemetry refers specifically to 
the use of telemetry to measure and report biological data from live humans or animals. 
The transfer of information in telemetry systems often involves wireless systems (e.g. 
radio or infrared systems) but can sometimes involve wired communication. The wireless 
transmission allows information to be monitored and recorded at locations remote from 
the site of recording. 
 
The most common examples of biotemeletry are in the clinical setting. Coronary Care 
Units often employ radiotelemetry systems to monitor the ECGs of patients. This allows 
the heart rates and, more importantly, the heart rhythms of patients to be monitored at all 
times whilst patients are moving freely within the unit. Within pre-clinical biological 
research, telemetry systems are most frequently used to record biological data from in vivo 
disease models or to monitor the effects of certain pharmacological treatments. Commonly 
recorded data include ECG (to monitor variations in heart rate and ECG morphology, and 
for arrhythmia detection) and blood pressure. The main strength of using a telemetry 
system is that the data can be acquired without the need for restraint or anaesthesia. 
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2.4.2 ECG-Telemetry System 
A Data Sciences International (DSI, Minneapolis) telemetry system, which included 
implantable ECG-telemetry transmitters, telemetry receivers units and data exchange 
matrices, was used (Figure 2-2). For each rat, a CA-F40 radiotelemetry transmitter (DSI, 
Minneapolis) was implanted in the peritoneal cavity. The transmitter device contained a 
magnetic reed switch and was switched on or off by passing a magnet close to the rat. 
When the transmitter was on, it transmitted radiotelemetry signals at an AM (Amplitude 
Modulation) frequency of 455KHz and a range of approximately 40cm. The transmitter 
was confirmed to be on by placing an AM radio close to the animal to confirm the 
presence of a periodic signal. 
 
Each rat was housed in an Individually Ventilated Cage (Techniplast, Italy), which in turn 
was placed in a custom-built telemetry rack that contained metal dividers between 
separate compartments to prevent cross-talk between different telemetry transmitter-
receiver pairs. Each cage was placed approximately 1-2cm above a receiver unit (RPC-1, 
DSI, Minneapolis), which was well within the range of the transmitters. Radiowave 
signals transmitted by each transmitter were detected by its corresponding receiver, and 
data were then amplified and filtered via a Data Exchange Matrix (DSI, Minneapolis), 
before being transferred to a local desktop computer. The data were acquired using ART 
3.1 software (DSI, Minneapolis) and were stored on a local external hard drive. 
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Figure 2-2: ECG-Telemetry System – Each Individually-Ventilated Cage (IVC) is placed 
in close proximity to its corresponding telemetry receiver, in a custom-made cage rack 
with metal dividers to separate different cage compartments and prevent telemetry cross-
talk. 
 
2.4.3 Telemetry implantation surgery 
The pre-operative care and anaesthesia for telemetry device implantation surgery were as 
described in Section 2.3.2. For each rat, anaesthesia was induced with a 5% 
isoflurane/95% oxygen mixture and the rat then transferred onto a Bain coaxial circuit. 
Maintenance anaesthesia was with 2.5% isoflurane via a nose cone, without the need for 
intubation, as the thoracic cavity remained sealed throughout the procedure. Analgesia, 
antibiotics and pre-operative fluids were given as described in Section 2.3.2.  The anterior 
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abdominal wall and right upper chest wall were shaved and sterilised with 1% 
Chlorhexidine (AstraZeneca, UK). 
 
A midline abdominal skin incision was performed followed by a midline laparotomy 
incision along the linea alba, avoiding the major abdominal vessels and nerves as shown 
in Figure 2-3. The muscles of the anterior abdominal wall were retracted to allow access 
to the abdominal cavity. If the animal had an osmotic minipump in situ from a previous 
surgery, the minipump was removed at this stage. The main body unit of the ECG-
telemetry transmitter (CA-F40, Data Sciences International, Minneapolis, USA) was then 
sutured and secured onto the inner aspect of the left anterior abdominal wall using a 4-0 
Ethicon polyester suture (Ethibond Excel suture, Johnson & Johnson Ethicon, UK). Once 
secured, the two biopotential leads were tunnelled through the abdominal wall. The 
positive lead was secured with a 4-0 Ethicon polyester suture to the anterior surface of the 
upper left abdominal wall, just inferior to the left ventricular apex. The second 
biopotential lead (negative lead) was tunnelled subcutaneously towards the region of the 
upper right chest wall. A small 1cm incision was then made over the right pectoralis 
muscle to allow direct access to this lead. The lead was then secured onto the anterior 
surface of the right pectoralis muscle. The positioning of the two biopotential leads in this 
configuration allowed for the recording of a Lead II Configuration ECG. 
 
Once both biopotential leads were secured into their appropriate locations, the transmitter 
was switched on using a magnet and the signal was assessed using an AM radio. If the 
signal was acceptable (i.e. a clear periodic signal was heard on the radio), the transmitter 
was then switched off with the magnet. The laparotomy was closed with a continuous 
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suture using 4-0 Ethicon polyester suture and both skin incisions (abdominal and right 
upper chest) were closed with interrupted sutures. 
 
 
Figure 2-3: Telemetry implantation surgery: (A) Midline laparotomy, (B) Telemetry 
transmitter secured to inner abdominal wall, (C) Path tunneled for positive lead towards 
lower left chest, (D) Positive lead secured into place, (E) Path tunnelled for negative lead 
towards right upper chest, (F) Negative lead tunnelled into position. 
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The anaesthetic was then weaned and the rat was returned to its cage after it regained 
consciousness. Animals were single-housed in individually-ventilated cages in a stable 
environment, and maintained with standard rat chow and water ad libitum. Animals were 
checked on a daily basis for signs of distress and for signs of wound infection or 
dehiscence. Rat cages were placed in a custom made telemetry cage rack (Tecniplast, 
Italy) as described above, and each cage was placed 1-2cm above its corresponding 
telemetry receiver (RPC-1 Receiver, Data Sciences International, Minneapolis, USA) so 
that telemetry signals can be transmitted to the receiver regardless of the position of the rat 
within its cage. 
 
2.4.4 Recording protocols 
ECG-telemetry recordings were made to document the incidence of ventricular 
arrhythmias in vivo. Unless stated, telemetry recordings were made at least one week after 
device implantation. Recording were generally not made in the first week post-surgery as 
any arrhythmias documented in that period could have been a result of the stresses of 
surgery. When recordings were made, ECG was recorded continuously for 24 hours to 
prevent diurnal variation influencing the number of arrhythmia documented. 
 
2.4.5 Arrhythmia analysis 
ECG-telemetry data were recorded and stored using ART 3.1 software (Data Sciences 
International, Minneapolis, USA). Files in ART 3.1 format (stored as 20MB files) were 
then converted into IOX files, which were compatible with the EMKA analysis 
programme. These files were subsequently analysed using EMKA ECG-Auto software 
(EMKA, France).  
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The EMKA ECG-auto software allowed for programmable automated ECG analysis for 
arrhythmia detection (Figure 2-4). The software was able to store a library of P-QRS-T 
complexes, which could then be compared with recorded ECG complexes. The basis of 
this automated arrhythmia analysis involved comparing every recorded ECG complex to a 
library of known QRS morphologies of ventricular ectopics (VEs) or ventricular 
premature beats (VPBs), to determine if each individual recorded ECG complex was a 
ventricular beat or a regular sinus rhythm beat. Following identification of all the 
ventricular complexes, the software would then calculate the total number of ventricular 
beats over that recording period. 
 
In practice, the arrhythmia analysis was not fully automated, and required user input to 
ensure maximum sensitivity and specificity in appropriately identifying ventricular 
ectopics. Because the morphologies of the ventricular ectopics and the regular sinus 
rhythm complexes were different from one animal to the next, it was important to select 
the appropriate P-QRS-T morphologies from the library to compare against the analysed 
recording for each animal. At the start of each analysis, the user would manually screen 
the recording for ventricular complexes and then select the appropriate files from the 
library that matched the morphologies of those ventricular complexes to perform the 
analysis. Analysis parameters were set to ensure maximum sensitivity to ensure that all 
ventricular arrhythmias were detected (and minimise false negatives). Because parameters 
were set to maximise sensitivity, the software would occasionally wrongly identify 
artefact or normal sinus rhythm beats as ventricular arrhythmias. In order to maximise 
specificity of the analysis (and eliminate false positives), the user would then manually 
verify each ECG complex identified by the software as ventricular arrhythmia, and also 
classify the arrhythmia as a single isolated ventricular ectopic (VE), a couplet (2 
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consecutive VEs), a triplet (3 consecutive VEs), ventricular tachycardia (4 or more 
consecutive ventricular beats) or ventricular fibrillation. Classification of arrhythmias was 
performed as defined by the Lambeth Conventions (Walker et al., 1988). 
 
 
Figure 2-4: Example of automated ECG analysis. (A) Pre-analysis ECG recording, (B & 
C) Automated analysis software correctly identified abnormal ECG complexes (denoted 
by red dots) by comparing with library of typical ventricular complexes. 
 
2.5 Ex vivo Isolated Rat Heart studies 
The isolated perfused rat heart preparation was used for regional ischaemia-reperfusion 
experiments, regional acute ischaemia experiments, acute metabolic stress studies, optical 
mapping studies and arrhythmia provocation protocols. 
 
2.5.1 History of the Isolated Perfused Heart Preparation 
Few experimental preparations have been used as widely in cardiovascular research over 
the past century as the isolated perfused heart preparation. The isolated heart preparation 
was first described by Elias Cyon and Carl Ludwig in Leipzig in 1866 (Cyon, 1866). 
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These pioneering isolated heart studies were performed in frogs, a cold-blooded species. 
Frog hearts are different from mammalian hearts in that they contain only three chambers, 
two atria and one ventricle, with no coronary circulation. The initial experiments by Cyon 
and Ludwig involved cannulating the vena cava, and pumping rabbit serum into the heart 
via the cannula. The serum was expelled through the aorta and recirculated back to the 
vena cava by a glass tube that was surrounded by a glass cylinder filled with fluid, which 
could be used to control the temperature of the circulating serum.  
 
The frog heart was easy to study in isolation as it did not have a coronary circulation and it 
was sufficient to circulate the serum through the atria and ventricle as the exchange of 
metabolites and gases to cardiac muscle tissue was achieved by diffusion. However, 
isolating and perfusing the mammalian heart proved to be more of a challenge because of 
the coronary circulation. In the 1880s, Henry Martin was one of the first researchers to 
attempt to perfuse the mammalian heart in a heart-lung preparation, by isolating a dog 
heart from its systemic circulation and perfusing it through an artificial system through the 
right atrium (Martin, 1883). 
 
However, it was Oskar Langendorff, back in 1897, who first established the isolated 
perfused mammalian heart preparation as it is known today (Langendorff, 1898). 
Langendorff’s key contribution was to perfuse the ascending aorta retrogradely via an 
aortic cannula. Instead of cannulating the right heart circulation and allowing the blood to 
circulate through the right heart into the lungs and through the left heart before perfusing 
the coronary arteries, as done by Martin, the coronary arteries were perfused directly 
through the aorta. Retrograde flow down the ascending aorta closed the aortic valve 
leaflets and forced the perfusate to enter the coronary arteries via their ostia at the aortic 
	   99 
root. The perfusate would then pass through the entire circulation before exiting via the 
coronary sinus into the right atrium. Using this technique, Langendorff was able to 
maintain spontaneous cardiac activity in isolated cat and dog hearts for several hours by 
perfusing with defibrinated blood. 
 
Although there have been modifications to the apparatus and the choice of perfusate over 
the years, the core principle of perfusing isolated hearts retrogradely via the ascending 
aorta has remained unchanged over the past century. The isolated perfused heart 
preparation, often referred to as the “Langendorff heart” has been widely used since, 
firstly by physiologists, biochemists and morphologists to study heart biology, and latterly 
by pharmacologists to study the effects of drugs on the heart (Skrzypiec-Spring et al., 
2007; Zimmer, 1998). 
 
2.5.2 Description of the Isolated Rat Heart Preparation 
Modern isolated perfused heart preparations are all modifications of the original 
Langendorff experiments. In general, hearts are explanted and rapidly cannulated via the 
ascending aorta. Hearts are then perfused via the aortic cannula using a perfusate that 
mimics the ionic concentration of plasma (Krebs & Henseleit, 1932). The perfusate is 
warmed to 37oC and bubbled with an O2/CO2 gas mixture to maintain a physiological pH 
of 7.35-7.45. As described above, retrograde perfusion of the ascending aorta closes the 
aortic valve leaflets and sends the oxygenated perfusate through the coronary arteries. The 
perfusate exits into the right atrium and is expelled from the heart via the pulmonary 
artery. This coronary effluent can be collected to measure coronary flow rate. 
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Figure 2-5: A fixed-pressure perfusion Langendorff apparatus. A constant hydrostatic 
pressure of 80-100 cm H20 was maintained by filling the perfusate reservoirs to the 
appropriate levels. 
 
There are two types of perfusion for isolated heart studies, constant-pressure perfusion 
(Figure 2-5) and constant-flow perfusion, each with their own advantages and 
disadvantages. As suggested by its name, the constant-pressure perfusion maintains a 
fixed hydrostatic perfusion pressure, either by maintaining a tall column of perfusate 
within the Langendorff apparatus (80-100 cm H20) or by elevating the perfusate reservoir 
to the desired height. The constant-pressure perfusion system has the advantage of letting 
autoregulatory mechanisms alter and determine the coronary flow rate, either by coronary 
artery vasodilatation or vasoconstriction, depending on the physiological context. Fixed 
pressure systems are thought to be more physiological, especially in experiments of 
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ischaemia, where the occlusion of a coronary artery can lead to alterations of muscle tone 
in other coronary arteries and alter coronary flow. A fixed perfusion pressure system was 
used in the acute regional ischaemia and acute ischaemia-reperfusion experiments 
described below. 
 
The second type of perfusion is constant-flow perfusion. These systems involve the use of 
a peristaltic pump to drive a constant flow rate of perfusate through the coronary arteries. 
This system overrides the autoregulatory mechanisms and the amount of perfusate 
delivered is not altered in response to changes in heart rate or contraction. This system of 
perfusion was used in the optical mapping experiments described below as the optical 
mapping experiments were performed on immobilised hearts perfused with excitation-
contraction uncoupler. The removal of the contraction-relaxation process reduced flow 
through the coronary arteries at physiological perfusion pressures (Davies et al., 2006), 
and therefore a fixed-flow system was more appropriate for these optical mapping 
experiments. 
 
There are multiple advantages to using an isolated perfused heart preparation. This 
preparation is highly reproducible, and has the potential for high throughput studies with 
excellent cost effectiveness. Just under 400 isolated heart studies were performed in this 
thesis, which would not have been feasible in a larger animal model. Another advantage of 
this preparation is the removal of exogenous variables that may act as confounding 
factors. The lack of neurohormonal input and vascular coupling allows for studies 
specifically into myocardial physiology without these confounding variables. This 
preparation is also very versatile and allows for studies into contractile function, coronary 
vascular flow, electrophysiology as well as cardiac metabolism. Because of the easy 
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access to the coronary arteries in a free-hanging isolated heart, this preparation is 
particularly suitable for studies of acute ischaemia-infarction and reperfusion (Curtis 
1998; Curtis & Hearse, 1989a; Curtis et al., 1987). This preparation is also excellent for 
arrhythmia studies to assess the effects of acute ischaemia-reperfusion or the effects of 
drugs on arrhythmia incidence and thresholds. It also readily allows for studies into the 
electrophysiology of intact myocardium, for example using optical mapping (as described 
in Section 2.6). 
 
There are also several disadvantages to the isolated perfused heart preparation. The lack of 
neurohormonal input and vascular coupling mentioned above, whilst having its 
advantages, is also simultaneously a disadvantage of this preparation. The lack of neuronal 
input into the ex vivo heart limits its utility as a model for studying cardiac diseases with 
significant neuronal involvement such as atrial fibrillation (Volders, 2010; Zhang & 
Mazgalev, 2010). However, ex vivo preparations with preserved sympathetic and 
parasympathetic innervation now exist to allow studies into the role of the autonomic 
nervous system on cardiac electrophysiology (Mantravadi et al., 2007).  
 
The isolated perfused heart preparation also suffers from the fact that the heart is unloaded 
during the experiment, and thus the potential influence of left ventricular filling pressures 
and stretch on myocardial physiology is lost. Another disadvantage is that the lack of 
colloidal osmotic pressure in the perfusate can result in oedema of the heart preparation 
(Skrzypiec-Spring et al., 2007), although this is mainly an issue for lengthier experiments. 
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2.5.3 Isolated Perfused Rat Heart Protocol 
For all ex vivo isolated perfused heart studies, the following protocol was used to perfuse 
and stabilise hearts on a Langendorff apparatus. Adult male Sprague-Dawley rats were 
killed by cervical dislocation, consistent with methods described in Schedule 1 of the 
Animals (Scientific Procedures) Act 1986 (Parliament, 1986). For each animal, an incision 
was made into the anterior abdominal wall. The diaphragm was then pierced and the 
thoracic cavity was exposed. The heart, together with surrounding lung tissue, trachea and 
thymus, were rapidly excised and immediately placed in a petri dish containing chilled 
(4°C), heparinised, oxygenated Krebs-Henseleit solution. Care was taken to ensure that 
the aorta was not disrupted in the process of excising the heart and that the entire aortic 
arch was preserved. 
 
Dissection was performed with the heart in the petri dish containing ice-cold Krebs-
Henseleit solution. The heart was submerged below the surface of the solution during 
dissection to avoid inadvertent air embolism into the coronary arteries. The thymus, 
trachea and surrounding lung tissue were dissected away and the aorta was identified. The 
aorta was dissected at the level of the right brachiocephalic artery to preserve the entire 
length of the ascending aorta. The heart was gently compressed 3-5 times to expel any 
residual blood in the coronary circulation.  
 
The heart was then mounted onto a Langendorff apparatus at a slow drip rate. The 
ascending aorta was temporarily attached to the aortic cannula of the Langendorff 
apparatus using a small Bulldog clip (World Precision Instruments, UK), before being 
secured to the cannula using a 2-0 silk suture (Johnson & Johnson Ethicon, UK). Once the 
heart was secured, the tap to the aortic cannula was fully opened and the heart was 
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perfused with modified Krebs-Henseleit solution (in mmol/L: NaCl 118.5, CaCl2 1.85, 
KCl 4.5, Glucose 11.1, NaHCO3 25.0, MgSO4 2.5, NaH2PO4 1.4) gassed with 95% O2/5% 
CO2 at 37°C ± 0.5°C and pH 7.35 ± 0.05. Perfusion pressure through the aorta was 
constant and maintained between 80-100 cm H2O. The median time between explant and 
perfusion on the Langendorff apparatus was <60 seconds. 
 
A silver unipolar sensing electode was placed at the left ventricular anterolateral wall to 
record unipolar electrograms, with the reference electrode attached to the aortic cannula 
(Figure 2-6). These electrodes were connected to a Bioamplifier and PowerLab data 
acquisition system (AD Instruments, Sydney, Australia), and the signals were recorded at 
a sampling frequency of 1 kHz and displayed using CHART 5.5 software (also AD 
Instruments).  
 
Each heart was stabilised for 10 minutes before any further intervention was performed. 
During this period, the electrogram was monitored live using CHART 5.5 software to 
detect any arrhythmias and to monitor heart rate. Coronary flow rate (CFR) was measured 
by collecting the effluent from the perfused heart and weighing the effluent. The 
experiment was terminated and the heart was discarded if spontaneous ventricular 
arrhythmias were documented, if heart rate was <200 beats per minute, or if CFR was 
<10ml/min after the stabilisation period. The experiment only proceeded in the absence of 
these exclusion criteria. 
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Figure 2-6: An example of an ex vivo isolated heart experiment. The heart is attached to 
the cannula via the aorta, and an occluder tube is occluding the LAD artery to generate 
myocardial ischaemia. Unipolar electrograms were recorded using a silver electrode. 
 
2.5.4 Regional Ischaemia-Reperfusion Protocol 
Ex vivo ischaemia-reperfusion experiments were performed to assess the effects of 
pharmacological treatments on the incidence of reperfusion arrhythmias. Hearts were 
isolated and perfused on a Langendorff apparatus as described in Section 2.5.3. After 
hearts were successfully attached to the aortic cannula and perfused, a 4.0 Ethicon silk 
ligature (Johnson & Johnson Ethicon, Livingston, UK) was placed around the left anterior 
descending artery 1-2mm distal from where it emerges beneath the left atrium, but without 
any tension on the ligature (Figure 2-7). 
 
Following 10 minutes of stabilisation, hearts were perfused with a pharmacological agent 
or control perfusate, depending on the specific experiment. Each heart was then subjected 
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to regional ischaemia in the left anterior descending (LAD) artery territory, as shown in 
Figure 2-7. The silk ligature placed earlier around the LAD artery was tightened using a 
polythene occluder tube placed over the suture, thereby occluding flow through the artery. 
The successful occlusion of the LAD artery was confirmed by a >30% reduction in 
coronary flow rate (CFR) as assessed by measuring the amount of coronary effluent, in 
conjunction with an alteration in the axis and morphology of the unipolar electrogram 
(shown in Figure 2-8).  
 
Figure 2-7: Regional Ischaemia-Reperfusion Experiments. The suture around the left 
anterior descending (LAD) artery was tightened with an occluder tube to generate 
ischaemia, then released to simulate reperfusion. 
 
Depending on the experiment, hearts were subjected to brief durations of regional 
ischaemia (between 5 and 9 minutes), before the occluding suture was released to restore 
flow across the LAD artery and reperfuse the myocardium supplied by the artery. The 
relationship between duration of ischaemia and the incidence of reperfusion VT/VF in rat 
hearts is “bell-shaped” (Bernier et al., 1989), and different durations of ischaemia were 
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assessed to determine the optimum duration to be on the steep part of this bell-shaped 
relationship (see Section 4). Reperfusion was confirmed by an increase in CFR towards 
that of pre-ischaemic values. The reperfusion phase was continued for 15 minutes with 
continuous electrogram monitoring. The incidences of ventricular arrhythmias during the 
ischaemic and reperfusion periods were recorded. Ventricular arrhythmias were classified 
according to the Lambeth Conventions guidelines (Walker et al., 1988). 
 
 
Figure 2-8: Two examples (A & B) of electrogram changes with ischaemia and 
reperfusion. Regional ischaemia is confirmed by changes in electrogram morphology, 
including changes in QRS axis and T wave morphology, and widening of QRS complex. 
 
2.5.5 Acute Regional Ischaemia Protocol 
Ex vivo acute regional ischaemia experiments were performed to assess the effects of 
acute regional ischaemia on Cx43 phosphorylation, and to assess the effects of 
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pharmacological agents on these changes. Hearts were isolated and perfused on a 
Langendorff apparatus as described in Section 2.5.3. As described in Section 2.5.4, a 4.0 
Ethicon silk ligature (Johnson & Johnson Ethicon, Livingston, UK) was placed then 
around the left anterior descending artery 1-2mm distal from where it emerges beneath the 
left atrium, but without any tension on the ligature (Figure 2-7). 
 
Following 10 minutes of stabilisation, hearts were perfused with a pharmacological agent 
or control perfusate, depending on the specific experiment. Each heart was then subjected 
to regional ischaemia in the left anterior descending (LAD) artery territory, as described in 
Section 2.5.3, by tightening the silk ligature with an occluder tube. For acute ischaemia 
experiments, the ligatures were maintained for 30 minutes, and the electrogram changes 
and arrhythmia incidences were documented. Hearts were flash frozen in liquid nitrogen at 
the end of the 30 minutes of ischaemia for further immunoblotting experiments to 
determine Cx43 quantity and phosphorylation status (Section 2.9). 
 
2.5.6 Global Low-flow Ischaemia Protocol 
In order to assess the effects of acute metabolic stress on action potentials and conduction 
and the effects of gap junction modulators on these changes, a global low-flow ischaemia 
model of acute metabolic stress was used, where hearts were perfused with non-
oxygenated perfusate at low coronary flow rates. This model was selected because of the 
need for simultaneous optical mapping to record optical action potentials during acute 
metabolic stress (Section 2.6). The global no-flow ischaemia model was less suitable for 
optical mapping experiments as complete cessation of flow invariably resulted in the 
shrinkage of the heart and a significant change in its position within the optical mapping 
chamber, thus making it impossible to accurately compare changes in action potentials 
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and conduction velocity pre- and post- acute metabolic stress. The global low-flow 
ischaemia model was more suitable for optical mapping experiments as the maintenance 
of a degree of coronary flow, albeit at a reduced rate, maintained the heart in its original 
position in the mapping chamber, thus allowing for direct comparison of transmembrane 
voltage transients pre- and post- metabolic stress from the same region of the heart. 
 
Perfusion of isolated hearts with reduced coronary flow rates has previously been used as 
a model metabolic stress. It has been shown that a reduction in coronary flow rate can 
cause global ischaemia, leading to a drop in pH to approximately 6.8 after 5 minutes and 
an increase in the production of lactate (Kupriyanov et al., 1999; van Binsbergen et al., 
1996). Perfusion with non-oxygenated perfusate has also been used as an alternative 
model of metabolic stress. Haugan et al reported that perfusion with glucose-free, non-
oxygenated perfusate can lead to a 30% slowing in conduction velocity (Haugan, et al., 
2005a; Haugan, et al., 2005b). In the metabolic stress studies described in this thesis, a 
combination of low-flow ischaemia and non-oxygenated perfusate was used. 
 
For these studies, hearts were isolated and perfused on a Langendorff apparatus as 
described in Section 2.5.3. Instead of using a fixed perfusion pressure system described in 
Section 2.5.3, a fixed flow rate system was used. Hearts were perfused at fixed coronary 
flow rates using a Peri-Star Pro peristaltic pump (World Precision Instruments-Europe, 
Stevenage, UK). Hearts were perfused at a CFR of 15ml/min with oxygenated Krebs-
Henseleit solution during stabilisation. After the initial 10 minutes of stabilisation, hearts 
were stained with a voltage-sensitive dye and perfused with an excitation-contraction 
uncoupler as described in the optical mapping section (Section 2.6.2). To induce acute 
metabolic stress, the coronary flow rate was reduced to 33% of baseline, from 15ml/min to 
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5ml/min, and hearts perfused with non-oxygenated perfusate (i.e not bubbled with O2/CO2 
mixture). Following 30 minutes of this acute metabolic stress, the coronary flow rate 
increased to that of baseline (15ml/min), and switched to the oxygenated perfusate. Hearts 
were perfused for a further 10 minutes to assess the recovery of hearts from acute 
metabolic stress. 
 
2.6 Optical mapping 
2.6.1 Background 
Optical mapping is a technique for recording biological data simultaneously over multiple 
sites using non-invasive optical methods. One application of this technique is the optical 
mapping of transmembrane voltage (Vm) transients using fluorescent voltage-sensitive 
dyes, which will be the focus of discussion for this section. 
 
Over the past 50 years, a great amount has been learnt about cardiac electrophysiology at 
the cellular and molecular levels. For example, the reductionist approach has enabled 
researchers using patch-clamp or microelectrode experiments to study membrane potential 
changes and the role of different ion channels in contributing to the cardiac action 
potential. Improved molecular biological techniques have also enabled researchers to 
understand the molecular basis of the electrophysiological processes of the cell and the 
remodelling processes that occur in disease. However, the heart consists of a 
heterogeneous population of cells that are interconnected via gap junction channels to 
form an electrical syncytium, and there has been a growing realisation that, in order to 
study the function of the heart as a complex whole organ, the spatial heterogeneities of 
cell properties need to be taken into account. This led to efforts to develop experimental 
techniques to study electrophysiology at the intact tissue and whole-heart level. 
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In the late 1960s and early 1970s, attempts were made to develop new techniques to 
record membrane potentials from multiple sites in an electrical syncytium by recording 
optical signals. The early attempts to measure voltage-dependent optical signals were 
based on intrinsic signals recorded without extrinsic dyes. These early efforts, driven by 
neuroscience research, measured light scattering and birefringence changes during nerve 
activity, which appeared to mirror changes in action potential (Cohen et al., 1968; Cohen 
et al., 1969). However, these initial methods suffered from poor signal-to-noise ratios, 
which subsequently led to a shift from measuring intrinsic signals to measuring extrinsic 
fluorescence emitted by exogenously added dyes. Hundreds of dyes were screened for 
voltage-sensitive properties in nerve axons, many of which improved the signal-to-noise 
ratio by tenfold compared to intrinsic signals (Cohen et al., 1974). These early discoveries 
of dyes with voltage-dependent optical responses led to the development of synthetic 
voltage-sensitive dyes with greater signal-to-noise ratios and lesser toxicity, which are 
now widely used in optical mapping studies in both cardiac and neuroelectrophysiology. 
 
2.6.2 Principles of optical mapping of transmembrane voltage (Vm) 
An optical mapping system consists of four components: (1) the heart stained with a 
voltage-sensitive dye, (2) a light source, (3) a system of optics, and (4) a photodetector 
(Figure 2-9). During an optical mapping experiment, the heart is firstly perfused and 
stained with a voltage-sensitive dye, which binds to the cell membrane. The dye is then 
excited by a light source with the appropriate excitation wavelength, which moves it into 
its excited state. When the dye returns to its ground state from its excited state, it emits 
photons of a wavelength that is longer than that of the excitation light. The system of 
optics then filters the emitted photons and focuses the light onto a photodetector, which 
quantifies the amount of emitted light.  
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Figure 2-9: Optical mapping system. A 3600 LED light source was directed towards a 
heart stained with voltage-sensitive dye. The emitted light passes through two dichroic 
mirrors, one splitting light towards a CCD camera for plain images, before being detected 
by a 256-photodiode array. For experiments described in this thesis, only mapping of 
transmembrane voltage (Vm) was performed, without simultaneous recording of calcium 
transients. 
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Because of the unique property of voltage-sensitive dyes, the changes in the quantity of 
filtered light detected by the photodetector is proportional to changes in transmembrane 
voltage (Vm), and this allows for the non-invasive assessment of transmembrane voltage 
changes. However, one important difference between optical action potentials and those 
recorded with intracellular microelectrodes is that the optical action potential signal arises 
from a volume of cells and represents a multicellular spatial average of transmembrane 
potentials from cells within that volume of tissue. 
 
2.6.2.1 Voltage-sensitive dyes 
Multiple potentiometric dyes have been synthesized to allow measurement of 
transmembrane voltage changes. Some common examples include di-4-ANNEPS, di-8-
ANNEPS and RH237. These dyes all exhibit voltage-dependent shifts of their emission 
spectra. As shown in Figure 2-10, at resting membrane potential, when the dye is excited, 
it will emit photons with a specific emission spectrum when returning to the ground state 
from the excited state. However, when the cell is depolarised, the emission spectrum is 
blue-shifted towards shorter wavelength. By using appropriate filters to select for light 
above certain wavelengths, a decrease in signal intensity will accompany membrane 
depolarisation. 
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Figure 2-10: Voltage-dependence of emission spectra of potentiometric dyes. At resting 
membrane potential, the dye emits a spectrum of light as shown on the left. The amount of 
filtered fluorescent light detected is F1. When the cell is depolarised, the spectrum is blue-
shifted so that a smaller amount of filtered light (F2) is detected. Changes in fluorescence 
intensity are proportional to changes in transmembrane voltage. 
 
There are four main mechanisms by which potentiometric dyes shift their emission spectra 
in response to membrane potential changes:  
(1) On-Off mechanism - dyes bind to the membrane when the cell is polarised and 
unbinds when the cell is depolarised. 
(2) Redistribution – dyes redistribute between the cytoplasmic compartment (when 
depolarised) and extracellular space (when polarised).  
(3) Reorientation – dye molecules reorientate within the cell membrane when changing 
between depolarised and polarised states. 
(4) Electrochromism – dye molecules within the cell membrane redistribute charge 
within the molecule when the cell depolarises. This charge shift within each molecule 
shifts the emission spectrum of the dye. 
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In practice, the first three mechanisms are less suitable for cardiac optical mapping. The 
“On-Off” and “Redistribution” mechanisms require significant molecular translocation, 
which is too slow to faithfully track membrane potential changes. The “Reorientation” 
mechanism is fast and displays submillisecond kinetics, but the magnitude of fluorescence 
change is too small. In practice, most of the commonly used potentiometric dyes shift their 
emission spectra by the electrochromism. 
 
2.6.2.2 Motion artefact 
One of the main technical challenges of optical mapping studies is dealing with motion 
artefact. The vigorous contractions of heart muscle move the heart within the optical 
mapping chamber and prevent the recording of optical action potential signals from the 
same site on the epicardial surface over the course of a cardiac cycle. Multiple strategies 
have been developed to reduce or eliminate motion artefact. Mechanical stabilisation 
within the optical mapping chamber can successfully reduce movement artefacts. Most 
optical mapping chambers are composed of two main components, i.e. the main front 
chamber and a second “rear component” that can be slid in as a piston into the front 
component to make a watertight seal. The position of the rear component can be adjusted 
so that it applies gentle pressure onto the posterior surface of the heart, thus pushing the 
heart onto the surface of the front component. This gentle wedging of the heart between 
the two main components stabilises the heart mechanically. 
 
However, mechanical stabilisation alone is often insufficient to remove all motion 
artefacts and there are concerns that excessive pressure applied to wedge the heart may 
generate ischaemia. Pharmacological agents are an alternative strategy to remove motion 
artefact, and have been used to uncouple cardiac cardiac excitation from contraction, thus 
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removing motion without altering electrical activity. Excitation-contraction uncouplers 
include 2,3-butanedione monoxime (2,3-BDM), a non-competitive inhibitor of myosin II, 
and cytocholasin D, an agent that inhibits actin filament polymerisation (Biermann et al., 
1998). However, these agents are not ideal as they have off-target pharmacological effects 
on ion channels and have both been shown to also alter action potentials, restitution and 
Ca2+ handling (Cheng et al., 2004; Kettlewell et al., 2004).  
 
Blebbistatin is a newer excitation-contraction uncoupler that acts to inhibit the adenosine 
triphosphatases (ATPases) associated with class II myosin isoforms (Straight et al., 2003), 
and was used in the optical mapping studies described in this thesis. Figure 2-11 shows 
transmembrane voltage signals before and during blebbistatin perfusion. Recent studies 
have shown that blebbistatin is a selective excitation-contraction uncoupler and has no 
significant effects on pacemaker activity, conduction, repolarisation, and intracellular 
calcium cycling (Fedorov et al., 2007). However, there are recent reports that blebbistatin 
can prolong monophasic action potential durations, as well as increasing the maximum 
slope of restitution and altering fibrillation threshold (Narang et al., 2011). Another 
limitation of using an excitation-contraction uncoupler is its effect on myocardial 
energetics, where the removal of myocardial contraction liberates ample ATP for 
electrophysiological processes (Sebbag et al., 2003), which may mask pathological 
processes that would have otherwise be observed in a contracting heart (Lou et al., 2011). 
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Figure 2-11: Effects of excitation-contraction uncoupling on movement artefact. Top: 
Significant movement artefact seen on transmembrane voltage signals. In this example, in 
addition to the artefact due to contraction, there is a second artefact whose periodicity does 
not match the periodicity of stimulation. This second component may be due to motion 
caused by the peristaltic pump. Bottom: Movement artefact eliminated with blebbistatin.  
 
2.6.2.3 Optics 
Fluorescent light emitted from the heart preparation must be filtered and focused onto a 
detector. The optics of an optical mapping system typically consist of a collecting lens, 
one or more dichroic mirrors, focusing lenses, and filters. The light from the heart 
preparation passes through the collecting lens before being split with dichroic mirrors, 
which will reflect light below a certain wavelength, whilst allowing light above that 
wavelength to pass through. The light then passes through the appropriate emission filter 
and is focussed onto the detector or camera. 
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2.6.2.4 Detectors 
Detectors are required to detect the optical signal, measure their intensity and convert that 
into an electrical signal. There are three main classes of photodetectors commonly used 
for cardiac optical mapping experiments: (1) Photodiode arrays (PDAs), (2) Charge-
coupled devices (CCDs), and (3) Complementary metal–oxide–semiconductor (CMOS) 
detectors. For the experiments described in this thesis, a 256-photodiode array detector 
was used.  
 
Photodiode arrays consist of multiple photodiodes configured in a 2-dimensional array, 
with each diode detecting optical signals from a specific location on the epicardial surface 
of the heart. Each photodiode instantaneously converts photoexcited charge carriers into 
current flow, with the magnitude of current proportional to the detected light intensity, and 
the current is then converted to voltage using a preamplifier. Each photodiode is 
connected to its own preamplifier and the current from multiple diodes are converted and 
amplified in parallel. This parallel readout of the photodiodes provides a high temporal 
resolution, which is a major advantage of PDAs over CCD systems, where pixels are read 
out sequentially. PDAs also generally have a greater dynamic range and better signal-to-
noise ratios compared to CCD cameras. However, PDAs have poorer spatial resolution as 
typical systems consist of only several hundred photodiodes, whereas CCD arrays can 
contain up to several hundred thousand elements. Although photodiode arrays and CCD 
cameras have been the two main forms of detectors used for cardiac optical mapping, over 
recent years, CMOS cameras have been developed for optical mapping and these newer 
cameras have both excellent temporal and spatial resolutions. 
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2.6.3 Optical mapping protocol 
Hearts were mounted and stabilised on a Langendorff apparatus as described above in 
Section 2.5.3. For each heart, a stimulating electrode was placed on the anterolateral left 
ventricle. Hearts were then placed and perfused inside a perspex optical mapping chamber 
(Cairn Research, Faversham, UK) (Figure 2-12). Hearts were positioned so that the 
anterolateral wall of the left ventricle was facing the optical mapping apparatus. Two non-
contact sensing silver electrodes (GRASS F-E2-48 needle electrodes, GRASS 
Technologies, UK) were connected to the modified optical mapping chamber to record 
field electrocardiograms. These electrodes were connected to a Bioamplifier and 
PowerLab data acquisition system (AD Instruments, Sydney, Australia), and the signals 
were recorded at a sampling frequency of 1 kHz and displayed using CHART 5.5 software 
(AD Instruments, Sydney, Australia).  
 
Hearts were perfused with a fixed-flow system, using a Peri-Star Pro peristaltic pump 
(World Precision Instruments-Europe, Stevenage, UK). Hearts were perfused at a CFR of 
15ml/min during stabilisation. After the initial 10-minute stabilisation period, hearts were 
stained with a voltage-sensitive dye (25µl of 1mg/ml RH237 in dimethyl sulfoxide; 
Invitrogen, Paisley, UK). The bolus of RH237 was given over 30 seconds via a side-arm 
on the Langendorff apparatus. Hearts were also perfused with blebbistatin (Sigma-
Aldrich, Gillingham, UK) to reduce and eliminate motion artefacts during the experiment. 
A loading concentration of 30µM was used until motion artefact was eliminated, and a 
maintenance concentration of 10µM was used for the remainder of the experimental 
period. 
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Figure 2-12: Optical mapping experiments. Top left: Optical mapping experimental set-
up. Top right: heart in perspex optical mapping chamber. Bottom: Transmembrane voltage 
transients recorded during sinus rhythm (SR), ventricular tachycardia (VT) and ventricular 
fibrillation (VF). 
 
To record optical action potentials, an optical mapping set-up as shown in Figure 2-12 was 
used. Monochromatic LEDs were used to excite the epicardial surface of the hearts 
(excitation wavelength 530nm). Light was then collected through a lens and split with a 
dichroic mirror at 630 nm. The longer wavelength portion was passed through an emission 
filter (660 nm) and this was then detected using a Hamamatsu 256 photo-diode array 
detector (16 x 16 square pixel array) (Cairn Research, Faversham, UK). The 16 x 16 array 
corresponded to an area of 16mm x 16mm. These optical signals were recorded at a 
sampling rate of 1kH with a spatial resolution of 1mm. The shorter wavelength light 
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portion was focused onto a charge-coupled device (CCD) camera to obtain plain images. 
The heart was brought into focus by adjusting the distance between the optical mapping 
chamber and the lens until the heart was in clear focus on the CCD plain image. Optical 
imaging data was acquired and displayed using QRecord software (Cairn Research, 
Faversham, UK). 
 
Signals were recorded at baseline during both sinus rhythm and during pacing from the 
left ventricular free wall (cycle length 200ms, 300bpm, stimulus 1mA) using a MicroPace 
stimulator (MicroPace, Auckland, New Zealand). These signals were recorded for 2 
seconds at a time. The QRecord software temporarily stores all data from the previous 30 
seconds in a cache. In the event of an arrhythmia, data from the seconds preceding the 
onset of arrhythmia were retrospectively retrieved from the cache and saved.  
 
2.6.4 Optical mapping data analysis 
All optical mapping data were analysed offline using Optiq software (Cairn Research Ltd, 
Faversham, UK) (Figure 2-13). Each file contained a two-second recording of 
fluorescence intensity for each of the 256 pixels. As previously described, changes in the 
intensity of fluorescence signal corresponded to changes in transmembrane voltage. The 
256 pixels on the 16 x 16 array corresponded to a 16mm x 16mm area on the mapping 
chamber, which recorded signals not only from the entirety of the anterior left ventricular 
epicardium, but also from areas around the heart in the mapping chamber. Therefore, for 
each file, user input was required to select the appropriate pixels that contained signals 
from the ventricular myocardium for analysis. These pixels were selected based on 
viewing the activation video on Optiq software and comparing with the plain image taken 
on the CCD camera. Only pixels with data clearly resembling that of ventricular optical 
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action potentials were selected. Typically, an area of between 8x8 to 10x10 pixels was 
selected for analysis.  
 
 
Figure 2-13: Optical mapping analysis. A screenshot from the Optiq analysis software: 
Six pixels were selected on the map on the top left. The transmembrane voltage transients 
for these pixels were displayed on the top right of the screen. 
 
Once the appropriate pixels were selected for analysis, a series of in-built analyses were 
performed. Three different measures of action potential duration (APD) were obtained. 
These measures of APD (APD90, APD75 and APD50), in milliseconds, corresponded to 
action potential durations measured to 90%, 75% and 50% of repolarisation respectively. 
Each two-second recording contained on average 10 optical action potentials (based on a 
pacing cycle length of 200ms). Up to 3 separate optical action potentials were analysed for 
each file, and an average value was taken. The dispersion of action potential durations was 
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calculated from these APD values, and presented as the standard deviation (S.D.) of 
optical action potential durations. 
 
Two variables were quantified to describe the upstroke of the action potential. Firstly, the 
rise time (in milliseconds) for each optical action potential was obtained – this was 
defined as the time taken for the fluorescence signal to rise from baseline to peak 
amplitude. Secondly, a value for maximum first derivative of the fluorescence signal 
(dF/dt max) was obtained – this is the maximum slope of the optical action potential 
upstroke. A value, in arbitrary units (U), was also obtained for the amplitude of the action 
potential. 
 
In addition to obtaining values to describe the optical action potential upstroke and 
duration as above, each pixel was also assigned an activation time to generate isochronal 
activation maps, and to calculate local conduction velocities and vectors. Local activation 
times were assigned based on the maximum first derivative of the fluorescent signal (dF/dt 
max) (Efimov et al., 2004). Activation maps were generated and local conduction 
velocities and vectors were derived, using MATLAB R2010a software (MathWorks, 
Massachusetts, USA). Activation maps were generated from the activation time data using 
the in-built “Contour” function on MATLAB. Local conduction velocities and conduction 
vectors were calculated using the method previously described by Salama and colleagues 
(Figure 2-14) (Salama et al., 1994). Mathematicians Eugene Chang and Chris Cantwell 
helped to develop the MATLAB function to perform these analyses. 
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Figure 2-14: Local conduction velocity calculations. For each pixel, a gradient vector of 
activation was calculated by taking into account the activation times of the surrounding 
four pixels. The local conduction velocity has the same direction this vector and has a 
magnitude that is the inverse of magnitude of the gradient vector of activation. 
 
Upon assigning each pixel a conduction velocity and conduction vector value as shown in 
Figure 2-15, isochronal activation maps and local conduction velocity maps were 
generated on MATLAB using the “Contour” function and a graphical illustration of the 
distribution of conduction vectors was generated using the “Compass” function (Figure 2-
15). The dispersion of conduction velocity was calculated as the standard deviation (S.D) 
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of the local conduction velocity measurements. The dispersion of conduction vectors was 
calculated as the standard deviation (S.D.) of conduction vectors from the mean vector 
(Ding et al., 2010). 
 
 
Figure 2-15: Optical mapping analysis. Top left: Heart in optical mapping chamber. Top 
right: An isochronal activation map with superimposed local conduction vectors 
(magnitude and direction indicated by the length and orientation of arrows respectively). 
Bottom left: Dispersion of conduction vectors on a compass plot. Bottom right: Local 
conduction velocity map.  
 
2.7 Arrhythmia provocation studies 
In order to measure and compare the susceptibility of post-infarction hearts to ventricular 
tachyarrhythmias, two arrhythmia provocation protocols were performed on isolated, 
perfused hearts. Extrastimuli programmed electrical stimulation protocols were performed 
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to induce re-entrant arrhythmias, while isoprenaline pulse protocols were used to assess 
vulnerability of hearts to catecholamine-induced arrhythmias. 
 
 
Figure 2-16: Arrhythmia provocation protocols. Top: Ventricular tachycardia (VT) and 
ventricular fibrillation (VF) induced with and extrastimulus PES protocol. Bottom: 
Spontaneous arrhythmias during isoprenaline (ISO) pulse protocol (VE: ventricular 
ectopic, NSVT: non-sustained ventricular tachycardia). 
 
2.7.1 Principles of Programmed Electrical Stimulation 
Programmed electrical stimulation (PES) protocols are currently widely used in clinical 
electrophysiology and were first performed in the late 1960s by Hein Wellens and Phillipe 
Coumel (Durrer et al., 1967). These protocols were initially used to induce and terminate 
supraventricular tachycardias and to diagnose the mechanisms of these arrhythmias in 
individual patients. They were subsequently also used in the 1970s to induce ventricular 
tachycardias in patients, and it was found that PES could reproduce some clinical 
tachycardias (Wellens et al., 1972; Wellens et al., 1974). Studies using these protocols 
provided the first evidence that the majority of ventricular tachycardias in the post-
infarction setting were re-entrant in nature (Wellens et al., 1974). 
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Although initially used to induce and elucidate the specific tachycardia mechanisms in 
individual patients, programmed stimulation became recognised as a risk stratification tool 
to identify patients at risk of ventricular arrhythmias in the 1980s (Richards, 1983a; 
Richards, 1983b). Arrhythmia inducibility at PES became a recognised marker of 
increased risk of sudden cardiac death (SCD) in post-infarction patients (Wilber et al., 
1990; Buxton et al., 2000). A positive PES study was an eligibility criteria in some early 
defibrillator trials (Moss et al., 1996; Buxton et al., 1999), and was one of the criteria for 
implanting defibrillators in patients in the earlier versions of National Institute of Clinical 
Excellence (NICE) Guidelines to clinicians in the UK. 
 
However, in recent years, it has become recognised that PES alone is an inadequately 
sensitive or specific risk stratification tool to identify patients at risk of sudden cardiac 
death (Goldberger, 2010). This may partly be attributed to the fact that the risk of sudden 
cardiac death is a continuum, and any test that seeks to dichotomise risk and to divide 
patients into low- and high-risk groups based on an arbitrary cut-off will inevitably have 
inadequate sensitivity and specificity (Goldberger et al., 2011). It may also be partly 
explained by the fact that PES predominantly induces re-entrant arrhythmias, whilst 
sudden cardiac death is a syndrome caused not just by re-entrant ventricular arrhythmias, 
but also by non-reentrant tachyarrhythmias as well as bradyarrhythmias (Bloch Thomsen 
et al., 2010). A third reason is that the risk of sudden cardiac risk changes over time, and a 
single test at a single time-point is unlikely to accurately reflect the dynamic nature of 
SCD risk. 
 
Although an imperfect tool to dichotomise risk, PES remains a validated test to measure 
re-entrant arrhythmia thresholds and susceptibility on a continuum of risk, and is widely 
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applied to quantify arrhythmias susceptibility in experimental disease models (Hamlin, 
2007). Many variations of PES protocols have been used in such studies, but were all 
based on the same principles of the original protocols designed by Wellens et al (Durrer et 
al., 1967). A typical protocol involves pacing the heart at a fixed cycle length for a number 
of consecutive beats (S1 drive train) followed by an extrastimulus (S2). The S1-S2 
interval is then gradually reduced until S2 falls on the refractory period of the final S1 
beat. The protocol is then repeated with a second extrastimulus (S3) with gradually 
reducing S2-S3 intervals, followed by the addition of a third extrastimulus (S4) in the 
same manner. This is then repeated for a different S1-S1 interval. These extrastimulus 
PES protocols were designed based on the principle that a critically-timed extrastimulus 
may coincide with a vulnerable window when part of the myocardium has recovered from 
the previous activation whilst some parts remain refractory, thus setting up re-entry. 
 
2.7.2 Programmed Electrical Stimulation (PES) protocols 
Extrastimulus programmed electrical stimulation (PES) protocols were performed ex vivo 
to measure the vulnerability of hearts to re-entry arrhythmias (Figure 2-16), and are 
similar to those previously used by Lyon et al on isolated, perfused rat hearts (Lyon et al., 
2011). Protocols were modified from those used in the clinical cardiac electrophysiology 
labroratory (Wellens et al., 1972). PES protocols were performed using a reserviced 
MicroPace stimulator (MicroPace, Auckland, New Zealand), previously used for 
programmed stimulation in the clinical laboratory. Hearts were paced from the left 
ventricle with a 20-beat S1 drive train (cycle length 120ms, 500bpm, stimulus 1mA) 
followed by an extrastimulus with an S1-S2 coupling interval of 100ms. The S1-S2 
coupling interval was decreased at 2ms intervals until an arrhythmia was induced or until 
ventricular refractoriness. Subsequently, a second and a third extrastimulus (S3 & S4) 
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were introduced and the coupling intervals were also reduced progressively at 2ms 
intervals until refractory. All arrhythmias induced were recorded on CHART 5.5 software 
via a Powerlab data acquisition system (AD Instruments, Sydney, Australia), for offline 
analysis. 
 
The arrhythmia susceptibility of each heart at Programmed Electrical Stimulation was 
quantified by assigning it an Arrhythmia Inducibility Score. The score was based on that 
previously described in the literature (Belichard et al., 1994). Belichard et al described a 
score whereby hearts were deemed inducible for VT/VF if 6 or more ventricular beats 
were provoked by PES, and the VT/VF was classified as sustained if greater than 15 beats 
(equivalent of approximately 1 second) were provoked. Those definitions were used in 
this thesis. The definitions of VT/VF were different from the Lambeth Conventions used 
for spontaneous arrhythmias (Walker et al., 1988), where VT was defined as 4 or more 
ventricular beats. The higher cut-off of 6 beats for PES was in part because PES in rodent 
hearts often provoked short bursts of polymorphic VT of 4 beats of less, of unknown 
significance, and the higher cut-off of 6 beats was designed not to included these. 
 
An Arrhythmia Inducibility Score of 0 to 6 was assigned to each heart based on the 
number of extrastimuli required to induce VT/VF and on the sustained or non-sustained 
nature of arrhythmia induced: 6 = sustained VT/VF on S1S2 protocol, 5 = non-sustained 
VT/VF on S1S2 protocol, 4 = sustained VT/VF on S1S2S3 protocol, 3 = non-sustained 
VT/VF on S1S2S3 protocol, 2 = sustained VT/VF on S1S2S3S4 protocol, 1 = non-
sustained VT/VF on S1S2S3S4 protocol, 0 = no arrhythmia induced. 
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2.7.3 Isoprenaline Pulse Protocol 
Hearts were also subjected to isoprenaline (ISO) challenge as a second arrhythmia 
provocation measure (Figure 2-16). Hearts were perfused with 1µM isoprenaline (Sigma-
Aldrich) for 20 minutes and ventricular arrhythmias were documented. The electrogram 
was recorded using CHART 5.5 software via a Powerlab data acquisition system (AD 
Instruments, Sydney, Australia), for subsequent offline analysis. The total incidence of 
ventricular arrhythmias provoked by isoprenaline challenge was recorded. Classification 
of arrhythmias was performed as defined by the Lambeth Conventions (Walker et al., 
1988). 
 
2.8 Immunohistochemistry 
2.8.1 Principles of immunohistochemistry 
Immunohistochemistry is a technique used to determine the location and distribution of 
specific proteins. This technique is based on the principle of specific interactions between 
an antibody and its corresponding antigen. The primary antibody is designed to bind 
specifically to the protein under investigation. This antibody is formed by injecting an 
animal with a peptide sequence from the protein under investigation. The animal then 
detects this as a foreign protein and raises an immune response to clear the protein. As 
part of the humoral immune response, B-lymphocytes secrete antibodies that specifically 
target that peptide sequence. This antibody is then purified from the serum of the animal 
to be used to specifically target and bind to the protein of choice in immunohistochemistry 
experiments.  
 
Once the sample under investigation has been incubated with the primary antibody 
directed against the protein of choice, it is then incubated with a secondary antibody that 
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specifically targets the primary antibody. Secondary antibodies are conjugated to a 
fluorescent marker, which can be visualised under a microscope using an epifluorescence 
filter or by confocal microscopy. The specific binding of primary antibody to protein and 
of secondary antibody to primary antibody means that the locations of the fluorescent 
signal as visualised under the microscope correspond to the locations of the protein of 
interest. Although an excellent technique for protein localisation, some limitations include 
potential false-negatives due to poor antibody penetrance into tissue and false-positives 
due to non-specific antibody binding. 
 
2.8.2 Cryosectioning of frozen tissue and slide preparation for Cx43 immunolabelling 
Hearts from in vivo and ex vivo experiments were frozen and stored at -80oC. Hearts were 
then sectioned on a cryostat (Thermo Shandon, Thermo Scientific, UK) to produce 
sections of 10µm thickness, and slices were collected on glass slides (VWR, UK) 
previously coated with Poly-L-lysine. Slides were stored at -20oC until they were used for 
immunolabelling (Section 2.8.3) or histological staining (Section 2.10). 
 
2.8.3 Cx43 Immunolabelling Protocol 
The majority of the Cx43 immunolabelling experiments were performed by Simon Cooper 
and Jeremy Kalindjian, who were fourth-year Imperial College London medical students 
doing BSc projects under my supervision. Slides were fixed and permeabilised with 100% 
methanol at -20oC for 5 minutes. The remainder of the protocol was performed at room 
temperature. Following two 5-minute washes with phosphate buffered saline (PBS), 
sections were incubated with a blocking buffer (1% bovine serum albumin made up in 
PBS) for 30 minutes. Slides were then incubated with the primary anti-Cx43 antibody for 
2 hours. A mouse anti-Cx43 immunoglobulin G (IgG) raised against a synthetic peptide 
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corresponding to positions 252 to 270 of rat Cx43 (MAB 3067 Chemicon International) 
was used at a 1:1000 dilution in BSA block buffer solution. Following incubation with the 
primary antibody, slides were again washed with PBS (3 x 5-minute washes) before 
incubation with the secondary fluorescent antibody. A goat Cy3-conjugated anti-mouse 
antibody (Chemicon) was used in a 1:500 dilution in BSA block buffer solution. Sections 
were then washed again with PBS (3 x 5-minute washes) before being mounted with 
Vectashield 1400 Hard Set mountant (Vector Laboratories, UK), and glass cover slips 
were applied onto the slides. Immunolabelled slides were stored at +4oC in the dark to 
preserve fluorescence. 
 
2.8.4 Analysis of Cx43 distribution 
Distribution of Cx43 was quantified using a previously-described Cx43 lateralisation 
score (Figure 2-17) (Patel et al., 2001). Analysis was performed under a Nikon Eclipse 
TE200 epifluorescent microscope at a magnification of x40. Each microscopic field was 
assigned a Cx43 lateralisation score based on the proportion of cells within that field that 
had Cx43 immunolabel on the lateral membranes. A score of 1 to 5 was assigned (Score 1 
= <10% of cells in the microscopic field had lateralised Cx43, Score 2 = 10% to 19.9%, 
Score 3 = 20% to 29.9%, Score 4 = 30% to 39.9%, Score 5 = 40% or more). Selected 
sections were also examined on a scanning confocal laser microscope (Zeiss Pascal, Carl 
Zeiss Microimaging), and images processed using Zeiss LSM image Browser (Carl Zeiss 
Microimaging) and analysed.  
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Figure 2-17: Cx43 lateralisation scoring: Examples of a low score with little Cx43 
lateralisation and an example of a high score with significant lateralisation (as denoted by 
arrows). 
 
2.9 Immunoblotting 
2.9.1 Principles of SDS-PAGE and Western Blotting 
Western blotting was used to quantify the level of expression of Cx43. This is a multistep 
procedure that involves separating proteins from tissue homogenates by their molecular 
weight using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
transferring the proteins to a membrane, and then probing for the protein of interest using 
specific antibodies. 
 
SDS-PAGE is a means of separating proteins by their electrophoretic mobility, which is a 
function of molecular weight and length of the polypeptide chain. After lysis of cells and 
solubilisation of proteins, protein samples are denatured to remove secondary, tertiary and 
quarternary protein structures using SDS and reducing agents such as mercaptoethanol. 
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This creates long linear polypeptide chains that become coated with negatively charged 
SDS, which overwhelms any positive charge in the protein molecule. The binding of SDS 
to the molecule is dependent on the length of the protein. Therefore, the protein mobility 
depends exclusively on its size and not on its shape or its intrinsic charges that depend on 
the presence of charged amino acid residues. 
 
Denatured protein samples are then loaded onto a polyacrylamide gel and an electrical 
current applied. The proteins, which are coated with negatively charged SDS, will migrate 
towards the positive electrode. Because the polyacrylamide gel is made up of a meshwork 
of polymerised fibres, the proteins have to pass through the pores within this mesh to 
migrate towards to positive electrode. This creates a condition where larger proteins move 
more slowly through the acrylamide gel matrix whereas smaller proteins can move faster. 
Electrophoretic mobility is therefore a function of molecular weight, and the separation of 
proteins by polyacrylamide gel electrophoresis (PAGE) results in distinct protein bands 
separated based on molecular weight. 
 
After separation by electrophoresis, the proteins are transferred by electroblotting onto a 
polyvinylidene fluoride (PVDF) membrane, which binds protein with high affinity. The 
membrane is then incubated with a primary antibody directed against the protein of 
choice, using the same principles described in Section 2.8.1 for immunohistochemistry. 
Because the PVDF membrane binds all proteins, the membrane is blocked by incubation 
with non-fat dry milk (NFDM) to prevent non-specific binding of the primary antibody. 
Following incubation with the specific primary antibody, the membrane is incubated with 
alkaline phosphatase-conjugated secondary antibodies. The alkaline phosphatase 
precipitates the combination of nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-
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indolyl-phosphate (BCIP), to form a blue colour for visualisation by eye. The quantity of 
protein in each band is then quantified by densitometry. 
 
To correct for variations in protein loading onto the different lanes of the polyacrylamide 
gel, a sister gel is stained using Coomassie blue, which is a general protein stain. Since the 
vast majority of total protein in the heart is constituted by actin and myosin, the bands for 
actin and myosin on the Coomassie stained gel can be quantified and used to correct for 
differences in protein quantity across different lanes. 
 
2.9.2 Separation of junctional and non-junctional connexin protein 
In some Western blotting experiments, junctional Cx43 (docked) and non-junctional Cx43 
(undocked) were quantified separately. To separate out the junctional and non-junctional 
Cx43, a weak detergent (Triton-X 100) was used to solubilise single connexons. As 
docked, gap junctional channel connexons are resistant to solubilisation by this weak 
detergent, centrifugation of this sample will produce a supernatant containing the non-
junctional connexin proteins, with the pellet containing the gap junctional connexin 
proteins (Musil & Goodenough, 1991). The pellet can then be dissolved in a stronger 
detergent (SDS), and both the supernatant (containing non-junctional connexins) and the 
dissolved pellet (containing gap junctional connexins) can then be processed separately 
using the principles of SDS-PAGE described above to quantify junctional and non-
junctional Cx43 separately. 
 
2.9.3 Protocol for Cx43 Western Blotting 
The majority of Western blotting experiments were performed by Eugene Chang, an 
Imperial College London MRes student, and Amanda Owusu-Agyei, a fourth-year 
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Imperial College London medical student, both of whom were doing projects under my 
supervision, as well as by Pravina Patel. Tissue previously stored at -80oC was pulverised 
to a fine powder in liquid nitrogen. For experiments where total Cx43 was quantified 
without separating out junctional Cx43 from non-junctional Cx43, the samples were 
solubilised with a solubilisation buffer (SB20 buffer) containing 20% sodium dodecyl 
sulphate (SDS 20%, 0.1mol/l Tris pH 6.8, 10mmol/l EDTA) (Coppen et al., 1999), to give 
a concentration of 0.1mg frozen sample per 1µl buffer, before mercaptoethanol was added 
to give a final concentration of 2.5% mercaptoethanol.  
 
For experiments where junctional (docked) Cx43 was separated from non-junctional 
(undocked) Cx43, Triton extraction buffer (which contained 1% Triton-X 100 and a 
protease inhibitor cocktail (P8340, Sigma-Aldrich, UK) in a Tris/NaCl solution) was 
added to the powder samples to give a concentration of 0.1mg frozen sample per 1µl 
buffer, and sonicated and centrifuged at 20,000G for 30 minutes. The resulting 
supernatant contained non-junctional Cx43 (undocked) whilst the pellet contained 
junctional Cx43 (docked). Following extraction of the supernatant, the pellet was re-
suspended in SB20, using the same volume as the Triton-X100, and sonicated for 30 
seconds to lyse the double membranes. Equal volumes of Triton extraction buffer were 
added to the docked samples and SB20 was added to the undocked sample so that all 
samples were in the same ratio of 1:1 Triton extraction buffer/SB20 to prevent any 
differences in migration in the gel due to a difference of detergent concentrations. Samples 
were vortexed thoroughly and stored at -80˚C. Junctional and non-junctional Cx43 were 
quantified separately. Protein estimation was then performed based on the Lowry method 
(BioRad DC Assay kit containing reagent S and solutions A and B).  
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SDS-PAGE gels were prepared and run using a BioRad Mini-PROTEAN Tetra 
Electrophoresis System. Polyacrylamide gels were made according the Laemmli 
discontinuous buffer system consisting of a lower separating gel and an upper stacking 
gel. The separating gel (12.5%) was made up using 4.5ml 30% Acrylamide/0.8% Bis, 2.5 
ml 1.5M Tris pH 8.8, 3.1ml dH2O, 0.1ml 10% SDS, 0.05ml 10% ammonium persulfate 
(APS) and 0.05ml 10% tetramethylethylene diamine (TEMED), with the APS and 
TEMED added last to start polymerisation.  The stacking gel (4.5%) was made up using 
1.5ml 30% Acrylamide/0.8% Bis, 2.5ml 1.5M Tris pH 8.8, 5.7ml dH2O, 0.1ml 10% SDS, 
0.1ml 10% APS and 0.1ml 10% TEMED. The upper and lower buffer reservoirs were 
filled with running buffer (0.192M Glycine/ 0.025M Tris/ 0.1% SDS). 5µg of protein was 
loaded in each well and the gel was run at 60V until the dye front was through the 
stacking gel, and subsequently run at 150V. With the protein bands separated, the gel was 
electrophoretically transferred onto a polyvinylidene fluoride membrane (PVDF) using the 
BioRad Mini Trans-Blot Electrophoretic Transfer Cell system at 6V/cm (30V) overnight 
in a tank filled with transfer buffer (running buffer with 10% methanol). 
 
Following transfer, the PVDF membrane was blocked with non-fat dry milk (NFDM) 
block (Tris buffered saline pH7.6 (TBS)/4% NFDM/ 0.1% Tween20/1% BSA) for 1 hour. 
The membrane was then incubated with a primary antibody directed against Cx43 (MAB 
3067 Chemicon International) at 1:500 dilution for 1 hour. After washes with wash buffer 
(TBS/ 0.1% Tween20/ 1% BSA), the membrane was incubated with an alkaline 
phosphatase conjugated anti-mouse secondary antibody (Pierce) at 1:2500 dilution for 1 
hour, and then developed using the nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-
indolyl-phosphate (BCIP) system (Promega Corp) to allow visualisation of Cx43 bands. 
The combination of NBT and BCIP was precipitated by the alkaline phophatase and 
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allows a blue colour to develop at the site of enzymatic activity. The amount of Cx43 in 
each band was quantified by densitometry to measure the intensity of each band. For each 
immunoblot, a sister gel was stained with Coomassie blue stain (50% methanol/ 10% 
acetic acid/ 0.1% Coomassie blue). Cx43 band intensities were corrected for total protein 
loading using the actin band on a coomassie-stained gel.  
 
Figure 2-18: Sample Western blot showing three distinct bands for Cx43. These bands are 
often referred to P2, P1 and P0, with reference to the phosphorylation status of the 
carboxy-terminus of the Cx43 protein. Tissue subjected to ischaemia (lanes 2, 3 and 5) 
had greater proportions of P0. 
 
2.10 Myocardial histology 
Histological staining was performed to assess infarct size and morphology. Haematoxylin 
and Eosin (H&E) is a staining protocol to stain for cell nuclei and cytoplasm. 
Haematoxylin stains the nuclei blue and eosin stains the eosiniophilic structures in the 
cytoplasm pink. Masson’s Trichrome is a three-colour staining protocol to distinguish 
cells from surrounding connective tissue. Nuclei stain dark blue, cytoplasm and muscle 
fibres stain red and collagen displays blue colouration. The majority of histological 
staining experiments were performed by Simon Cooper and Jeremy Kalindjian, who were 
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fourth-year Imperial College London medical students doing BSc projects under my 
supervision.  
 
2.10.1 Haematoxylin and Eosin (H&E) Staining 
Slides were sectioned into 10µm slices as described in Section 2.8.2. Sections were fixed 
in 100% methanol at -20˚C for 5 minutes, followed by staining in Harris Haematoxylin 
solution for a further 5 minutes. Slides were then briefly placed under running tap water 
and dipped quickly in an acid/alcohol mixture (70% ethanol/1% HCl) before being stained 
with eosin for 2 minutes. Slides were washed to remove excess stain before dehydration 
through graded ethanols (70%, 90%, 100%, and 100%) for 30 seconds each. Slides were 
placed in xylene (3 x 5 minutes) before being mounted with DPX mounting medium 
(Sigma-Aldrich). 
 
2.10.2 Masson’s Trichrome Staining 
Slides were sectioned into 10µm slices as described in Section 2.8.2. Sections were fixed 
in 100% methanol at -20˚C for 5 minutes, followed by staining in Harris Haematoxylin 
solution for a further 5 minutes. After washing with deionised water, the sections were 
stained in Biebrich Scarlet – Acid Fuschin for 10 minutes and then rinsed with deinonised 
water. Sections were then differentiated in a 50%-50% mixture of Phosphotungstic and 
Phosphomolybdic acid solution for 10 minutes followed by staining with Anniline blue 
staining for 1 minute. Slides were then rinsed again before before differentiation in 1% 
acetic acid for 5 minutes and dehydration through graded ethanols (70%, 90%, 100%, and 
100%) for 30 seconds each. The slides were then dipped in xylene (three 5-minute 
periods). Finally, coverslips were applied with DPX mounting medium (Sigma-Aldrich). 
Slides were stored at room temperature. 
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2.10.3 Measurement of infarct size 
Cryostat sections (10 µm) stained with Masson’s trichrome were used for infarct size 
analyses. Digital images were acquired with high resolution scanning of slides using (HP 
Scanjet G2710). To measure infarct size, planimetry analysis was performed offline using 
Adobe Photoshop CS3 v10.0. Using a previously validated planimetry protocol, the 
endocardial and epicardial circumferences of the infarct were measured for each section, 
and the infarct size quantified as the proportion of the endocardial and epicardial 
circumference bounded by the infarct across the different slices of the heart (Pfeffer et al., 
1991; Pfeffer et al., 1985). The extent of infarction was measured by this method instead 
of measuring volumes as the latter will underestimate the original loss of myocardium 
because of the thinning of the infarct and the compensatory hypertrophy of remote non-
infarcted myocardium (Pfeffer et al., 1979).  
 
2.10.4 Histomorphometry of the infarct border zone 
Masson’s Trichrome-stained sections were used for histomorphometry to assess the 
heterogeneity of fibrosis. All analyses of images were performed blinded to treatment 
group. The infarct border zone (IBZ) was localized under light microscopy using a Nikon 
–Eclipse TE200 microscope. Digital images were acquired using a Nikon digital sight DS-
Vi1 camera and NIS-Elements BR 3.2 software.  The IBZ was sampled systematically by 
panning around the IBZ at a constant tracking rate and images were acquired every 5 
seconds until the entire IBZ was sampled.  
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Figure 2-19: Image processing for histomorphometry. (1) A sample microscope image of 
a Masson’s Trichrome stained infarct border zone. (2) This image was converted into an 
RGB stack and grayscale image generated. (3) Thresholding and smoothing were then 
performed on ImageJ to accurately identify islands of fibrosis, allowing values for length 
of interface (yellow lines) and area of fibosis (red area) to be derived. (4) Subsequent 
overlay of lines of interface (yellow lines) on original microscope image showing good 
correlation (Scale bar = 100µm).  
 
Images were then analysed offline using ImageJ Software (NIH). As shown in Figure 2-
19, each image was converted into a RGB stack and the Red colour image of the RGB 
stack was used for analysis as this allowed the greatest differentiation between fibrosis 
and surviving myocardium. Thresholding and smoothing were then performed to 
accurately identify the islands of fibrosis and the lines of interface between fibrosis and 
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surviving myocardium. The areas covered by fibrotic tissue and the lengths of interface 
were quantified. 
 
The heterogeneity of fibrosis was then quantified using a novel Interface Complexity 
Ratio, defined as the ratio of the length of interface between fibrosis and surviving 
myocardium to the area of fibrosis in that microscopic field (Figure 2-20). Infarct border 
zones with greater heterogeneity of fibrosis have greater ratios, i.e. greater interface 
between fibrotic and myocardial tissue per unit area of fibrosis. The inter-observer and 
intra-observer coefficients of variation for this method were 12% and 10% respectively. 
 
Figure 2-20: Infarct Border Zone Histomorphometry. The Interface Complexity Ratio 
was used to quantify heterogeneity of fibrosis. As shown by the three hypothetical 
examples of infarct border zone morphologies, complex heterogeneous scarring would 
produce high ratios, whereas homogeneous scarring would produce low ratios. 
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2.11 Statistical analysis 
Statistical analyses were performed using Prism 5.0 software (GraphPad Software, 
California, USA). Results in the text are presented as the arithmetic mean ± standard error 
of the mean (S.E.M.). Error bars on graphs represent the standard error of the mean. The 
Student’s t-test was used to compare means of two groups. Analysis of variance 
(ANOVA) tests were performed to compare mean values between multiple groups and 
post-hoc Tukey’s test was subsequently used if ANOVA was significant. Non-parametric 
equivalents were used where appropriate. The logrank test was used to compare freedom 
from reperfusion arrhythmias between groups. P<0.05 was considered significant. Non-
significant results are referred to as NS (i.e. not significant). 
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Chapter 3: 
Establishing an ex vivo 
ischaemia-reperfusion model 
to study reperfusion arrhythmogenesis 
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3.1 Introduction 
3.1.1 Reperfusion ventricular arrhythmias 
Ventricular arrhythmias, can occur within seconds of restoration of blood flow to 
previously ischaemic myocardium, as initially shown by Tennant and Wiggers just under 
a century ago (Tennant & Wiggers, 1935). Reperfusion after brief periods of ischaemia, 
lasting seconds to minutes, occurs in the context of coronary artery vasospasm (Prinzmetal 
et al., 1959), or unstable angina, and is associated with reperfusion ventricular arrhythmias 
(Tzivoni et al., 1983). Reperfusion after longer periods of ischaemia lasting several hours 
occurs during percutaneous coronary intervention for patients with acute myocardial 
infarction, which is also associated with reperfusion arrhythmias (Mehta et al., 2004). 
 
3.1.2 Mechanisms of reperfusion arrhythmias 
The arrhythmogenic mechanisms that underlie reperfusion VT and VF are thought to 
relate to the abrupt electrophysiological and biochemical changes brought about by the 
restoration of blood flow (Manning et al., 1984). Myocardial ischaemia causes a series of 
progressive electrophysiological changes, including the slowing of action potential 
upstroke, the reduction in action potential duration and gap junction uncoupling (Akar & 
Akar, 2007). Subsequent reperfusion of ischaemic myocardium triggers rapid restoration 
of action potentials towards that of pre-ischaemic levels (Murdock et al., 1980; Kaplinsky 
et al., 1981). The abrupt recovery of action potentials is not equally rapid in the first few 
seconds, and there is marked spatial heterogeneity in action potentials immediately after 
reperfusion (Downar et al., 1977), which may contribute to the occurrence of reperfusion 
arrhythmias by predisposing to re-entry (Corr & Witkowski, 1983; Wit & Janse, 2001). 
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3.1.3 Ex vivo models to study reperfusion arrhythmias 
The ex vivo isolated rat heart preparation, as described in Section 2.5, is well suited to 
arrhythmia and electrophysiology studies, and has been extensively used to study the 
arrhythmic effects of acute ischaemia and reperfusion (Curtis et al., 1987; Manning & 
Hearse, 1984). The consistent nature of rat coronary anatomy and the lack of collateral 
arterial blood supply in rat hearts make it a suitable species for experimental studies of 
reperfusion arrhythmias (Johns & Olson, 1954; Curtis et al., 1987).  Several factors are 
known to be determinants of susceptibility to reperfusion-induced ventricular arrhythmias 
in experimental ischaemia-reperfusion studies, and these need to be considered when 
deciding on the appropriate design for a model to study reperfusion arrhythmias. One key 
factor that determines reperfusion arrhythmia susceptibility in experimental models is the 
size of the ischaemic zone (Curtis & Hearse, 1989b). It is also known that the duration of 
ischaemia prior to reperfusion is a determinant of reperfusion arrhythmia susceptibility 
(Manning & Hearse, 1984). This relationship between ischaemia duration and reperfusion 
arrhythmia incidence has been shown to be bell-shaped for multiple species, though the 
time window of vulnerability varies from species to species (Manning & Hearse, 1984).  
 
3.1.4 Effect of heart rate on reperfusion arrhythmias 
It has been shown in ex vivo experimental studies that heart rate during these experiments 
can alter susceptibility to reperfusion arrhythmias (Bernier et al., 1989). Hearts paced at 
faster heart rates were shown to have increased incidences of both ischaemia- and 
reperfusion-induced ventricular arrhythmias. However, it is unclear if the heart rate during 
ischaemia or the heart rate at reperfusion is more important in determining reperfusion 
arrhythmia susceptibility. There are several plausible mechanistic explanations as to why 
either may be important. 
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Increased heart rates during ischaemia can accelerate the development of ischaemia, with 
greater heart rates leading to greater degrees of ischaemic injury and increased arrhythmia 
susceptibility upon reperfusion. The heart rate at reperfusion may also be important as 
increased heart rates during reperfusion can increase the slope of the APD restitution 
curve, thus increasing likelihood of alternans, wavebreak and fibrillation (Nolasco & 
Dahlen, 1968). Increased heart rates at reperfusion may also increase cytosolic calcium 
concentrations and increase propensity to delayed afterdepolarisations and triggered 
arrhythmias. The importance of heart rate at reperfusion in determining reperfusion 
arrhythmia susceptibility was demonstrated in a study showing that vagal stimulation to 
reduce heart rate at reperfusion reduced reperfusion VF incidence (Zuanetti et al., 1987). 
 
The following studies described in the chapter were performed: (1) to determine the 
optimum ischaemia duration to be used to assess the effects of gap junction modulation on 
reperfusion arrhythmogenesis, (2) to characterise the effects of heart rate on reperfusion 
arrhythmias, and (3) to characterise the electrophysiological changes that occur during 
acute regional ischaemia and reperfusion in this model. 
 
3.2 Methods 
3.2.1 Studies to assess the effects of ischaemia duration on reperfusion arrhythmias  
3.2.1.1 Ischaemia-reperfusion protocol 
The incidence of reperfusion arrhythmias is influenced by the duration of ischaemia 
preceding reperfusion (Manning & Hearse, 1984). For most species, the relationship 
between the duration of ischaemia and the incidence of reperfusion arrhythmias is bell-
shaped in nature. This relationship between ischaemia duration and reperfusion arrhythmia 
incidence in isolated, perfused Sprague-Dawley rat hearts in our system was examined.  
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Thirty Sprague-Dawley rat hearts were explanted and perfused as described in Section 
2.5.3 and subjected to regional left anterior descending artery ischaemia as described in 
Section 2.5.4. Five different durations of ischaemia were studied (5, 6, 7, 8 and 9 minutes 
ischaemia), with 6 hearts in each of the five groups. Ischaemia was confirmed by a 
reduction in coronary flow rate (by weighing coronary effluent), and an alteration in 
electrogram morphology. The epicardial unipolar electrogram was recorded throughout 
ischaemia and for a further 15 minutes during reperfusion, and the incidence of 
arrhythmias was recorded. The primary endpoints were the incidences of reperfusion 
ventricular tachycardia (VT) and ventricular fibrillation (VF).  
 
3.2.2 Studies to assess the effects of heart rate on reperfusion arrhythmia incidence 
3.2.2.1 Ischaemia-reperfusion protocol 
Heart rate is thought to be a determinant of reperfusion arrhythmia incidence following 
regional ischaemia (Bernier et al., 1989), though it is unclear whether heart rate during 
ischaemia or heart rate at the time of reperfusion is more important in determining 
reperfusion arrhythmia risk. The influence of heart rates during regional ischaemia-
reperfusion on reperfusion arrhythmia incidence was studied. Atrial pacing and ivabradine 
(IVA), a selective If current blocker with heart rate lowering effects (Borer et al., 2003), 
were used to control and alter heart rates during the experiments. Ivabradine was kindly 
provided by Servier Laboratories, France.  
 
Twenty-five Sprague-Dawley rat hearts were explanted and perfused as described in 
Section 2.5.3 and subjected to 8 minutes of regional left anterior descending artery 
ischaemia followed by reperfusion as described in Section 2.5.4. As shown in Figure 3-1, 
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these hearts were divided into 5 groups with different hearts rates throughout the duration 
of ischaemia and at the time of reperfusion: 
 
Group 1 – Control (n=10): Hearts were subjected to 8 minutes ischaemia and followed by 
10 minutes reperfusion, without pacing or ivabradine. 
Group 2 – 1µM ivabradine (IVA, n=10): Hearts were perfused with 1µM ivabradine, 
starting 5 minutes before onset of ischaemia and then throughout the whole experiment. 
This group had reduced heart rates at onset of ischaemia, throughout the duration of 
ischaemia and at reperfusion. 
Group 3 – Ivabradine bolus at reperfusion (n=5): Hearts were perfused with a 1ml bolus 
of 100µM ivabradine one minute prior to reperfusion. This group had reduced heart rates 
at reperfusion. 
Group 4 – 1µM ivabradine + atrial pacing during ischaemia and reperfusion (n=5): 
Hearts were perfused with 1µM ivabradine, starting 5 minutes before onset of ischaemia 
and then throughout the whole experiment. In addition, hearts were paced from the right 
atrium with a bipolar stimulating electrode at 300 beats per minute (bpm) from the onset 
of ischaemia through to the end of the experiment. 
Group 5 – 1µM ivabradine + atrial pacing across reperfusion (n=5): Hearts were 
perfused with 1µM ivabradine, starting 5 minutes before onset of ischaemia and then 
throughout the whole experiment. In addition, hearts were paced from the right atrium at 
300 beats per minute (bpm) starting 30 seconds before reperfusion and for a further 
minute after onset of reperfusion. 
 
The primary endpoints were reperfusion ventricular tachycardia (VT) incidence and 
reperfusion ventricular fibrillation (VF) incidence.  
	   150 
 
Figure 3-1: Study protocol for acute ischaemia-reperfusion experiments to assess the 
effect of heart rate during ischaemia and reperfusion on reperfusion arrhythmia incidence. 
 
3.2.2.2 Global no-flow ischaemia with optical mapping protocol 
In order to assess the effects of heart rate on the rate of onset of ischaemia-induced 
electrophysiological changes, optical mapping experiments were performed on a global 
ischaemia model. Ten Sprague-Dawley rat hearts were isolated and perfused as described 
in Section 2.5.3, and stained with a voltage-sensitive dye (RH237) and perfused with an 
excitation-contraction uncoupler (blebbistatin) as described in Section 2.6.3, before being 
subjected to global ischaemia by cessation of flow through the aortic cannula. To assess 
the effects of heart rates, two groups were chosen to produce two extremes of heart rates 
during global no-flow ischaemia: 
 
Group 1 – Ivabradine (IVA): Hearts were perfused with 1µM ivabradine, starting 5 
minutes before the onset of global ischaemia, to reduce heart rate during global ischaemia 
(n=5). 
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Group 2 – Pacing at 300pbm: Hearts were paced at 300 beats per minute (bpm) from the 
onset of ischaemia through to the end of the experiment, to increase heart rate during 
global ischaemia (n=5). 
 
Transmembrane voltage (Vm) transients were recorded every 30 seconds to study the 
changes induced by global no-flow ischaemia. The primary endpoint was the time to loss 
of electrical excitability with ventricular pacing. The secondary endpoint was the 
conduction velocity after 10 minutes of global ischaemia. 
 
3.2.3 Optical mapping of regional ischaemia-reperfusion 
To assess the effects of regional ischaemia and reperfusion on action potentials and 
conduction velocities, optical mapping experiments were performed during regional 
ischaemia-reperfusion. Six hearts were isolated and perfused, and stained with a voltage-
sensitive dye (RH237) and perfused with an excitation-contraction uncoupler 
(blebbistatin) as described in Section 2.6.3. Hearts were then subjected to 8 minutes 
regional ischaemia by occluding the LAD artery as described in Section 2.5.4, followed by 
reperfusion. Hearts were perfused with a fixed-flow system, with hearts perfused at 
15ml/min at baseline and during reperfusion, and at 7.5ml/min during regional ischaemia. 
The flow rate during ischaemia was selected based on beating heart fixed-pressure 
perfusion ischaemia-reperfusion studies, where there was an approximate 50% reduction 
in coronary flow rate with regional ischaemia. Transmembrane voltage (Vm) transients 
were recorded pre-ischaemia, and at one-minute intervals during ischaemia and 
reperfusion. On each occasion, signals were recorded for 2 seconds during sinus rhythm 
and during ventricular pacing. Changes in action potentials and conduction velocity during 
ischaemia-reperfusion were analysed offline as described in Section 2.6.4. 
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3.3 Results 
3.3.1 Effects of ischaemia duration on reperfusion VT/VF incidence 
Reperfusion after several minutes of regional ischaemia often resulted in reperfusion 
ventricular tachycardia (VT) and ventricular fibrillation (VF), as shown in the example in 
Figure 3-2. The incidence of reperfusion VT/VF was dependent on the duration of 
ischaemia prior to reperfusion. For the range of ischaemia durations studied (5 to 9 
minutes ischaemia), there was an ascending sigmoidal relationship between the duration 
of ischaemia and the incidence of reperfusion VT/VF (Figure 3-3). This range of 
ischaemia durations formed the upstroke of the bell-shaped relationship between 
ischaemia duration and reperfusion arrhythmia incidence. 
 
Reperfusion VT incidence increased with ischaemia duration (5 minutes ischaemia: 0% 
VT, 6 minute: 33%, 7 minutes: 66%, 8 minutes: 83%, 9 minutes: 100%; χ2 test, p=0.01), 
with a similar pattern observed for reperfusion VF incidence (5 minutes ischaemia: 17% 
VF, 6 minute: 17%, 7 minutes: 66%, 8 minutes: 83%, 9 minutes: 83%; χ2 test, p=0.02). 
The steep parts of these sigmoidal relationships for both reperfusion VT and VF were 
between 6 and 8 minutes of ischaemia duration. 
 
The mean time to VT and time to VF were not significantly different for the different 
ischaemia durations (Mean time to VT: 6 minutes ischaemia: 7.9 ± 0.3 s, 7 minute: 8.2 ± 
2.8 s, 8 minutes: 6.4 ± 1.4 s, 9 minutes: 9.9 ± 1.5 s; P=NS) (Mean time to VF: 6 minutes 
ischaemia: 11.7 ± 0.0 s, 7 minutes: 13.1 ± 8.4 s, 8 minutes: 19.5 ± 4.6 s, 9 minutes: 13.8 ± 
3.4 s; P=NS).  
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Figure 3-2: A representative unipolar electrogram trace showing the onset of ventricular 
tachycardia (VT) several seconds after reperfusion, which progressed to ventricular 
fibrillation (VF). 
 
 
Figure 3-3: Relationship between the duration of ischaemia and the incidence of 
reperfusion ventricular tachycardia (VT) and ventricular fibrillation (VF). Six experiments 
were performed for each ischaemia duration. The ascending part of this bell-shaped 
relationship was between 5 and 9 minutes of ischaemia (n=6 per study arm). 
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As described above, multiple factors interact to determine reperfusion VT/VF 
susceptibility. Potential confounding variables for these experiments were the heart rate at 
onset of ischaemia, heart rate at reperfusion and degree of ischaemia (Figure 3-4), and it 
was important to determine that the observed relationship between ischaemia duration and 
arrhythmia incidence shown in Figure 3-3 was not due to differences in these confounders 
between groups. As shown in Figure 3-4, these potential confounding variables were not 
different between groups, and therefore did not affect the arrhythmia incidence data. 
 
 
Figure 3-4: Potential confounders: (A) Heart rate at ischaemia onset, (B) Heart rate at 
reperfusion, (C) Reduction in coronary flow rate with regional ischaemia. These were not 
different between groups (n=6 per study arm). 
 
3.3.2 Effects of heart rate on reperfusion VF incidence 
3.3.2.1 Ischaemia-reperfusion studies 
Ivabradine and atrial pacing were used to create five groups with different heart rates at 
onset of ischaemia, during the course of ischaemia, and at reperfusion, to study the 
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influence of heart rate on reperfusion arrhythmia susceptibility. Figure 3-5 and Table 3-1 
show the heart rates for these five groups. The percentage reduction in coronary flow rate, 
which is a measure of the size of the ischaemic zone and a potential confounding variable, 
was not different between groups (Group 1: 50 ± 3 %, Group 2: 44 ± 4 %, Group 3: 43 ± 7 
%, Group 4: 51 ± 4 %, Group 5: 51 ± 7 %, P=NS). 
 
 
Figure 3-5: Heart rates pre-ischaemia and during regional ischaemia for the five study 
groups (**P<0.01 vs. Control) (Group 1: n=10, Group 2: n=10, Group 3: n=5, Group 4: 
n=5, Group 5: n=5). 
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 HR at ischaemia onset Mean HR during 
ischaemia 
HR at reperfusion 
Group 1 309 ± 13 273 ± 14 276 ± 14 
Group 2 240 ± 13 ** 191 ± 11 ***  168 ± 13 *** 
Group 3 329 ± 21 ## 261 ± 20 # 201 ± 29 * 
Group 4 235 ± 20 * 300 ± 0 ### 302 ± 0 ### 
Group 5 243 ± 18 213 ± 20 301 ± 0 ### 
Table 3-1: Heart rate at ischaemia onset, mean heart rate during ischaemia and heart rate 
at reperfusion for the five study groups. (*P<0.05, **P<0.01, ***P<0.001 vs. Group 1 -
Control; #P<0.05, ##P<0.01, ###P<0.001 vs. Group 2 - Ivabradine). 
 
Group 1 was the control group, and had heart rate governed by sinus rhythm. Group 2 was 
perfused with ivabradine and, compared with control, had reduced heart rates at ischaemia 
onset (P<0.01), during ischaemia (P<0.001) and at reperfusion (P<0.001). Group 3 had 
boluses of ivabradine at reperfusion only, so had significantly slower heart rates at 
reperfusion compared with control (P<0.05). Group 4 had ivabradine perfusion with 
simultaneous atrial pacing throughout I-R, so compared with Group 2 (Ivabradine only), 
had increased heart rates during ischaemia (P<0.001) and at reperfusion (P<0.001). Group 
5 had ivabradine perfusion with pacing across reperfusion, and compared with Group 2, 
had increased heart rates at reperfusion (P<0.001). 
 
These differences in heart rates during ischaemia and at reperfusion, created using 
different combinations of atrial pacing and ivabradine administration, resulted in varying 
incidences of reperfusion arrhythmias across groups (Figure 3-6). Ivabradine perfusion to 
lower heart rate throughout ischaemia and reperfusion reduced reperfusion VF incidence 
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to 20% compared to 90% in control hearts (P<0.001). The anti-arrhythmic effects of 
ivabradine in this context can be attributed solely to its heart rate lowering effect, as atrial 
pacing at 300bpm with concomitant ivabradine administration abolished ivabradine’s anti-
arrhythmic effect (100% VF incidence for Group 4). 
 
Figure 3-6: (A) Freedom from reperfusion VT, (B) Reperfusion VT incidence, (C) 
Freedom from reperfusion VF, (D) Reperfusion VF incidence. (*P<0.05, **P<0.01, 
***P<0.001 vs. Control) (Group 1: n=10, Group 2: n=10, Group 3: n=5, Group 4: n=5, 
Group 5: n=5). 
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Groups 3 and 5 were designed to assess if the heart rate at reperfusion alone was an 
important determinant of reperfusion arrhythmia susceptibility. The arrhythmia incidences 
in these groups suggest that heart rate at reperfusion was not an important factor. A bolus 
of ivabradine just before reperfusion to lower heart rate at reperfusion (Group 3) did not 
significantly reduce reperfusion VF incidence compared to controls (80% vs. 90%). 
Similarly, ivabradine perfusion plus atrial pacing at reperfusion only to increase heart rate 
at reperfusion (Group 5) did not significantly increase reperfusion VF incidence compared 
to ivabradine alone (40% vs. 20%). From these results, the main determinant of 
reperfusion arrhythmia susceptibility was not the heart rate at reperfusion, but the mean 
heart rate throughout the duration of regional ischaemia. As shown in Figure 3-7, there 
was an excellent linear correlation between mean heart rate during ischaemia and the 
subsequent reperfusion arrhythmia incidence (Reperfusion VT: Pearson’s r2=0.96, 
P=0.003; Reperfusion VF: Pearson’s r2=0.98, P=0.001). 
 
 
Figure 3-7: Reperfusion VT and VF incidence plotted against mean heart rate during 
regional ischaemia, showing linear correlation between the two variables. 
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3.3.2.2 Optical mapping of global ischaemia studies 
Optical mapping studies during global no-flow ischaemia showed that heart rate was an 
important determinant of the rate of onset of ischaemia-induced electrophysiological 
changes, as shown in Figure 3-8. The study was designed to create two groups with 
different heart rates during global ischaemia. Heart rate was reduced in the ivabradine 
group (223 ± 12 bpm) compared to paced hearts (300 bpm) at onset of ischaemia 
(P<0.01). Heart rate slowed progressively in the ivabradine after onset of global 
ischaemia, until a cessation of spontaneous activity by 5 minutes of global ischaemia, 
whilst heart rate was maintained at 300bpm in the paced group. 
 
Figure 3-8: (A) Time to loss of electrical excitability was delayed in ivabradine group, 
(B) Greater amount of conduction slowing for paced hearts after 10 minutes of global 
ischaemia (n=5 in each study group) (*P<0.05). 
 
Hearts in the ivabradine group, which had significantly slower heart rates, had delayed 
onset of loss of electrical excitability compared to paced hearts (27.7 ± 4.3 mins vs. 14.5 ± 
0.6 mins, P=0.02), as shown in Figure 3-8. The onset of conduction slowing was also 
	   160 
delayed in the ivabradine group as shown by the series of activation maps in Figure 3-9. 
Following 10 minutes of global ischaemia, there was less conduction slowing in 
ivabradine-perfused hearts compared to paced hearts (Conduction veolcities: IVA 30.6 ± 
1.9 cm/s vs. Paced 18.8 ± 3.6 cm/s, P=0.03).  
 
Figure 3-9: Isochronal activation maps during ventricular pacing showing progressive 
conduction slowing with global ischaemia. This process was accelerated in the paced 
group compared to the ivabradine group. (Red is early activation, blue-violet is late 
activation). 
 
3.3.3 Optical mapping of regional ischaemia-reperfusion 
3.3.3.1 Conduction velocity during ischaemia-reperfusion 
Figure 3-10A shows the epicardial activation maps during ventricular pacing for the left 
ventricular anterior wall of a control heart during ischaemia-reperfusion. During 
ischaemia, there is progressive slowing of epicardial activation as evidenced by the 
progressive crowding of isochronal lines. This conduction slowing was rapidly reversed 
within the first minute following reperfusion. The corresponding maps of local conduction 
velocities also depict this pattern of conduction slowing during ischaemia and rapid 
restoration of epicardial conduction following reperfusion.  
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Figure 3-10: Optical mapping of transmembrane voltage (Vm) during ischaemia-
reperfusion. (A) Representative changes in optical action potentials (APs), epicardial 
activation and local conduction velocity maps with regional left anterior descending 
(LAD) artery ischaemia and subsequent reperfusion. (Blue is early activation, red is late 
on activation maps, blue is slow conduction and red is fast on conduction velocity map). 
Action potential duration shortened, optical APs had smaller amplitudes with ischaemia 
and conduction velocities slowed with ischaemia. These changes were restored to pre-
ischaemic levels rapidly with reperfusion (Vertical bars: AP amplitude at baseline, 
Horizontal bars: 100ms). (B) Optical APs superimposed to show changes in AP with 
ischaemia and reversal of changes with reperfusion. 
 
	   162 
Figure 3-11 shows the changes in conduction delay across a 0.6 cm2 area of the left 
ventricular anterior wall for during ischaemia and subsequent reperfusion. There was a 
significant increase in conduction delay at peak (8 minutes) ischaemia compared to 
baseline (26.3 ± 1.5 ms vs. 9.7 ± 0.2, P<0.001). Reperfusion resulted in a rapid decrease in 
conduction delay and recovery of conduction velocity (7.5 ± 0.9 ms at 1 minute post-
reperfusion, P<0.001 vs. peak-ischaemia). Conduction velocity recovered fully after 1 
minute of reperfusion and was not significantly different to that of baseline, pre-ischaemic 
levels.  
 
Figure 3-11: Conduction delay across a 0.6 cm2 area on the left ventricular epicardial 
surface during ventricular pacing (n=6). There was progressive slowing of conduction 
during ischaemia and a sudden recovery of conduction velocity to baseline values 
following reperfusion. (**P<0.01 vs. baseline, ***P<0.001 vs. baseline, #P<0.001 vs. 
peak-ischaemia). 
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3.3.3.2 Optical action potentials during ischaemia-reperfusion 
Figure 3-12 shows the changes in action potential duration (APD90, APD75, APD50), 
action potential upstoke (rise time, dF/dtmax) and optical action potential amplitude over 
the course of 8 minutes of left anterior descending (LAD) artery territory ischaemia and 
subsequent reperfusion. There was a progressive shortening of APDs with increasing 
duration of ischaemia (P<0.001 for peak-ischaemia vs. baseline) and a reversal of these 
changes with reperfusion. Ischaemia also produced a progressive reduction in the slope of 
the upstroke of the optical action potential (P<0.001 for peak-ischaemia vs. baseline), with 
a reversal of these changes with reperfusion. Values for these measures of optical AP 
duration and upstroke are shown in Table 3-2. 
 
 Baseline 8 mins ischaemia 3 mins reperfusion 
APD90 (ms) 92 ± 6 61 ± 3 *** 80 ± 12 
APD75 (ms) 72 ± 5 47 ± 3 *** 62 ± 10 
APD50 (ms) 43 ± 4 33 ± 3 * 41 ± 8 
Rise time (ms) 8.8 ± 0.1 11.8 ± 1.2 * 8.9 ± 0.1 
dF/dtmax (U/s) 17.3 ± 1.4 12.9 ± 1.7 * 19.6 ± 0.7 
AP ampltide (%) 100 61 ± 6 *** 65 ± 10 *** 
Conduction delay (ms) 9.7 ± 0.2 26.3 ± 1.5 *** 7.3 ± 1.2 
Table 3-2: Values of epicardial conduction delay, APD90, APD75, APD50, Rise time, 
dF/dtmax and optical AP amplitude at baseline, after 8 minutes of regional ischaemia and at 
3 minutes after reperfusion (n=6) (*P<0.05, ***P<0.001 vs. Baseline). 
 
 
	   164 
 
Figure 3-12: Changes in optical action potentials during regional ischaemia and 
reperfusion: (A-C) Optical action potential durations shortened with ischaemia and 
lengthened with reperfusion. (D-E) Slope of the optical action potential upstroke reduced 
with ischaemia and increased with reperfusion. (F) Changes in optical AP amplitude. 
(n=6) (*P<0.05, **P<0.01, ***P<0.001 vs. Baseline). 
 
3.4 Discussion 
The studies described in this chapter were performed to establish an appropriate ex vivo 
model of ischaemia-reperfusion to study reperfusion arrhythmias, upon which to 
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determine the effects of gap junction modulation on reperfusion arrhythmogenesis. There 
are several known determinants of susceptibility to reperfusion arrhythmias in such 
models, and these were specifically studied with a view to optimising the study design for 
the gap junction modulation experiments described in Chapter 6. 
 
3.4.1 Reproducibility of ischaemic zone size 
Reperfusion arrhythmias have been shown to be critically dependent on the size of the 
occluded (ischaemic) zone (Curtis & Hearse, 1989b). Curtis et al showed that occluded 
zone size correlated positively with an arrhythmia score, irrespective of the site of 
ischaemia, in an ex vivo rat model of ischaemia-reperfusion. It was therefore important to 
establish a model whereby the size of the ischaemic zone is consistent and reproducible 
across experiments. In the experiments described above, the ligatures were placed based 
on anatomical landmarks, at the level of the lower edge of the left atrial appendage. 
Because of the consistent nature of rat coronary anatomy (Halpern, 1957; Johns & Olson, 
1954), this approached produced consistent ischaemic zone sizes, as evidenced by the data 
on changes in coronary flow rate with ischaemia. In a constant-pressure perfusion system, 
the percentage reduction in coronary flow during ischaemia is a surrogate for the 
ischaemic zone size.  The data above showed that the magnitudes of coronary flow 
reduction were consistent across different study groups. Pooled analysis of all the 55 
regional ischaemia-reperfusion experiments described in this chapter showed that the 
mean percentage coronary flow reduction was 48% with a standard deviation of 5%, and a 
resulting coefficient of variation of 10%.  
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3.4.2 Optimum ischaemia duration to study reperfusion arrhythmias 
Another strong determinant of reperfusion arrhythmia susceptibility is the duration of 
regional ischaemia preceding reperfusion. Manning and Hearse showed that the 
relationship between reperfusion arrhythmia incidence and the preceding ischaemia 
duration is bell-shaped for multiple species (Manning & Hearse, 1984). Thirty 
experiments were performed to determine this relationship in this Sprague-Dawley rat 
model of ischaemia-reperfusion. Experiments of varying ischaemia durations were 
performed, and the results showed that the ascending part of this bell-shaped relationship 
was between 5 minutes and 9 minutes of ischaemia, with the steep part of this relationship 
between 6 and 8 minutes of ischaemia.  
 
In order to assess the effects of any pharmacological intervention on reperfusion 
arrhythmia susceptibility, the ideal duration of ischaemia would be within the steep part of 
this bell-shaped relationship (i.e. between 6 and 8 minutes) to maximise the sensitivity of 
the study to detect any effect of that intervention. These results guided the design of the ex 
vivo ischaemia-reperfusion experiments, described in Chapter 6, which were performed to 
assess the effects of gap junction modulation on reperfusion arrhythmia susceptibility. 
Two study protocols were used for those studies: a 6-minute ischaemia-reperfusion 
protocol, which had maximum sensitivity in detecting any pro-arrhythmic effects, and an 
8-minute ischaemia-reperfusion protocol, which had maximum sensitivity in detecting any 
anti-arrhythmic effects. 
 
3.4.3 Effect of heart rate on reperfusion arrhythmia susceptibility 
In addition to ischaemic zone size and ischaemia duration, heart rate is another known 
determinant of reperfusion arrhythmia susceptibility. Bernier et al performed left atrial 
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pacing at different rates during ex vivo ischaemia-reperfusion experiments on Wistar rat 
hearts and showed that atrial pacing throughout the experiment led to a rate-dependent 
increase in the incidence of reperfusion-induced ventricular fibrillation (VF) from 25% in 
unpaced hearts to greater than 90% when the rate was 420 bpm or higher, and speculated 
that this was probably due to the effect of heart rate on development of ischaemic injury 
(Bernier et al., 1989). 
 
The ischaemia-reperfusion studies performed in this chapter confirmed that heart rate is an 
important determinant of reperfusion arrhythmia susceptibility. Treatment with 
ivabradine, a specific If current blocker with heart rate lowering effects (Borer et al., 
2003), during ischaemia and reperfusion significantly reduced the incidence of reperfusion 
VF from 90% in control hearts to 20%. To ascertain if this anti-arrhythmic effect of 
ivabradine was due to its heart rate lowering effect or due to another unknown action of 
ivabradine, a further group of experiments were performed where ivabradine-treated 
hearts were also atrially paced at 300 bpm to abolish the heart rate reducing effects of 
ivabradine. The increased heart rate in paced hearts also abolished the anti-arrhythmic 
effects of ivabradine, with a VF incidence of 100% in this group, suggesting that 
ivabradine reduced reperfusion arrhythmia susceptibility through heart rate reduction. 
 
A further two groups of experiments were performed to determine whether heart rate 
during ischaemia or heart rate during reperfusion was a more important determinant of 
reperfusion arrhythmia susceptibility. A brief period of atrial pacing to increase heart rate 
during reperfusion, or a bolus of ivabradine immediately before reperfusion to reduce 
heart rate during reperfusion, both failed to significantly alter reperfusion arrhythmia 
incidence. These results suggest that the heart rate at reperfusion is not an important factor 
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in determining reperfusion arrhythmia susceptibility. In fact, the more important 
determinant of reperfusion arrhythmia susceptibility was the mean heart rate throughout 
the duration of regional ischaemia, as shown in Figure 3-8. Analysis of data pooled from 
all the study groups showed a very strong correlation between mean heart rate during 
ischaemia and subsequent reperfusion arrhythmia incidence. 
 
Optical mapping experiments were performed to assess the effects of heart rate on the 
speed of onset of ischaemia-induced electrophysiological changes. These experiments 
showed that increased heart rates were associated with accelerated onset of ischaemia-
induced changes, including earlier loss of electrical excitability and greater degrees of 
conduction slowing. These results provide a possible explanation for the observation that 
higher heart rates were associated with greater arrhythmia incidences. Increased heart 
rates may increase arrhythmia susceptibility by increasing the depth of ischaemia and 
accelerating the electrophysiological changes associated with ischaemia, such as 
conduction slowing. These accelerated ischaemia-induced changes may lead to greater 
heterogeneities in action potentials and conduction upon reperfusion and predispose to re-
entry arrhythmias. The accelerated changes may also lead to increased generation of 
reactive-oxygen species and calcium overload, which can then increase the likelihood of 
triggered arrhythmias. 
 
Data from both the ischaemia-reperfusion studies and the optical mapping experiments in 
this chapter demonstrate the importance of heart rate as an arrhythmia determinant, and 
highlight the need to exclude heart rate as a confounding variable when comparing 
arrhythmia incidences in different treatment groups.  
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3.4.4 Changes in optical action potentials during acute ischaemia-reperfusion 
The experiments of optical mapping during ischaemia-reperfusion described in this 
chapter demonstrated a clear pattern of changes to the optical action potential during acute 
ischaemia and subsequent reperfusion. Ischaemia has previously been shown to result in 
rapid depolarisation of the resting membrane potential (Fozzard & Makielski, 1985), and a 
consequent suppression of myocyte excitablility by voltage-dependent inactivation of the 
fast sodium inward current (INa), which is associated with a slowing of the action potential 
(AP) upstroke (Kléber, 1987). Acute ischaemia has also been shown to be associated with 
a shortening of action potential duration, and a reduction of action potential amplitude 
(Akar & Akar, 2007).  
 
The studies in this chapter showed that these previously described action potential changes 
were also observed in optical action potentials. There was a progressive slowing of the AP 
upstroke, reduction in AP duration and reduction in AP amplitude over the course of 8 
minutes of regional ischaemia. The observed slowing of the optical action potential 
upstroke can be attributed to a reduction in membrane excitability, due to reduced INa and 
ICa(L) in the context of acidosis, increased potassium concentrations and ATP depletion, 
and conduction slowing (Shaw & Rudy, 1997b). The observed shortening of the optical 
action potential reflects the shortening of cellular action potentials during acute ischaemia, 
which is due to a combination of increased outward currents and decreased inward 
currents (Shaw & Rudy, 1997b). Elevated extracellular potassium increases outward 
current by a direct effect on potassium currents, IK1 and IKr. Also, outward current is 
enhanced by the decrease in ATP, which opens the normally dormant IK(ATP). Inward 
current reduction is the result of both acidotic and anoxic reduction of ICa(L). 
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Reperfusion following this brief period of ischaemia resulted in rapid restoration of optical 
APs to their pre-ischaemic levels. It has been suggested that this rapid restoration of action 
potentials can create heterogeneities in the first few seconds following reperfusion and 
increase arrhythmia susceptibility (Wit & Janse, 2001). 
 
3.4.5 Changes in conduction velocity during acute ischaemia-reperfusion 
The optical mapping studies also demonstrated progressive slowing of conduction over 
the 8 minutes of acute ischaemia, with rapid recovery of conduction velocities upon 
reperfusion. Ischaemia leads to acidosis, anoxia, ATP depletion and increased 
extracellular potassium, which combine to cause the slowing of conduction (Shaw & 
Rudy, 1997a). Although part of this ischaemia-induced conduction slowing can be 
attributed a reduction in membrane excitability (Shaw & Rudy, 1997c), gap junction 
uncoupling may also partly mediate the observed conduction slowing in early ischaemia. 
 
Acute ischaemia has been shown to cause gap junction uncoupling (de Groot & Coronel, 
2004), due to the combination of ATP depletion , increased levels of intracellular Ca2+ and 
H+ and accumulation of amphipathic lipid metabolites (Beardslee et al., 2000; Verrecchia 
et al., 1999). This process of gap junction uncoupling leads to conduction slowing, 
although the timing of the onset of gap junction uncoupling in acute ischaemia is unclear. 
Previous studies measuring extracellular resistance in arterially-perfused rabbit papillary 
muscle have shown that gap junction uncoupling occurs 10-15 minutes after the onset of 
ischaemia in rabbit papillary muscle (Kléber et al., 1987). However, other studies suggest 
that gap junction uncoupling occurs earlier during myocardial ischaemia and can occur 
within several minutes of onset of ischaemia. Acute ischaemia causes a rapid decrease in 
pH to approximately 6.4 after 5 minutes (Garlick et al., 1979), which would expected lead 
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to significant uncoupling of gap junction channels within that time-frame (S. Liu et al., 
1993). It has been demonstrated that preservation of gap junction coupling in a 5-minute 
regional ischaemia-reperfusion protocol reduced reperfusion VT, also suggesting that a 
degree of gap junction uncoupling occurs within the first 5 minutes of ischaemia 
(Anyukhovsky et al., 2010). It is therefore likely that the conduction slowing observed 
during the first eight minutes of acute regional ischaemia in the experiments described 
above may be in part attributed to gap junction uncoupling, as well as to a reduction in 
membrane excitability. 
 
3.5 Summary 
The ex vivo isolated perfused heart is a suitable preparation for ischaemia-reperfusion 
experiments to study reperfusion arrhythmogenesis. The size of the ischaemic zone, the 
duration of ischaemia, and the heart rate during ischaemia are all known determinants of 
arrhythmia susceptibility in this model and must be taken into account when designing 
study protocols to investigate reperfusion arrhythmogenesis. Acute ischaemia was 
associated with progressive slowing of the action potential upstroke, shortening of the 
action potential duration and conduction slowing, all of which were restored to pre-
ischaemic values several minutes after reperfusion. 
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Chapter 4: 
Establishing a chronic MI model  
to study post-infarction arrhythmogenesis 
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4.1 Background 
4.1.1 Ventricular arrhythmias in the chronic post-myocardial infarction setting 
Ventricular arrhythmias are responsible for the majority of the 100,000 and 300,000 
sudden deaths per year in the UK and USA respectively (Morgan et al., 2006; Zheng et al., 
2001), with myocardial infarction (MI) being the principal underlying cause for these 
lethal tachyarrhythmias (Huikuri et al., 2001). The majority of sudden cardiac deaths in 
patients with myocardial infarction occur months to years after their index event (Adabag 
et al., 2008). It is known that some of these post-MI arrhythmias arise from the infarct 
border zone, where fibrotic scar connects and interfaces with surviving myocardium (de 
Bakker et al., 1988). Heterogeneous scarring with varying degrees of fibrosis and varying 
subendocardial myocardial tissue preservation produces the anatomical substrate that 
supports these re-entrant arrhythmias (de Bakker et al., 1993; Fenoglio et al., 1983). The 
slowing of conduction that occurs in the surviving bundles of myocardium within the 
infarct border zone, associated with altered connexin43 distribution (Peters et al., 1997), 
further increases the likelihood of sustaining re-entrant arrhythmias. 
 
4.1.2 Determinants of post-infarction arrhythmia susceptibility 
The main strategy to prevent sudden cardiac death due to arrhythmias in the post-
myocardial infarction (MI) population is to insert Implantable Cardioverter Defibrillators 
(ICDs) (Goldenberg et al., 2010; AVID, 1997; Moss et al., 1996; Moss et al., 2002). 
However, this remains largely unsatisfactory because the clinical tests currently used to 
risk stratify patients into high- and low-risk groups such as left ventricular ejection 
fraction (LVEF) and programmed electrical stimulation (PES) have poor specificities and 
sensitivities (Goldberger, 2010). One of the main reasons that underlie poor risk 
stratification and patient selection for ICDs is the incomplete understanding of all the 
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factors that determine arrhythmia susceptibility in the chronically infarcted heart (Daubert, 
2009). 
 
It has previously been shown that infarct size is a determinant of arrhythmia susceptibility, 
with larger infarcts being more susceptible to post-MI ventricular arrhythmias (Bello et 
al., 2005). The infarct border zone morphology is also an important factor, with late-
gadolinium MRI studies showing that patients with larger areas of infarct border zones (or 
peri-infarct zones) have greater arrhythmia susceptibility (Yan et al., 2006; Schmidt et al., 
2007). These results suggest that there are structural differences in infarct morphology that 
can be used to identify hearts susceptible to ventricular arrhythmias post-MI. However, 
little is known about the specific differences in electrophysiology between arrhythmic and 
non-arrhythmic infarcted hearts, and if there are any identifiable electrophysiological 
determinants of post-MI arrhythmia susceptibility that exist. 
 
4.1.3 Models of chronic MI to study post-infarction arrhythmogenesis 
Preclinical experimental models of MI have been used to study the sequelae of myocardial 
infarction for nearly a century. Early coronary occlusion experiments were performed in 
dogs (Gross et al., 1937), but these models had signification variations in outcomes as a 
result of the underlying variations in coronary anatomy in that species, leading to coronary 
occlusion models being developed in smaller animals, such as the rat. One advantage of 
the rat chronic myocardial infarction model is the consistency of infarct sizes that are 
generated surgically, which is the result of two factors. Firstly, the coronary anatomy in 
rat is relatively consistent across animals (Halpern, 1957), and the surgical ligation of a 
coronary artery tends to result in reproducible ischaemic zones. Another factor is that the 
rat heart has relatively few collateral vessels (Maxwell et al., 1987), which mean that 
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coronary artery ligation readily induces myocardial infarction compared with highly 
collateralised species such as the guinea pig. 
 
The rat heart also has the advantage of being ideally suited to whole-heart ex vivo 
electrophysiology studies. The size of the rat heart makes it suitable for optical mapping 
studies to study the changes in electrophysiology that occur in the different regions of 
healed, chronic MI hearts and to investigate the electrophysiological remodelling 
processes that are involved in post-MI arrhythmogenesis. Previous optical mapping 
studies on chronically infarcted rat hearts have shown that this experimental model can 
reproduce many of the electrophysiological characteristics associated with MI in patients, 
such as slow conduction, conduction block and reentrant excitation (Mills et al., 2006) 
The rat MI model has also been shown to be suitable for optical mapping studies to 
investigate the electophysiological properties of the infarct border zone, and to study scar-
related re-entrant ventricular tachycardia (Ding et al., 2010). 
 
The following studies described in the chapter were performed to establish an 
experimental chronic myocardial infarction model to investigate: 
(1) the electrophysiological changes that are present in the chronic healed infarct, 
(2) the possible determinants of arrhythmia susceptibility in this chronic MI model, 
(3) the effects of acute gap junction modulation on late post-infarction arrhythmogenesis 
(described in Chapter 7). 
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4.2 Methods 
4.2.1 Myocardial infarction surgery 
Male Sprague-Dawley rats (250-300g, aged 9-12 weeks) were subjected to surgical 
myocardial infarction (MI) surgery as described in Section 2.3.3. A total of 45 cases were 
initially performed as part of the surgical learning curve. Subsequently, a further 24 MI 
cases were performed to characterise the electrophysiology and arrhythmogenicity of the 
4-week MI model, as described below. Four sham MI surgery cases were also performed. 
 
4.2.2 Telemetry implantation 
Of the sixteen survivors from the cohort of 24 rats described in Section 4.2.1 above, ten 
animals had a further procedure to have ECG-telemetry devices implanted. Three of the 
four sham-operated animals had telemetry devices implanted. The telemetry implantation 
surgery was performed as described in Section 2.4.3. 
 
4.2.3 ECG-Telemetry recording and analysis 
For the ten MI animals and 3 sham animals implanted with telemetry transmitters, ECG 
was recorded at 4 weeks post-myocardial infarction. Recordings were performed for 72 
hours, often over weekends to minimise disturbance to the animals during the recording 
periods. Recordings were commenced at 8am and terminated at the same time 3 days later. 
ECG-analysis was performed for a full 24-hour period to take into account any diurnal 
variation. Arrhythmia detection analysis was performed as described in Section 2.4.5. 
 
4.2.4 Optical mapping 
At four weeks post-MI, the sixteen surviving animals were sacrificed and the hearts were 
isolated and perfused on a Langendorff apparatus as described in Section 2.5.3. Hearts 
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were then stained with RH237, a voltage-sensitive dye, and perfused with blebbistatin, an 
excitation-contraction uncoupler, before being subjected to optical mapping of 
transmembrane voltage (Vm) as described in Section 2.6.3. Transmembrane voltage 
transients were recorded during sinus rhythm and during ventricular pacing at various 
cycle lengths between 240ms and 100ms. 
 
4.2.5 Arrhythmia provocation protocols 
With simultaneous optical mapping, selected hearts were subjected to arrhythmia 
provocation protocols to induce ventricular arrhythmias. All sixteen MI hearts and 4 
sham-operated hearts were subjected to Programmed Electrical Stimulation (PES) with up 
to 3 extrastimuli to induce arrhythmias as described in Section 2.7.2. In addition, 8 out of 
the 16 MI hearts and 4 sham-operated hearts underwent isoprenaline pulse protocols as 
described in Section 2.7.3 to assess susceptibility to catecholamine-induced arrhythmias. 
 
4.2.6 Histological staining and analysis 
Following the optical mapping and arrhythmia provocation protocols, all sixteen hearts 
were flash-frozen in liquid nitrogen. Hearts were then sectioned on a cryotome as 
described in Section 2.8.2 and stained with Masson’s trichrome as described in Section 
2.10.2 to visualise areas of fibrosis. Infarct size for each heart was quantified as described 
in Section 2.10.3. 
 
4.2.7 Cx43 immunohistochemistry 
Cryosections were also immunolabelled for Cx43 using the immunohistochemistry 
protocol described in Section 2.8.3. The distribution of Cx43 in the infarct border zone 
was then assessed using the Cx43 lateralisation score detailed in Section 2.8.4. 
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4.3 Results 
4.3.1 Acute mortality from MI surgery 
Of the first 45 MI surgery cases performed as part of the surgical learning curve, 21 
animals did not survive the procedure due to a combination of acute ischaemic 
arrhythmias and excess bleeding, giving an acute mortality rate of 47%. This was 
significantly higher than subsequent mortality rates, which fell once the appropriate 
surgical expertise had been acquired. For the subsequent cohort of 24 rats, which 
underwent surgical MI to characterise the 4-week chronic MI model, 8 animals died 
acutely, predominantly due to acute ischaemic ventricular arrhythmias following 
successful left anterior descending artery occlusion. This equated to an acute mortality rate 
of 33%. The 16 survivors were used for telemetry, optical mapping, ex vivo arrhythmia 
provocation studies, histological staining and immunohistochemistry experiments 
described below. All four sham-operated animals survived the surgical procedure. 
 
4.3.2 In vivo ECG-telemetry  
ECG-telemetry recordings were performed to record the incidence of spontaneous 
ventricular arrhythmias in vivo. Figure 4-1 shows representative ECG-telemetry 
recordings from post-myocardial infarction rats, with examples of ventricular arrhythmias. 
As part of preliminary studies to assess the incidence of ventricular arrhythmias over the 
first four weeks post-myocardial infarction, ECG-telemetry data from a separate cohort of 
four post-MI rats (MI surgery performed by Dr Alexander Lyon) were analysed. As 
shown in Figure 4-2, there were two time windows of arrhythmia susceptibility in these 
animals (P=0.03). The incidence of sustained arrhythmias, defined as episodes of 
ventricular arrhythmias consisting of two or more ventricular beats in succession, was 
greatest in the first 24 hours following MI, with the number of episodes gradually 
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decreasing over the first week post-MI. There is then a second peak of arrhythmia 
incidence at 3 to 4 weeks post-MI. 
 
 
Figure 4-1: Representative in vivo ECG-telemetry traces showing spontaneous ventricular 
arrhythmias four weeks after myocardial infarction. These arrhythmias were in the form of 
single ventricular ectopics, couplets or non-sustained ventricular tachycardia (VT) as 
shown above. 
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Figure 4-2: Two time windows of peak spontaneous arrhythmia incidence in first four 
weeks post-MI. (A) Total incidence of ventricular beats, (B) number of episodes of 
sustained arrhythmias. There were two periods of vulnerability to sustained arrhythmias, 
which were immediately after MI and at 3-4 weeks post-MI (n=4). 
 
ECG-telemetry recordings were also perfomed on 10 animals out of the cohort of 16 rats 
that survived myocardial infarction and on the three sham-operated animals, as described 
in Section 4.3.1. Telemetry recordings were performed at 4 weeks after myocardial 
infarction to document the incidence of spontaneous ventricular arrhythmias for this 
cohort at the chronic stable healed infarct stage. There was significant variation of 
spontaneous arrhythmia incidence across MI animals at 4 weeks post-MI with a geometric 
mean 46 VEs over 24 hours (95% CI 46 to 334 VEs/24 hours) (median 13 VEs/24 hours,  
interquartile range 7 – 1091 VEs/24 hours), as shown in Figure 4-3. This was in 
comparison to sham-operated animals, which had a geometric mean of 14 VEs/ 24 hours 
(95% CI 46 to 334 VEs/24 hours) (median 13 VEs/14 hours, interquartile range 11 – 17 
VEs/24 hours). 
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Figure 4-3: Wide range of spontaneous in vivo ventricular arrhythmia incidence at 4 
weeks post-MI (range 7 to 7012 VEs/24 hours; n=10) compared to sham-operated animals 
(range 11 to 17 VEs/24 hours; n=3). Solid line denotes geometric means. 
 
4.3.3 Optical mapping of Chronic MI hearts 
At four weeks post-MI, the 16 animals were sacrificed and hearts were explanted and 
perfused ex vivo for optical mapping studies to record transmembrane voltage (Vm) 
transients. Optical action potentials (APs) recorded from the infarct zone, the infarct 
border zone (IBZ) and the remote viable myocardium had different morphologies, as 
shown in Figure 4-4. As shown in a representative example in Figure 4-5, rise times were 
longer, signal amplitudes were smaller, and APD dispersion was greater in the infarct and 
border zones. Conduction velocity was significantly slower in the infarct border zone 
compared to remote, viable myocardium. 
 
Figure 4-6 shows action potential duration (APD) values and APD dispersion values for 
the different regions of the infarcted heart. Mean APD90, APD75 and APD50 were not 
different between the infarct zone (Inf), infarct border zone (IBZ) and remote viable 
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myocardium (Rem). These mean APD values were also not different when compared with 
control non-MI hearts (Con).  
 
There were greater heterogeneities in APDs in the infarct border zone and infarct zone for 
all three measures of APDs, compared with remote viable myocardium from MI hearts 
and with non-MI control hearts. For example, dispersion of APD90, quantified as the 
standard deviation of APD90 measurements, was 4.8 ± 0.7 ms at the infarct border zone 
compared with 1.7 ± 0.3 ms in the remote non-infarcted myocardium of MI hearts 
(P<0.05), and 1.6 ± 0.3 ms in non-MI control hearts. 
 
 
Figure 4-4: Different morphologies of optical action potential recordings from the remote, 
viable myocardium, infarct border zone and infarct zone. APs have smaller amplitudes 
and slower upstrokes in the infarct border zone and infarct zone. 
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Figure 4-5: Representative maps from one chronic MI heart subjected to transmembrane 
voltage (Vm) mapping. Maps show significant regional differences, with greater rise times 
(more red), smaller amplitudes (more blue), and greater APD dispersion (greater 
variability) in the infarct and border zones. Conduction velocity was slower in the infarct 
border zone (greater crowding of isochrones on activation map, blue regions on 
conduction velocity map). 
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Figure 4-6: Action potential durations (APD) and APD dispersion (n=16 MI hearts). (A-
C) mean APD90, APD75 and APD50 were not different between remote, viable 
myocardium (Rem), infarct border zone (IBZ) and infarct zone (Inf) of MI hearts, and 
non-MI control hearts (Con). (D) Dispersion of APD90 was greater in the IBZ compared 
to remote myocardium. (E & F) Dispersion of APD75 and APD50 were greater in IBZ 
and MI zone compared to remote myocardium, (*P<0.05, **P<0.01 vs. Rem; #P<0.05, 
###P<0.001 vs. Con). 
 
	   185 
 
Figure 4-7: Regional differences in rise time, conduction velocity and conduction vector 
dispersion (n=16 MI hearts). (A) Rise times were longer in infarct zone (Inf) and infarct 
border zone (IBZ) compared with remote myocardium (Rem) and control non-MI hearts 
(Con), (B) Dispersion of rise times were greater in infarct zone and IBZ, (C) Local 
conduction velocities were reduced in IBZ compared with remote myocardium and 
controls, (D) Dispersion of local conduction vectors was increased in the MI zone, 
(*P<0.05, **P<0.01, ***P<0.001 vs. Rem; #P<0.05, ##P<0.01, ###P<0.001 vs. Con; 
†P<0.05 vs. Inf.). 
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As shown in Figure 4-7, the rise times were longer in the infarct zone (17.9 ± 8.7 ms) and 
IBZ (12.7 ± 0.6 ms), compared with remote myocardium (8.2 ± 0.1 ms) and with control 
non-MI hearts (8.7 ± 0.1 ms). Conduction velocities were slower in the IBZ (34.2 ± 3.2 
cm/s) than in the remote non-infarcted myocardium (67.7 ± 3.8 cm/s, P<0.001) and in 
control non-MI hearts (72.7 ± 3.8 cm/s, P<0.001). The dispersion of local conduction 
vector directions was greater in the infarct zone (45.3 ± 6.3 degrees) compared to IBZ 
(22.0 ± 2.6 degrees) and remote myocardium (27.9 ± 2.7 degrees) (both P<0.01). 
 
4.3.4 Programmed electrical stimulation (PES) 
Extrastimulus PES protocols, as shown in Figure 4-8 were performed to induce ventricular 
arrhythmias. Figure 4-9 shows the proportion of hearts in which VT or VF was induced on 
PES. Proportions of MI hearts with inducible VT/VF of greater than 1s for S2, S3 and S4 
protocols were 44%, 56% and 63% respectively. This was greater than in sham-operated 
hearts, where the proportions of hearts with inducible VT/VF of greater than 1s for S2, S3 
and S4 protocols were 25%, 25% and 25% respectively. 
 
Figure 4-8: Two sample electrocardiogram (ECG) traces during programmed electrical 
stimulation.  
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Figure 4-9: Proportion of hearts with inducible arrhythmias (+ve), with one (S2), two 
(S3) or three extrastimuli (S4) for MI hearts (n=16) and for sham-operated hearts (n=4). 
There were greater proportions of hearts that were inducible at PES for any given number 
of extrastimuli. 
 
4.3.5 Isoprenaline (ISO) pulse protocol 
Eight MI hearts were subjected to the isoprenaline pulse protocol. Isoprenaline infusion 
(1µM) caused ventricular arrhythmias in all 8 chronic MI hearts. These arrhythmias were 
in the form of isolated ventricular ectopics (VEs), couplets, triplets or runs of non-
sustained VT as shown in Figure 4-10. There was a wide range of incidence of ventricular 
arrhythmias in MI hearts over the course of 20 minutes of isoprenaline perfusion, with a 
geometric mean of 29 VEs over 20 minutes (95% CI 5 – 176 VEs) (median: 36 VEs, 
interquartile range of 6 to 195 VEs) (Figure 4-11). This was in comparison to 13 VEs in 
sham-operated hearts (geometric mean; 95% CI 2 – 176 VEs; median: 15 VEs, 
interquartile range of 5 to 36 VEs). 
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Figure 4-10: Sample electrocardiogram traces before and during ISO pulse protocols. Top 
two traces show sinus rhythm pre-ISO and sinus tachycardia with 1µM ISO. Bottom two 
traces show ventricular arrhythmias with isoprenaline, in the form of isolated ventricular 
ectopics and runs of non-sustained VT (NSVT). 
 
Figure 4-11: Wide range of arrhythmia incidence over 20 minutes of 1µM isoprenaline 
perfusion in MI hearts (range 1 to 470 VEs/20 mins; n=8), compared to sham-operated 
hearts (range 3 to 44 VEs/20 mins; n=4). Solid lines denote geometric mean. 
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4.3.6 Infarct size 
Of the sixteen animals that survived MI surgery, fourteen had significant infarcts visible 
by eye, as shown in the four examples in Figure 4-12. The other two hearts had patchy 
scarring on visual inspection, but no evidence of transmural infarction. Out of the fourteen 
hearts with significant transmural scars, twelve out of fourteen scars extended to the apex. 
 
 
Figure 4-12: Four representative plain photographs of chronic MI hearts. Areas of scar 
(white areas) can be easily visualised. Fourteen out of sixteen MI hearts had clearly visible 
anteriolateral LV scars similar to the four shown in this figure. 
 
Figure 4-13 shows slices from a representative MI heart stained with Masson’s Trichrome. 
Infarct size was measured by calculating the percentage of the endocardial and epicardial 
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circumferences bounded by the infarct on Masson’s Trichrome-stained slices. Using this 
method, infarct size ranged from 10% to 33%, with a mean of 20.3% and a standard 
deviation of 7.7%. For the cohort of 16 animals that had MI surgery, the coefficient of 
variation (CV) for infarct size was 38%. 
 
Figure 4-13: Representative images of Masson’s Trichrome-stained biventricular heart 
slices from one chronic MI heart. Areas of fibrosis were stained blue and myocardium was 
stained red/pink. Slices were stained at 500µm intervals. A transmural anterior infarct was 
clearly visible in this heart at multiple levels. 
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4.3.7 Cx43 immunolabelling 
Cx43 immunolabelling showed the presence of Cx43 immunolabel predominantly at the 
ends of cardiomyocytes at the intercalated discs. Cx43 immunolabel was occasionally 
found at the lateral membranes of the cardiomyocytes (lateralisation of Cx43), and this 
was mainly observed at the infarct border zone. Mean Cx43 lateralisation score at the 
infarct border zone was 2.0 with a standard deviation of 0.8. 
 
Figure 4-14: Confocal microscopy images of Cx43 immunolabelled slices from chronic 
MI hearts. Left: Normal Cx43 immunolabelling at the ends of cardiomyocytes in left 
ventricular tissue remote from the infarct. Yellow arrows show Cx43 label at the 
intercalated discs. Right: An example of Cx43 maldistribution in tissue from the infarct 
border zone. Cx43 immunolabel is located at the lateral membranes (blue arrows) in 
addition to the intercalated discs (yellow arrows). Scale bar = 50µm. 
 
 
 
 
	   192 
4.3.8 Determinants of arrhythmia susceptibility in a 4-week rat model of chronic MI 
Analyses were performed to assess if infarct border zone conduction velocity, conduction 
vector dispersion, infarct size and Cx43 lateralisation were determinants of arrhythmia 
susceptibility in this cohort of chronic MI rats. Hearts were ranked by arrhythmogenicity 
using data from ECG-telemetry, PES and ISO challenge, and median values were 
calculated. Hearts were then separated into two equally-sized groups for each of the three 
measure of arrhythmogenicity, with the more arrhythmic (+) group containing hearts with 
values above the median and the less arrhythmic (-) group containing hearts with values 
below the median.  
 
As shown in Figure 4-15, PES(+) had significantly slower conduction velocities compared 
to PES(-) hearts (27.6 ± 3.9 cm/s vs. 39.3 ± 4.1 cm/s, P<0.05). Infarct size was not a 
confounding variable in this comparison as infarct size was not different between PES(+) 
and PES(-) hearts (20.0 ± 2.9 % vs. 18.1 ± 4.0 %, P=NS). Infarct border zone conduction 
velocity was not different when comparing ISO(+) against ISO(-) hearts or when 
comparing Telemetry(+) against Telemetry(-) hearts. Infarct zone and IBZ conduction 
vector dispersion, infarct size and IBZ Cx43 lateralisation were not different between (+) 
and (-) groups for all three measures of arrhythmogenicity. 
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Figure 4-15: Comparison of IBZ conduction velocity, conduction vector dispersion, 
infarct size and IBZ Cx43 lateralisation between more arrhythmic (+) hearts and less 
arrhythmic (-) hearts. IBZ conduction velocity was slower in PES(+) vs. PES(-) hearts. 
(*P<0.05) (PES: n=16, ISO: n=8, In vivo: n=10). 
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4.4 Discussion 
4.4.1 Chronic myocardial infarction model 
Surgical ligation of the left anterior descending artery reliably created transmural 
myocardial infarction in rats. The lack of collateral flow in the rat coronary circulation 
meant that myocardial infarction was readily induced by coronary artery ligation 
(Maxwell et al., 1987). The cessation of blood flow to the ischaemic myocardium, leads to 
a process of cell death followed by replacement of myocardium with fibrous tissue. 
Myocardial infarction also leads to remodelling of the ventricle, including hypertrophy of 
the non-infarcted myocardium, deposition of fibrosis in the viable myocardium (Weber et 
al., 2008) and expansion of the infarct scar (Opie et al., 2006). The remodelling processes 
eventually leads to a heart failure phenotype, which is evident after 16 weeks in this model 
(Lyon et al., 2011). 
 
A four-week model was selected for the studies described in this thesis because the aim 
was to establish a stable, chronic MI model, before the onset of the heart failure 
phenotype. This chronic, stable, healed infarct model will allow for studies into the 
specific role of the infarct scar and infarct border zone in post-MI arrhythmogenesis 
without the confounding effects of heart failure. The hearts were not studied before 4 
weeks as it has previously been shown that process of replacement of necrotic tissue with 
fibrous scar, as well as the subacute post-MI electrical remodelling changes, take at least 
four weeks to stabilise. Cleutjens et al studied the timeline of collagen degradation and 
synthesis in the infarcted rat heart, and demonstrated four stages to wound healing after 
myocardial infarction (Cleutjens et al., 1999). Phase 1, which occurs in the first 24 hours 
following onset of myocardial infarction, is characterised by cardiomyocyte death, 
through both necrosis and apoptosis. This cell death evokes an acute inflammatory 
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response (Phase 2), occuring between 12 hours and 4 days after MI onset, which is 
characterised by inflammatory cell infiltration, cytokine release and complement 
activation. Phase 3 of cardiac wound healing (formation of granulation tissue) starts 2-3 
days after MI onset with the deposition of extracellular matrix proteins, first in the border 
zone between infarcted and non-infarcted tissue, and later in the central area of the infarct. 
This is followed by collagen production by myofibroblasts, and cross-linkage of collagens 
over the next few weeks. At 3 weeks post-MI, Phase 4 (repair and remodelling) begins, 
and the collagen becomes completely cross-linked and a mature scar is formed. Although 
this process of repair and remodelling continues indefinitely, granulation tissue is 
completely replaced by mature scar at 4 weeks post-MI. Therefore, a 4-week post-MI 
model is appropriate for studies into the role of the healed infarct scar and infarct border 
zone in arrhythmogenesis. 
 
In addition, the sub-acute electrical remodelling that occurs post-MI can take several 
weeks to stabilise. Ursell et al demonstrated that resting membrane potential, and action 
potential amplitude and upstroke velocity of cells from the epicardial border zone of 
canine infarcts were all reduced at 5 days post MI, but returned to normal by 2 weeks 
(Ursell et al., 1985). Action potential durations progressively shortened over the first two 
weeks post-MI, with a loss of the action potential plateau. However, these did not return to 
control levels until 1-2 months after MI (Ursell et al., 1985; Pinto & Boyden, 1999). 
Again, these data suggest that studies into the electrophysiology of the chronic healed 
infarct should ideally take place after at least 4 weeks post-MI.  
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4.4.2 Arrhythmia susceptibility in the 4-week MI model 
The 4-week MI model described in this chapter was susceptible to spontaneous in vivo 
ventricular arrhythmias, as documented on ECG-telemetry, as well as provoked 
arrhythmias on programmed electrical stimulation and isoprenaline challenge. There was a 
range of arrhythmia susceptibility in the cohort described above. The variation in 
arrhythmia susceptibility mirrors that seen in that the post-MI population in humans, 
where some individuals are particularly susceptible to arrhythmias, whilst others with 
similar-sized infarcts are seemingly resistant to these arrhythmias (Daubert, 2009). This 
natural variation in arrhythmia susceptibility allowed sub-analyses to be performed to 
probe potential factors that may be important in determining post-MI arrhythmic risk, 
described below. The susceptibility of this model to both spontaneous and provoked 
arrhythmias also makes it suitable for studies to investigate any anti- or pro-arrhythmic 
effects of pharmacological interventions, and this 4-week chronic MI model was used for 
gap junction modulator studies described in Chapter 7. 
 
4.4.3 Electrophysiology of the healed infarct 
The optical mapping experiments in this chapter provided insight into the 
electrophysiology of the chronic, stable post-MI heart. These studies showed that hearts 
with transmural infarcts had significant slowing of macroscopic conduction across the 
infarct border zone, with a longitudinal conduction velocity that is approximately half that 
of remote myocardium. The slowing of conduction observed is consistent with other 
optical mapping studies of chronic infarction (Mills et al., 2006; Takahashi et al., 2004). 
The magnitudes of conduction slowing are also comparable to previous optical mapping 
studies of infarcted rat hearts. In the studies described in this chapter, the conduction 
velocity was 49% slower in the infarct border zone (34.2 ± 3.2 cm/s) compared to the 
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remote non-infarcted myocardium (67.7 ± 3.8 cm/s). This was very similar to the 53% 
conduction slowing seen in the border zone (37 cm/s) compared to remote myocardium 
(70 cm/s) seen in the study by Ding et al (Ding et al., 2010). Although Mills et al did not 
quantify border zone conduction velocity, their data showed a conduction velocity of 49 
cm/s in the remote myocardium, which was also comparable to the results in this chapter 
(Mills et al., 2006). 
 
The slowing of macroscopic conduction across the infarct border zone may in part be due 
to “zigzag” conduction along tortuous paths (de Bakker et al., 1993). Work by de Bakker 
and colleagues on human myocardium demonstrated that the slowing in macroscopic 
conduction was due to conduction following pathways lengthened by branching and 
merging bundles of surviving myocytes ensheathed by collagenous septa. The observed 
slowing at the infarct border zone may also be attributed to changes in microscopic 
conduction velocity. Redistribution of connexins and gap junctions (Peters et al., 1997), 
reduction in action potential amplitude and upstoke (Lue & Boyden, 1992), reduction in 
the inward sodium current (INa) and altered INa kinetics (Pu & Boyden, 1997), have all 
been demonstrated in the canine infarct border zone, and these observations have been 
associated with microscopic conduction slowing (Cabo et al., 2006). 
 
The studies also showed a prolongation of the rise time of the optical action potentials in 
the infarct border zone compared to remote myocardium, which was also observed by 
Ding et al in their study (Ding et al., 2010). Because the optical action potential is a 
summation of signals from all cells within that pixel, the rise time of the optical action 
potential reflects both conduction velocity across that pixel as well as Na-channel activity 
(Kléber, 2005). This is unlike action potentials derived from transmembrane recordings in 
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single cells, where the upstroke solely reflects sodium channels. From these studies, it was 
not possible to ascertain the cause the prolongation of rise time of the action potential. 
 
Mean action potential durations were shown not to be different between the remote 
myocardium, infarct border zone and the infarct zone, which was again consistent with 
previous optical mapping studies (Mills et al., 2006). Mills and colleagues also found no 
differences in APDs between the different regions of MI hearts. Their APD90 values for 
remote myocardium, infarct border zone and infarct zone were 102ms, 104ms and 105ms 
respectively. These values were similar to the results above (85ms, 91ms and 92ms 
respectively), although their observed APDs were consistently slightly longer. 
 
Although mean APDs were not different between the different regions of the MI heart, 
there was an increase in the heterogeneity of action potential durations in the infarct 
border zone. Ursell et al, using microelectrode techniques, showed that action potential 
durations from the infarct border zone were comparable to control at the chronic, healed 
infarct stage (Ursell et al., 1985). This was in line with the optical mapping data above, 
which showed no difference in mean action potential durations between the infarct border 
zone and remote, viable myocardium. However, the mapping studies also revealed 
increased heterogeneity in action potential durations in the infarct border zone. This 
increased dispersion of repolarisation is known to increase the risk of functional re-entrant 
arrthymias (Antzelevitch, 2007), and may partly account for the arrhythmogenic role of 
the infarct border zone. 
 
During optical mapping studies, optical action potential signals were also detected from 
the epicardial surface of transmural infarcts, although these were of smaller amplitude and 
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had prolonged rise times. The source of these optical signals may either be from bundles 
or islands of surviving myocardium within the infarct scar, or may be the result of light 
scattering. Walker et al investigated the source of optical action potential signals from the 
epicardial surface of rabbit infarcts and concluded these signals arose from remnant 
groups of myocytes in the mid-wall and epicardium of the infarct scar (Walker et al., 
2007). Histological staining of tissue sections from our rat model of chronic MI confirms 
the presence of bundles of surviving myocardium within areas of dense infarct, which may 
account for the optical action potentials recorded from the infarct in this model. Analysis 
of the activation patterns during sinus rhythm and ventricular arrhythmia also support the 
idea that these signals are true action potentials arising from the infarct scar and not due to 
light scattering. On the occasions when ventricular arrhythmias were mapped in MI hearts, 
the activation sequence of signals in the MI zone sometimes followed a clear pattern 
suggestive of re-entry. This temporal pattern of optical signals would not have been 
observed in the MI zone if the signals were the result of light scattering. 
 
4.4.4 IBZ conduction velocity as a determinant of arrhythmia susceptibility 
Comparison of PES(+) and PES(-) hearts showed that PES(+) hearts had significantly 
slower macroscopic conduction across the infarct border zone on optical mapping, 
suggesting that IBZ conduction velocity may be a determinant of arrhythmia susceptibility 
post-MI. The importance of the infarct border zone morphology as an arrhythmia 
determinant has previously been demonstrated in contrast-enhanced MRI studies in 
humans. Yan et al found that the extent of the structurally heterogeneoeus peri-infarct 
zone (or infarct border zone), as assessed by late-gadolinium MRI, was a strong predictor 
all-cause mortality and cardiovascular mortality (Yan et al., 2006). Similarly, Schmidt et 
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al found that individuals with inducible arrhythmias on PES had greater extents of 
heterogeneous infarct border zone tissue (Schmidt et al., 2007).  
 
The electrophysiological correlate of the increased tissue heterogeneity seen in these MRI 
studies may be the greater magnitudes of conduction slowing across the border zone found 
in the PES(+) hearts in the optical mapping studies described above. Greater tissue 
heterogeneity would be expected to increase the tortuosity and path length across the 
infarct border zone, which then manifests as macroscopic conduction slowing across the 
border zone (de Bakker et al., 1993), as detected on epicardial optical mapping. These 
macroscopic conduction changes, in conjunction with slowing of microscopic conduction 
(Cabo et al., 2006), can predispose to re-entry. 
 
The importance of the infarct border zone in post-MI arrhythmogenesis has also been 
demonstrated in ventricular mapping studies indicating that re-entrant VTs often arise 
from the infarct border zone (Josephson et al., 1978; Josephson et al., 1980; Fenoglio et 
al., 1983). This is supported by substrate ablation studies showing that catheter ablation 
performed at the exit sites of VT circuits at the infarct border zone can successfully 
abolish previously inducible VTs (Marchlinski et al., 2000; Soejima et al., 2001).  
 
It is important to note that greater magnitudes of conduction slowing in the IBZ correlated 
with arrhythmia inducibility at PES, but not with other measures of arrhythmogenicity. 
When hearts were divided based on median values into more arrhythmic (+) vs. less 
arrhythmic (-) groups using isoprenaline challenge or in vivo spontaneous arrhythmia 
burden as assessed by continuous ECG-telemetry, differences in IBZ conduction velocity 
did not reach statistical significance. One explanation is that PES and isoprenaline pulse 
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protocols provoke different types of arrhythmias. PES extrastimuli protocols are designed 
to specifically induce substrate-dependent re-entrant arrhythmias, whereas isoprenaline 
pulse protocols provoke arrhythmias of both re-entrant and non-reentrant mechanisms. 
Therefore, one would expect PES protocols to be the most sensitive in identifying hearts 
with infarct border zone substrates that are susceptible to re-entrant arrhythmias. However, 
whether PES-induced arrhythmias reflect the mechanism of spontaneous in vivo VT 
remains to be determined. 
 
4.5 Summary 
A rat chronic myocardial infarction model was successfully developed and characterised. 
Anterior transmural infarcts were reliably created by ligation of the left anterior 
descending artery. The 4-week post-MI model represented a stable, chronic myocardial 
infarction model. This model possesses a natural range of arrhythmia susceptibility 
spontaneously in vivo and on arrhythmia provocation protocols, and is suitable as a model 
to test the effects of pharmacological interventions on post-MI arrhythmia susceptibility. 
In chronic MI hearts, macroscopic conduction was reduced and action potential duration 
dispersion was increased at the infarct border zone, both of which increase the 
susceptibility to arrhythmias. Conduction velocity in the border zone was slower in hearts 
that were more susceptible to PES-induced arrhythmias and may be a determinant of post 
MI arrhythmia susceptibility. 
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Chapter 5: 
Characterising the effects of 
gap junction modulators 
in intact myocardium 
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5.1 Background 
5.1.1 Gap junction modulators 
Gap junctions are clusters of transmembrane channels that mediate cell-to-cell coupling 
and allow the transfer of ions and small molecules between cells by directly linking the 
cytoplasmic components of adjacent cells (Kanno & Saffitz, 2001; Severs et al., 2004; 
Severs et al., 2008). In the heart, gap junctions also play an important role in mediating 
electrical coupling between cells, and thus have a major role in allowing the orderly 
spread of electrical excitation across the myocardial syncitium. Alterations in gap junction 
function and distribution are known to affect cardiac impulse propagation, and are 
associated with a variety of cardiac pathologies and cardiac arrhythmias (Severs et al., 
2004; Severs et al., 2008; Peters et al., 1995).  
 
Because abnormalities in gap junctions have been implicated in arrhythmogenesis, 
pharmacological gap junction modulators have been conceived as potential anti-
arrhythmic agents (Wit & Duffy, 2008) There are multiple pharmacological agents 
currently available that can modulate gap junction coupling. Carbenoxolone is a gap 
junction uncoupler, whereas AAP10 and rotigaptide are newer agents that enhance gap 
junction coupling. Gap junction modulators were discussed in detail in Section 1.10. 
 
The studies described in this chapter were performed to assess and characterise, in intact 
myocardium, the electrophysiological effects and mechanisms of action of: 
(1) carbenoxolone, a gap junction uncoupler 
(2) rotigaptide and ZP1210, which are peptides that increase gap junction coupling. 
ZP1210 is a new peptide related to rotigaptide (ZP123), obtained from the library 
of peptides from Zealand Pharma (Copenhagen, Denmark). 
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The secondary aim was to compare the relative efficacies of rotigaptide and ZP1210 to 
identify the appropriate peptide to be used for in vivo myocardial infarction studies 
(described in Chapter 7). 
 
Carbenoxolone has been previously shown to have an effect on normal hearts (de Groot et 
al., 2003; Kojodjojo et al., 2006), whist AAP10 and rotigaptide have been shown to have 
selective effects only on myocardium undergoing ischaemia or metabolic stress, without 
any significant effects on normal myocardium. Therefore, different models were used to 
characterise the effects of these gap junction modulators. The effects of carbenoxolone 
were studied in normal hearts, whilst the effects of rotigaptide and ZP1210 were studies in 
ischaemia and metabolic stress models. 
 
5.2 Methods 
All experiments described in this chapter were performed in adult male Sprague-Dawley 
rat hearts. All hearts were explanted and perfused ex vivo as described in Section 2.5.3 
before being subjected to the protocols described below. 
 
5.2.1 Carbenoxolone 
5.2.1.1 Carbenoxolone electrogram studies 
The initial concentration-response studies for carbenoxolone were performed to assess the 
effects of different concentrations of carbenoxolone on its effects on unipolar ventricular 
electrogram morphology. These studies were designed and performed during the initial 
set-up of the Langendorff apparatus, prior to the availability of optical mapping. Five 
hearts were perfused with increasing doses of carbenoxolone at 5-minute intervals, 
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starting with 100nM up to a maximum of 100µM, with continuous recording of the 
epicardial ventricular electrogram from the left ventricular free wall.  
 
A further five hearts were subjected to perfusion with 30µM carbenoxolone over 30 
minutes followed by 20 minutes of washout with perfusate to assess the reversibility of the 
carbenoxolone-induced electrogram changes. 
 
5.2.1.2 Carbenoxolone optical mapping studies 
To assess the effects of carbenoxolone on epicardial conduction velocity and optical 
action potentials, twelve hearts were subjected to optical mapping studies. Six hearts were 
perfused with 30µM carbenoxolone for 30 minutes, and another six hearts were perfused 
with perfusate alone. Transmembrane voltage transients were recorded every two minutes 
during sinus rhythm and ventricular pacing at a cycle length of 200ms. 
 
5.2.1.3 Carbenoxolone Western blotting studies 
To assess the effects of carbenoxolone on Cx43 phosphorylation and expression, four 
hearts were perfused with 30µM carbenoxolone and another four control hearts perfused 
with Krebs-Henseleit perfusate for 30 minutes. Hearts were flash-frozen after the ex vivo 
experiments, and Western blotting was performed as described in Section 2.9.2. The 
Western blotting experiments were performed by Eugene Chang, an Imperial College 
London MRes student, under my supervision. 
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5.2.2 Rotigaptide (ZP123) and ZP1210 
5.2.2.1 Rotigaptide and ZP1210 optical mapping studies 
To determine the effects of rotigaptide and ZP1210 on conduction and action potentials, 
optical mapping studies were performed in a metabolic stress model in 11 hearts. The 
global low-flow ischaemia protocol described in Section 2.5.6 was used as the model of 
metabolic stress. After stabilisation, hearts were treated with rotigaptide (n=3), ZP1210 
(n=3) or control perfusate (n=5) for 20 minutes. Hearts were then subjected to metabolic 
stress for 30 minutes before perfusion with oxygenated perfusate at normal coronary flow 
rates. Transmembrane voltage (Vm) transients were recorded every minute during sinus 
rhythm and ventricular pacing at a cycle length of 200ms. 
 
5.2.2.2 Rotigaptide and ZP1210 Western blotting studies 
To assess the effects of rotigaptide and ZP1210 on Cx43 phosphorylation and expression, 
12 hearts were subjected to regional left anterior descending (LAD) artery ischaemia as 
described in Section 2.5.5. After stabilisation, hearts were perfused with rotigaptide (n=4), 
ZP1210 (n=4) or control perfusate (n=4) for 20 minutes. The LAD artery was then ligated 
for 30 minutes. The heart was divided into 3 segments (ischaemic anterior left ventricle, 
non-ischaemic posterior left ventricle and non-ischaemic right ventricle) to assess the 
differential effects of these agents on ischaemic and non-ischaemic tissue, and flash-
frozen at the end of the experiments. Western blotting was then performed as described in 
Section 2.9.2. The immunoblotting experiments for rotigaptide were performed by Pravina 
Patel, whilst the ZP1210 experiments were performed by Amanda Owusu-Agyei, a fourth 
year medical student at Imperial College London, under my supervision. 
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5.3 Results 
5.3.1 Carbenoxolone 
5.3.1.1 Effect on ventricular electrogram morphology 
As shown in Figure 5-1, carbenoxolone produced significant changes to the duration, 
amplitude and axis of unipolar epicardial left ventricular electrogram. Specifically, there 
was a reduction in ventricular electrogram amplitude and an increase in electrogram 
(QRS) duration with carbenoxolone perfusion. 
 
 
Figure 5-1: Representative unipolar ventricular electrograms showing a reduction in 
amplitude and an increase in duration with carbenoxolone (CBX), and reversal of these 
changes with washout for two different hearts, A and B. 
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Figure 5-2: Concentration-response curves for carbenoxolone, with the epicardial 
ventricular electrogram amplitude and duration measured at various concentrations 
between 100nM and 100µM (n=5). 
 
Using unipolar epicardial electrogram amplitude and duration as markers of 
carbenoxolone activity, concentration-response curves were plotted for 5 hearts for 
concentration ranges between 100nM and 100µM (Figure 5-2). Based on these curves, the 
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concentration range at which carbenoxolone alters electrogram duration and amplitude 
was between 10µM and 100µM (EC50 for electrogram duration and amplitude were 48µM 
and 30µM respectively). 
 
Figure 5-3: (A) Unipolar electrogram duration increased with 30µM carbenoxolone and 
reversed with washout (n=5). (B) Unipolar electrogram amplitude reduced with 30µM 
carbenoxolone and reversed with washout (n=5). (*P<0.05, **P<0.01 vs. baseline). 
	   210 
Carbenoxolone washout studies were performed on a further 5 hearts to assess 
reversibility of these electrogram changes (Figure 5-3). Treatment with 30µM 
carbenoxolone produced a 61.9% ± 9.4% reduction in electrogram amplitude (Start: 
100%, CBX: 39.1% ± 9.4%, Washout: 106.7% ± 26.4%, ANOVA P<0.0001) and an 
85.8% ± 25.7% increase in electrogram duration (Start: 100%, CBX: 185.8% +/- 25.7%, 
Washout: 117.1% ± 13.9%, ANOVA P<0.0001). These changes in amplitude and duration 
reversed completely after 20 minutes of washout with perfusate. 
 
5.3.1.2 Effect on conduction velocity and optical action potentials 
Optical mapping of transmembrane voltage showed that carbenoxolone caused 
progressive slowing in epicardial conduction during ventricular pacing, as shown by the 
progressive crowding of isochrones in Figure 5-4. 
 
Figure 5-4: Isochronal activation maps showing progressive slowing of epicardial 
conduction during ventricular pacing, as evidenced by progressive crowding of isochronal 
lines over 30 minutes, with 30µM carbenoxolone. 
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Figure 5-5: (A) 30µM carbenoxolone reduced conduction velocity over 30 minutes 
(Control n=6, CBX n=6). (B) Rise time of optical action potential was not significantly 
different between control and CBX. (C) CBX perfusion did not alter APD90, APD75 or 
APD50. (D) Representative optical action potentials at baseline and after 30 minutes of 
perfusion with 30µM carbenoxolone. 
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Carbenoxolone at a concentration of 30µM reduced conduction velocity by 28.4 ± 2.8% 
after 30 minutes compared to baseline (P<0.01) (Figure 5-5A). The changes in conduction 
velocity occurred without any significant changes to optical action potential morphology 
(Figure 5-5D). The rise time of the optical action potential was 8.8 ± 0.2 ms after 30 
minutes of carbenoxolone compared with 8.4 ± 0.2 ms for control (P=NS) (Figure 5-5B). 
Action potential durations were also unaltered after 30 minutes of carbenoxolone 
compared to baseline (P=NS for APD90, APD75 and APD50) (Figure 5-5C). 
Carbenoxolone caused a non-significant increase in the dispersion of APD90, measured as 
the standard deviation of APD90 values, after 30 mins (Baseline 3.0 ± 0.3 ms, CBX 4.8 ± 
0.8 ms). 
 
5.3.1.3 Effect on Cx43 expression and phosphorylation 
The effects of carbenoxolone on Cx43 expression and phosphorylation were assessed by 
Western blotting. Thirty minutes of carbenoxolone perfusion did not alter total Cx43 
protein quantity (Control 1.00 ± 0.32 U, CBX 1.33 ± 0.31 U, P=NS). The amount of 
docked, gap junctional Cx43 was also not different between groups (Control 0.67 ± 0.10 
U, CBX 0.58 ± 0.03 U, P=NS). The ratio of phosphorylated to total Cx43 again was 
similar between groups (Control 0.79 ± 0.02, CBX 0.78 ± 0.02, P=NS). These data 
suggest that carbenoxolone caused conduction slowing and gap junction uncoupling 
through a mechanism independent of Cx43 gene expression, protein levels or 
phosphorylation status. 
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Figure 5-6: Carbenoxolone did not alter the ratio of phosphorylated Cx43 to total Cx43, 
as assessed by Western blotting (Control n=3, CBX n=4). The 43kDa band represented 
phosphorylated Cx43 and the 41kDa band represented dephosphorylated Cx43. 
 
5.3.2 Rotigaptide & ZP1210 
5.3.2.1 Effects on conduction velocity and optical action potentials 
In order to assess the effects of rotigaptide and ZP1210, experiments were conducted in a 
model of metabolic stress. There was slowing of conduction over 30 minutes of metabolic 
stress, as shown by the crowding of isochrones in the activation maps in Figure 5-7. 
Metabolic stress resulted in a 41.1 ± 5.6 % slowing of conduction. Both rotigaptide and 
ZP1210 attenuated this conduction slowing of in the context of metabolic stress, with 
reductions in conduction velocity of 21.8 ± 2.7% and 15.6 ± 4.6 % respectively (both 
P<0.05 vs. control). The magnitude of conduction slowing was attenuated to a greater 
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extent in rotigaptide hearts compared to ZP1210 hearts at the same concentration. For all 
three groups, conduction velocity was restored to that of baseline levels after 10 minutes 
of perfusion with oxygenated perfusate at normal coronary flow rates (Figure 5-8). 
 
 
Figure 5-7: Representative isochronal activation maps showing conduction slowing after 
30 minutes of metabolic stress. Both rotigaptide and ZP1210 attenuated the slowing of 
conduction. 
 
The attenuation of conduction slowing in the ZP1210 and rotigaptide groups occurred in 
the absence of significant changes to the action potential morphology (Figure 5-9). The 
rise time of the optical action potential and action potential durations (APD90, APD75 and 
APD50) were not different between the control, ZP1210 and rotigaptide hearts after 30 
minutes of metabolic stress. AP rise time and APDs were also not different when 
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compared to baseline pre-metabolic stress values. The lack of effects on action potentials 
suggest that the effects of rotigaptide and ZP1210 on conduction were most likely due to 
effects on gap junction coupling, and not through actions on active membrane ionic 
currents. 
 
 
Figure 5-8: Both rotigaptide and ZP1210 attenuated the conduction slowing that occurred 
in the context of metabolic stress compared to control. Conduction velocities were 
restored to baseline upon perfusion with oxygenated perfusate at normal coronary flow 
rates. (Rotigaptide n=3, ZP1210 n=3, Control n=5). 
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Figure 5-9: APD90, APD75, APD50 and the rise time of the optical action potentials 
were not different between control (CON), ZP1210 and rotigaptide (ROT) treated hearts 
after 30 minutes of metabolic stress compared with hearts pre-metabolic stress (Pre). 
(Rotigaptide n=3, ZP1210 n=3, Control n=5). 
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5.3.2.2 Effect on Cx43 expression and phosphorylation 
Western blotting experiments were performed in hearts subjected to regional LAD 
territory ischaemia to assess the effects of rotigaptide and ZP1210 on ischaemic and non-
ischaemic tissue. In the four control hearts, ischaemia resulted in significant 
dephosphorylation of Cx43. The proportion of phosphorylated Cx43 in the ischaemic 
anterior left ventricle (ALV) was 44.4 ± 1.3 %, compared with 77.2 ± 4.0 % in the non-
ischaemic posterior left ventricle (PLV) and 80.0 ± 8.0 % in the non-ischaemic right 
ventricle (RV) (P<0.05 for ALV vs. PLV and for ALV vs. RV). Although there was 
significant dephosphorylation of Cx43 in ischaemic tissue, there was no difference in total 
Cx43 protein quantity between ischaemic and non-ischaemic tissue (ALV 3.0 ± 0.4 U, 
PLV 2.4 ± 0.5 U, RV 2.7 ± 0.2 U, P=NS). There was also no difference in the amount of 
docked, gap junctional Cx43 ischaemic and non-ischaemic tissue (ALV 2.8 ± 0.5 U, PLV 
2.3 ± 0.5 U, RV 2.6 ± 0.3 U, P=NS). 
 
As shown in Figure 5-10A, hearts treated with ZP1210 had less dephosphorylation of 
Cx43 in ischaemic tissue. For ZP1210 hearts, the proportions of phosphorylated Cx43 
were 56.7 ± 6.6 % in ischaemic ALV, 64.3 ± 9.0 % in PLV and 77.6 ± 5.5 % in RV, P=NS 
between groups. The attenuation of Cx43 dephosphorylation in ischaemic tissue may 
explain the attenuation in conduction slowing seen in ZP1210 hearts described in Section 
5.3.3.1 above. The quantity of total Cx43 protein and the phosphorylated Cx43 was not 
different between ZP1210 and control, pointing to selective effects on ischaemic tissue. 
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Figure 5-10: (A) Sample Western blot showing increase in dephosphorylated Cx43 
(41kDa band) following 30 minutes of ischaemia in the anterior left ventricle (ALV) 
compared to the non-ischaemic posterior left ventricle (PLV) and right ventricle (RV). 
ZP1210 attenuated the dephosphorylation of Cx43. (B) Grouped data showing attenuation 
of Cx43 dephosphorylation in ALV in ZP1210 hearts (Control n=4, ZP1210 n=4) 
(*P<0.05). (C) Total Cx43 was not different between the ALV, PLV and RV for both 
control and ZP1210 hearts. 
	   219 
Similarly, rotigaptide treated hearts had smaller proportions of dephosphorylated Cx43 in 
ischaemic tissue. For the Western blots from the rotigaptide study, it was possible to 
discern three clear bands and these were quantified separately (Figure 5-11B). The three 
bands are thought to reflect Cx43 protein with different degrees of phosphorylation at the 
carboxy-terminus of the Cx43 protein (Solan & Lampe, 2007). P0 is the dephosphorylated 
Cx43 isoform, phosphorylation at amino acid position S364 and/or S365 is involved in 
forming the P1 isoform, whilst phosphorylation at S325, S328 and/or S330 is necessary to 
form a P2 isoform. Rotigaptide was found to significantly reduce P0 and increase P1 and 
P2 in ischaemic tissue compared to control (Figure 5-11C). The increase in P1 and P2 
isoforms may be the mechanism by which rotigaptide attenuates conduction slowing in the 
context of ischaemia and metabolic stress. Like ZP1210, the effects on Cx43 
phosphorylation was evident only in the ischaemic ALV, but not in the non-ischaemic 
PLV or RV, suggesting rotigaptide has selective effects on ischaemic myocardium. 
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Figure 5-11: (A) Proportions of the phosphorylated Cx43 isoforms (P2 and P1) and the 
dephosphorylated (P0) isoform after 30 minutes ischaemia (ROT: n=4, CON: n=4). (B) 
Representative Western blot for a control heart and a heart treated with rotigaptide (ROT) 
after 30 minutes ischaemia. (C) Increased P2 and P1 proportions and reduction in P0 
proportion for rotigaptide-treated hearts. (*P<0.05). 
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5.4 Discussion 
5.4.1 Effect of carbenoxolone on conduction and action potentials 
The optical mapping studies above showed that 30µM carbenoxolone slowed conduction 
velocity by 28% after 30 minutes, without any significant changes in optical action 
potential upstroke and duration. These findings are consistent with previous studies in the 
literature that have shown the specific gap junction uncoupling effects of carbenoxolone 
without any effect on action potentials or active membrane currents. De Groot and 
colleagues showed that 50µM carbenoxolone decreased longitudinal and transverse 
conduction velocity by 26% and 30% respectively in activation mapping studies 
performed on Langendorff perfused rabbit hearts (de Groot et al., 2003). They also 
showed a 21% reduction in coupling conductance in dual current clamp experiments on 
cell pairs, and an absence of any effect on calcium, potassium, and sodium currents, and 
action potential characteristics in isolated rabbit left ventricular and right atrial myocytes.  
 
Kojodjojo et al also provided evidence for the specific gap junction uncoupling effects of 
carbenoxolone in human myocardium (Kojodjojo et al., 2006). Patients undergoing 
cardiac catheter studies were given 100mg carbenoxolone orally, which caused reductions 
in wavefront propagation velocity of 27% and 23% in the right atrium and right ventricle 
respectively, without any changes in absolute effective refractory periods. Although 
studies in both animals and humans point to the specificity of carbenoxolone in 
uncoupling gap junctions without effects on action potentials in cardiac tissue, Vessey et 
al showed that 100µM of carbenoxolone inhibited voltage-gated calcium channels and 
synaptic transmission in the retina (Vessey et al., 2004). A possible explanation is that 
carbenoxolone at higher concentrations (100µM or greater) also affects calcium currents 
while lower concentrations (50µM or less) cause specific gap junction uncoupling effects. 
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Another possible explanation is the differential specificity of carbenoxolone on cardiac 
and neural tissue. 
 
5.4.2 Effect of carbenoxolone on electrogram morphology 
The administration of carbenoxolone caused a reduction in electrogram amplitude and an 
increase in electrogram duration. These changes were completely reversed after 
approximately 20 minutes of washout, in line with previous reports in the literature (de 
Groot et al., 2003). The prolongation of electrogram duration is consistent with the gap 
junction uncoupling effects of carbenoxolone causing slowing of conduction. This 
conduction slowing leads to delayed ventricular activation, which manifests as prolonged 
ventricular electrogram duration.  
 
There was also a reduction in the amplitude of the electrogram in all hearts studied and 
also an alteration in the axis of the QRS complex in two out of five hearts studied. These 
changes have also been observed in other carbenoxolone studies as well as studies on 
cardiac-restricted Cx43 knockout mice (de Groot et al., 2003; Morley et al., 2005). A 
couple of explanations exist for this diminution of electrogram amplitude. Morley et al 
proposed that the alterations in the amplitude and axis of the electrograms reflect altered 
ventricular activation patterns during sinus rhythm. Using high-resolution optical mapping 
in conditional Cx43 knockout mice, they observed multiple ectopic sites of ventricular 
activation on the epicardial surface, as opposed to the conventional apical epicardial 
breakthrough pattern. They postulated that the reduction in gap junction coupling in these 
knockout mice altered source-sink relationships at normally quiescent Purkinje-ventricular 
muscle junctions and led to paradoxical conduction across these junctions. The aberrant 
activation of the ventricles associated with collision of multiple wavefronts would result in 
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a reduction in amplitude of the electrogram, and on occasions lead to a change in 
electrogram axis.  
 
These Cx43 knockout studies provide a plausible explanation for the reduction in 
electrogram amplitude seen with gap junction uncoupling. However, in the optical 
mapping studies described above, the conventional apical epicardial breakthrough pattern 
was observed during sinus rhythm in all six hearts perfused with carbenoxolone, with no 
evidence of multiple ectopic breakthrough sites. Another explanation is that the reduction 
in electrogram amplitude was a direct result of conduction slowing.  Studies with the gap 
junction uncoupler palmitoleic acid also showed that gap junction uncoupling prolonged 
the duration of the QRS complex of the ECG as a result of conduction slowing (Dhein et 
al., 1999). This was associated with a dose-dependent reduction of electrogram amplitude, 
leading Dhein et al to conclude the changes in amplitude were due to conduction slowing.  
Spach and Dolber suggested that the amplitude of the extracellular potential deflection is 
determined primarily by the magnitude of the membrane ionic currents, and thus the peak-
to-peak amplitude of the ventricular activation signal would be expected to decrease when 
the electrogram duration is prolonged in the event of conduction slowing (Spach & 
Dolber, 1986). 
 
5.4.3 Mechanism of action of carbenoxolone 
Results from the immunoblotting studies showed no change in total Cx43 quantity or 
Cx43 phosphorylation status with carbenoxolone, suggesting that its gap junction 
uncoupling effects were not through these mechanisms. The lack of change in Cx43 
quantity and phosphorylation is consistent with previous studies (de Groot et al., 2003; 
Goldberg et al., 1996). Goldberg et al presented evidence showing that carbenoxolone 
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reduces gap junction coupling by altering connexon configuration within the gap junction 
plaque without obvious changes in protein synthesis or phosphorylation (Goldberg et al., 
1996). Freeze fracture electron microscopy of C6 glioma cells transfected with Cx43 and 
treated with carbenoxolone showed irregular connexon particle spacing and arrangements 
in gap junction plaques. This resulted in an approximately 30% decrease in particle 
density within gap junction plaques on the cell membrane, which could lead to reduced 
gap junctional intercellular communication. 
 
5.4.4 Effect of rotigaptide and ZP1210 on conduction and action potentials 
Rotigaptide and ZP1210 were shown to attenuate conduction slowing seen in the context 
of metabolic stress by 62% and 47% respectively. This increase in conduction velocity 
compared to control occurred in the absence of significant changes to the optical action 
potential. These data provide evidence for the specific actions of these peptides on 
improving gap junction intercellular communication without affecting action potentials, 
and are consistent with previous published work. 
 
Eloff et al used high-resolution optical mapping to measure conduction velocity and 
action potential duration from the ventricular epicardial surface of Langendorff-perfused 
guinea pig hearts, and showed that 80 nM rotigaptide reduced conduction slowing in a 
model of metabolic stress (acidosis) by approximately 60% (Eloff et al., 2003). Action 
potential durations were increased by approximately 10% in their metabolic stress model 
but were not different between control and rotigaptide, which was again consistent with 
the results above. They also assessed the effects of rotigaptide on sodium currents in 
isolated myocytes and found no significant effects, suggesting that the effects of 
rotigaptide on improving conduction velocity were due to its activity on gap junctions. 
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Although the results in this chapter and data from Eloff et al showed only a partial 
attenuation of conduction slowing with rotigaptide, other studies have shown that 
rotigaptide can completely abolish conduction slowing during metabolic stress. Haugan et 
al used a metabolic stress model whereby rat atria were subjected to superfusion with non-
oxygenated glucose-free Tyrodes buffer, and showed that rotigaptide completely 
abolished the 30% conduction slowing seen in the control group (Haugan et al., 2005a; 
Haugan et al., 2005b). These differences in the magnitude of effect of rotigaptide may 
reflect the differences in the choice of metabolic stress models, which may have produced 
different magnitudes of gap junction uncoupling. 
 
The reason a model of metabolic stress was used for the rotigaptide and ZP1210 studies in 
this chapter was that rotigaptide, and its predecessor AAP10, have both been shown to 
have selective effects only on myocardial tissue subjected to some form of metabolic 
stress. Rotigaptide has been shown to have no effect on myocardial tissue subjected to 
physiological conditions (Eloff et al., 2003; Haugan, et al., 2005b). Similarly, AAP10 was 
shown to have effects only in the ischaemic myocardium and border zone of a rabbit 
model of regional LAD ischaemia, but not in the non-ischaemic myocardium (Jozwiak & 
Dhein, 2008). These selective effects on ischaemic tissue give rotigaptide and its related 
peptides an advantage over conventional anti-arrhythmic agents, whose non-selective 
effects can on occasions be pro-arrhythmic. 
 
5.4.5 Mechanism of action of rotigaptide and ZP1210 
The immunoblotting experiments showed that rotigaptide and ZP1210 reduced the 
proportion of ischaemia-induced dephosphorylated Cx43 and increased the proportion of 
phosphorylated Cx43 isoforms, without affecting total Cx43 expression. These effects 
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were only seen in ischaemic tissue, with no effects found on non-ischaemic tissue. These 
data suggest that rotigaptide and ZP1210 may increase conduction velocity and maintain 
gap junction coupling by altering the phosphorylation status of Cx43, which is in line with 
previous work assessing the mechanism of action of these peptides. 
 
Acute ischaemia or metabolic stress is known to be associated with a reduction in 
phosphorylated Cx43 (Beardslee et al., 2000). Dephosphorylation of Cx43 may occur in 
ischaemia in part because the depletion of ATP alters the balance between the activity of 
protein kinases and phosphatases in favour of dephosphorylated Cx43 isoforms 
(Verrecchia et al., 1999). The altered phosphorylation status of Cx43 in this context has 
been shown to be important in the functional gating of gap junctions, with multiple serine 
sites playing an important role (Solan & Lampe, 2009; Lampe et al., 2006). Procida et al 
mutated serine to alanine at multiple sites on the Cx43 carboxy-tail to mimic constitutive 
dephosphorylation, and showed that cells with alanine at position Ser306 had a 57% 
reduction in gap junctional conductance, thus concluding that dephosphorylation of 
Ser306 partly explains the electrical uncoupling seen in myocardial ischaemia (Procida et 
al., 2009). Ser297 and Ser368 have also been shown to be dephosphorylated during acute 
ischaemia and are also thought to contribute to gap junction uncoupling (Axelsen et al., 
2006).  
 
Axelsen et al showed that suppression of dephosphorylation at Ser297 and Ser368 may be 
the mechanism by which rotigaptide improved gap junction coupling (Axelsen et al., 
2006). Similarly, Jozwiak et al demonstrated suppression of dephosphorylation at Ser368 
with AAP10 and postulated that as the mechanism of increased coupling in AAP10-
treated myocardium (Jozwiak & Dhein, 2008). Although the phosphorylation status at 
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specific serine sties were not specifically assessed in the studies in this chapter, it is 
possible that the increased phosphorylation of Cx43 seen in rotigaptide and ZP1210 hearts 
was related to increased phosphorylation at Ser297 and Ser368. 
 
Although there were significant effects on phosphorylation status, the Western blotting 
results showed no change in total Cx43 expression after short durations of treatment with 
rotigaptide or ZP1210 (< 1 hour). This is consistent with other short-term studies on 
rotigaptide, though there are reports in the literature that longer-term treatment with 
rotigaptide and AAP10 can affect Cx43 protein levels. Stahlhut et al showed that 
rotigaptide increased biosynthesis of Cx43 after 24 hours of treatment in neonatal 
ventricular myocytes (Stahlhut et al., 2006), whilst Easton et al demonstrated that AAP10 
increased Cx43 after 5-10 hours exposure (Easton et al., 2009). 
 
5.5 Summary 
Carbenoxolone, a gap junction uncoupler, was shown to reduce conduction velocity and 
increase the dispersion of action potential duration in ex vivo whole heart experiments. 
The mechanism of action of carbenoxolone appeared to be independent of changes to 
Cx43 expression or phosphorylation status. Rotigaptide and ZP1210, from the anti-
arrhythmic peptide (AAP) family, both attenuated conduction slowing during metabolic 
stress without altering action potential morphology. These agents may have increased gap 
junction coupling by maintaining phosphorylation of Cx43 during metabolic stress. 
Rotigaptide had a greater magnitude of effect compared to ZP1210 at equivalent 
concentrations. Carbenoxolone and rotigaptide are selective gap junction modulators, and 
are suitable as tools to assess the effects of gap junction modulation during acute 
myocardial infarction. 
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Chapter 6: 
Effects of gap junction modulation 
on reperfusion arrhythmogenesis 
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6.1 Introduction 
6.1.1 Reperfusion arrhythmias 
Reperfusion arrhythmias can occur within several seconds of restoration of blood flow to 
previously-ischaemic myocardium. Abrupt biochemical and electrophysiological changes 
brought about by the restoration of blood flow are thought to contribute to reperfusion 
arrhythmogenesis (Manning et al., 1984). One potentially pro-arrhythmic factor is the 
abrupt, spatially heterogeneous recovery of action potentials immediately following 
reperfusion (Downar et al., 1977). This spatial heterogeneity of action potentials increases 
the likelihood of re-entry and is thought to contribute to reperfusion arrhythmogenesis 
(Corr & Witkowski, 1983; Wit & Janse, 2001). 
 
6.1.2 Gap junctions and reperfusion arrhythmias 
Although the abrupt recovery of action potentials is thought to be an important factor in 
reperfusion arrhythmogenesis, it is unclear whether the recovery of gap junction coupling 
and conduction velocity also contribute to this process. Gap junction uncoupling is known 
to occur during acute ischaemia (Beardslee et al., 2000; de Groot & Coronel, 2004). 
Cascio et al showed that reperfusion of rabbit papillary muscles subjected to no-flow 
ischaemia can restore gap junction coupling and conduction velocities towards that of pre-
ischaemic values (Cascio et al., 2001). Importantly, it was shown that conduction velocity 
could be restored with reperfusion even after the onset of gap junction uncoupling, which 
was contrary to previous studies suggesting that gap junction uncoupling during ischaemia 
was a marker of impending cell death and was thus irreversible (Kléber et al., 1987). 
These studies raised the possibility that the recovery of gap junction coupling and 
conduction velocity during reperfusion may also play a role in reperfusion 
arrhythmogenesis. 
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Further evidence for the role of gap junction coupling in reperfusion arrhythmogenesis 
comes from a recent study showing that preserving gap junction during acute ischaemia-
reperfusion can reduce the incidence of reperfusion VT following 5 minutes of coronary 
occlusion (Anyukhovsky et al., 2010). These results suggest that changes in gap junction 
coupling may play a role in reperfusion arrhythmogenesis even after relatively brief 
periods of ischaemia.  
 
Based on these background studies, the hypotheses tested in this chapter were:  
(1) the abrupt restoration of gap junction coupling and recovery of conduction 
immediately following reperfusion is pro-arrhythmic, and  
(2) interventions that dampen the abrupt recovery or attenuate the magnitude of 
change in conduction velocity during reperfusion, by altering gap junction 
coupling, may be anti-arrhythmic.  
 
AAP10, a peptide that improves gap junction coupling (Muller et al., 1997b) and 
carbenoxolone (CBX), a known gap junction uncoupler (Kojodjojo et al., 2006), were 
used to test these hypotheses. Both agents have previously been shown to selectively 
affect gap junction coupling without significant effects on action potentials (de Groot et 
al., 2003; Muller et al., 1997a).  
 
6.2 Methods 
6.2.1 Ischaemia-Reperfusion Protocol 
Sixty-three adult male Sprague-Dawley rat hearts were explanted and perfused ex vivo as 
described in Section 2.5.3. The results from studies assessing the effects of ischaemia 
duration on reperfusion arrhythmia incidence (Section 3.3.1) showed that the steep 
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ascending part of the bell-shaped relationship is between six and eight minutes of 
ischaemia duration. Therefore, two different protocols were used in these studies to assess 
the effects of gap junction modulators in reperfusion arrhythmias: 
(1) 6 minutes ischaemia followed by reperfusion – to assess any pro-arrhythmic 
effects of gap junction modulation (n=30) 
(2) 8 minutes ischaemia followed by reperfusion – to assess any anti-arrhythmic 
effects of gap junction modulation (n=33). 
 
For each of these two protocols, following stabilisation, hearts were randomised to one of 
three treatment groups: 
(1) 50nM AAP10 to increase gap junction coupling (AAP10 was perfused with 0.05% 
Bovine Serum Albumin to prevent non-specific binding of the peptide to the 
surfaces of the Langendorff apparatus) 
(2) 30µM carbenoxolone (CBX) to reduce gap junction coupling 
(3) Krebs-Henseleit perfusate only (control group). 
 
These concentrations were selected based on previous studies showing the active 
concentration ranges for the anti-arrhythmic peptides (AAPs) (Muller et al., 1997a; Clarke 
et al., 2006) and carbenoxolone (Papp et al., 2007; de Groot et al., 2003) in modifying gap 
junction coupling, in conjuction with the concentration-response studies described in 
Chapter 5. Hearts were perfused with AAP10, carbenoxolone or perfusate for a further 5 
minutes before being subjected to regional ischaemia-reperfusion as described in Section 
2.5.4. The ischaemic duration was either 6 or 8 minutes depending on the protocol. The 
reperfusion phase was continued for 15 minutes with continuous electrogram monitoring. 
The incidence of ventricular arrhythmias during the ischaemic and reperfusion periods 
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were recorded and compared between groups. Ventricular arrhythmias were classified 
according to the Lambeth Conventions guidelines (Walker et al., 1988). 
 
6.2.2 Optical mapping of ischaemia-reperfusion 
A further 18 hearts were subjected to ischaemia-reperfusion as described above, with 
simultaneous optical mapping of transmembrane voltage (Vm). Hearts were perfused for 
optical mapping as described in Section 2.6.3, and stained with RH237, a voltage sensitive 
dye, and perfused with blebbistatin, an excitation-contraction uncoupler. Hearts were then 
randomised to treatment with 50nM AAP10 (n=6), 30µM carbenoxolone (n=6) or 
perfusate only (control; n=6). As above, hearts were perfused with drug or perfusate for a 
further 5 minutes before being subjected to 8 minutes of regional LAD ischaemia 
followed by reperfusion as described in Section 2.5.4. Coronary flow rate was 15ml/min at 
baseline and at reperfusion, and halved to 7.5ml/min during regional ischaemia. 
 
Transmembrane voltage signals were recorded at baseline pre-ischaemia, and at one-
minute intervals during ischaemia and reperfusion. Two-second recordings were obtained 
at each time-point during sinus rhythm and during ventricular pacing at a cycle length of 
200ms, using a MicroPace stimulator (MicroPace, Auckland, New Zealand). Optical 
mapping data was analysed as described in Section 2.6.4, and the differences in 
conduction velocities and optical action potentials were compared between the treatment 
groups. 
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6.3 Results 
6.3.1 6 minutes ischaemia-reperfusion protocol 
The 6 minutes ischaemia-reperfusion protocol was performed to detect any pro-arrhythmic 
effects of gap junction modulation on reperfusion arrhythmogenesis. Figure 6-1 shows 
Kaplan-Meier survival curves showing freedom from reperfusion VT and VF. As shown 
in Figure 6-1A, there were no significant differences in reperfusion arrhythmia incidence 
between the treatment groups for both reperfusion VT and VF, suggesting no pro-
arrhythmic effects of gap junction modulation. For reperfusion VF incidence, there was a 
lower incidence for the AAP10 group (10%) compared to control (30%), although this did 
not achieve statistical significance as the 6 minutes ischaemia-reperfusion protocol was 
not designed or powered to detect any anti-arrhythmic effects. Heart rate at ischaemia 
onset, heart rate at reperfusion and the percentage coronary flow reduction are known to 
be determinants of reperfusion arrhythmias and were potential confounding variables 
(Bernier et al., 1989; Curtis & Hearse, 1989b). These were not different between treatment 
groups (Figure 6-2A). 
 
6.3.2 8 minutes ischaemia-reperfusion protocol 
The 8 minutes ischaemia-reperfusion protocol was performed to detect any anti-
arrhythmic effects of gap junction modulation (Figure 6-1B). Both AAP10, which 
increased gap junctional intracellular communication, and carbenoxolone (CBX), which 
uncoupled gap junctions, reduced the incidence and significantly improved survival from 
reperfusion VF (Median survival from VF: AAP10 482.6s, CBX 59.8s, Control 18.2s; 
LogRank P<0.05 for AAP10 vs. Control and for CBX vs. Control). AAP10 also 
significantly improved survival from reperfusion VT (P<0.05) whilst there was a non-
significant improvement in survival from reperfusion VT in the CBX group (P=0.06) 
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(Median survival from VT: AAP10 480.2s, CBX 38.0s, Control 5.1s). In hearts that 
developed reperfusion VT, CBX delayed the onset of arrhythmia (median time to VT 
36.1s, IQR 3.9s-65.0s) compared to control (median 4.8s, IQR 2.6s-7.7s). 
 
Figures 6-2B shows the potential confounding variables for the varying incidences of 
reperfusion arrhythmias observed. Heart rate at ischaemia onset, heart rate at reperfusion 
and percentage coronary flow reduction were not different between groups, suggesting 
that the observed difference in reperfusion arrhythmia incidence was not due to 
differences in these confounding variables, but due to the effects of gap junction 
modulation. 
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Figure 6-1: Kaplan-Meier survival curves showing freedom from reperfusion VT and VF 
for control hearts and hearts treated with CBX and AAP10 (*P<0.05). (A) No difference 
between groups for 6 minutes ischaemia-reperfusion protocol (AAP10 n=10, CBX n=10, 
Control n=10). (B) Both AAP10 and CBX improved survival from reperfusion VF in the 8 
minutes ischaemia-reperfusion protocol (AAP10 n=10, CBX n=13, Control n=10). 
(*P<0.05 vs. control). 
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Figure 6-2: Potential confounding variables: heart rates at ischaemia and reperfusion and 
percentage coronary flow reduction were not different between control, carbenoxolone 
(CBX) and AAP10 hearts for the (A) 6 minutes ischaemia-reperfusion protocol (AAP10 
n=10, CBX n=10, Control n=10) and (B) 8 minutes ischaemia-reperfusion protocol 
(AAP10 n=10, CBX n=13, Control n=10). 
 
6.3.3 Effects of gap junction modulation on conduction during ischaemia-reperfusion 
Optical mapping experiments were performed during regional ischaemia-reperfusion to 
assess the effects of gap junction modulation on conduction velocities in this setting. As 
shown in Chapter 3, ischaemia caused progressive slowing of conduction during 
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ventricular pacing over the course of 8 minutes. This was then followed by the abrupt 
restoration of normal conduction velocities at 1 minute after reperfusion. Figure 6-3 shows 
representative epicardial activation maps for AAP10, CBX and control hearts at baseline, 
peak-ischaemia and post-reperfusion. As with control hearts, conduction also slowed 
during ischaemia and increased with reperfusion for AAP10 and CBX hearts. 
 
Figure 6-3: Representative epicardial activation maps pre-ischaemia, at 8 minutes 
ischaemia and at 1 minute reperfusion for control, CBX and AAP10 hearts. There was less 
conduction slowing in AAP10 hearts after 8 minutes ischaemia, and slower conduction in 
CBX hearts at 1 minute post-reperfusion. 
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Figure 6-4: Changes in epicardial conduction delay over 8 minutes ischaemia and 3 
minutes reperfusion. AAP10 attenuated conduction slowing during ischaemia, whilst CBX 
attenuated recovery of conduction during reperfusion (n=6 in each group) (*P<0.05 vs. 
control).  
 
Figure 6-4 shows the changes in conduction delay across a 0.6cm2 area of the anterior left 
ventricular myocardium supplied by the left anterior descending (LAD) artery at baseline, 
during LAD artery ischaemia and after reperfusion, comparing gap junction modulator 
groups to control. The time taken for activation to traverse this area of left ventricular 
myocardium is a measure conduction velocity. AAP10, a peptide that increases gap 
junction coupling, attenuated the degree of conduction slowing over the course of 8 
minutes of ischaemia. AAP10 resulted in 50% less conduction slowing compared to 
control after 8 minutes ischaemia (P<0.05). The conduction delay was restored to pre-
ischaemic levels within 1 minute of reperfusion. Carbenoxolone, a gap junction uncoupler, 
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produced greater conduction delays at baseline, but conduction delays were not different 
to control at peak ischaemia. After reperfusion, conduction velocities were partially 
restored towards control values but were significantly slower than control (P<0.05). 
 
Although AAP10 and CBX had opposite effects on gap junction coupling, their effects on 
conduction both resulted in smaller magnitudes of change in conduction at the time of 
reperfusion (both P<0.05 vs. control), as shown in Figure 6-5. Compared to control, 
AAP10 hearts had smaller magnitudes of recovery of conduction because there was less 
slowing of conduction during ischaemia, whereas CBX hearts had smaller magnitudes of 
recovery of conduction because conduction was slower post-reperfusion relative to 
control. As it is thought that the rapid, abrupt changes in action potentials and conduction 
during reperfusion is pro-arrhythmic, the attenuation of recovery of myocardial 
conduction in both the AAP10 and CBX hearts may account for the reduced incidence and 
improved survival from reperfusion VF observed in the studies described above. 
 
Figure 6-5: AAP10 and CBX both reduced the percentage change in conduction delay 
during reperfusion (n=6 in each group) (*P<0.05 vs. control).  
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6.3.4 Effects of gap junction modulation on optical action potentials during 
ischaemia-reperfusion 
The changes in optical action potentials during regional ischaemia and reperfusion were 
studied. As shown in Chapter 3, regional ischaemia resulted in a shortening of action 
potential duration and a reduction in amplitude of the optical action potential in the central 
ischaemic zone. These action potentials were rapidly restored to pre-ischaemic levels after 
reperfusion. Figure 6-6 shows representative optical action potentials at baseline, during 
ischaemia, and after reperfusion, from control, AAP10 and CBX hearts. The 
superimposition of optical action potential shows no gross differences between control 
and gap junction modulator groups. Optical action potentials from AAP10 and CBX 
hearts also underwent the same pattern of changes during ischaemia-reperfusion. 
 
Figure 6-7 and Table 6-1 shows the changes in action potential duration (APD90, APD75, 
APD50), action potential upstoke (rise time, dF/dtmax) and optical action potential 
amplitude over the course of 8 minutes of LAD territory ischaemia and subsequent 
reperfusion. There were no significant differences between groups for all these measures 
of action potential upstroke and duration over the course of ischaemia and reperfusion. 
These data suggest that the effects of AAP10 and CBX were specific for gap junctions 
without any gross effects on action potentials.  
 
There was a non-significant decrease in the rise time of the optical action potential in 
AAP10 hearts compared to control during ischaemia. Unlike from single cell recordings, 
the optical AP upstroke not only reflects membrane excitability and Na-channel activity, 
but because it is a summation of signals from all the cells in that 1mm x 1mm pixel, it also 
reflects conduction velocity across that pixel. The faster upstroke of the optical AP in 
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AAP10 hearts may simply reflect increased gap junction coupling and increased 
conduction velocity. 
 
 
Figure 6-6: Superimposed optical APs from control, carbenoxolone (CBX) and AAP10 
hearts at baseline, 4 minutes ischaemia, 8 minutes ischaemia and 2 minutes reperfusion, 
showing no differences between treatment groups.  
 
Although mean APDs were not different between groups, AAP10 did reduce the 
dispersion of action potential duration (APD90) after 8 minutes ischaemia compared with 
control and carbenoxolone (Standard deviation of APD90 measurements: AAP10 2.3 ± 
0.8 ms; CBX 5.1 ± 1.2ms; Control 4.9 ± 2.0ms, ANOVA P<0.01, Post-hoc Tukey’s 
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P<0.05 for AAP10 vs. control and CBX), and at 1 minute post-reperfusion. The reduced 
dispersion in APD can be attributed to increased gap junction intercellular 
communication, which allows for the passive equalisation of charge between cells to 
reduced regional differences in APDs. This reduction in APD dispersion may be a further 
mechanism by which AAP10 protects from reperfusion arrhythmias.  
 
Figure 6-7: Optical action potential (AP) changes during ischaemia-reperfusion. Optical 
APDs shortened, AP upstroke slowed and amplitude was reduced with ischaemia, and 
these changes reversed with reperfusion. These changes were not different between 
treatment groups (n=6 in each group).  
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  Control AAP10 CBX P value 
Conduction  Baseline 9.7 ± 0.2 9.3 ± 0.8 11.2  ± 0.5 NS 
delay (ms) 8 mins ischaemia 26.3 ± 1.5 * 17.3 ± 1.1 * 27.3 ± 1.5 <0.05 
 3 mins reperfusion 7.3 ± 1.2 8.8 ± 0.8 * 13.7 ± 1.2 * <0.05 
      
APD90 (ms) Baseline 92 ± 6 81 ± 6 81 ± 7 NS 
 8 mins ischaemia 61 ± 3 72 ± 9 63 ± 3 NS 
 3 mins reperfusion 80 ± 12 90 ± 6 90 ± 3 NS 
      
APD75 (ms) Baseline 72 ± 5 64 ± 6 64 ± 8 NS 
 8 mins ischaemia 47 ± 3 55 ± 7 49 ± 3 NS 
 3 mins reperfusion 62 ± 10 72 ± 6 68 ± 2 NS 
      
APD50 (ms) Baseline 43 ± 4 44 ± 4 42 ± 6 NS 
 8 mins ischaemia 33 ± 3 39 ± 4 33 ± 2 NS 
 3 mins reperfusion 41 ± 8 51 ± 6 44 ± 1 NS 
      
Rise time  Baseline 8.8 ± 0.1 8.7 ± 0.1 8.6 ± 0.1 NS 
(ms) 8 mins ischaemia 11.8 ± 1.2 10.6 ± 0.7 12.3 ± 1.0 NS 
 3 mins reperfusion 8.9 ± 0.1 8.9 ± 0.1 8.8 ± 0.1 NS 
      
dF/dtmax  Baseline 17.3 ± 1.4 20 ± 0.3 19.4 ± 0.4 NS 
(U/s) 8 mins ischaemia 12.9 ± 1.7 13.4 ± 0.9 12.1 ± 0.9 NS 
 3 mins reperfusion 19.6 ± 0.7 19.7 ± 0.4 18.7 ± 0.8 NS 
      
AP  Baseline 100 100 100 NS 
amplitude 8 mins ischaemia 61 ± 6 63 ± 4 60 ± 6 NS 
(%) 3 mins reperfusion 65 ± 10 59 ± 5 70 ± 13 NS 
Table 6-1 (Description on following page). 
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Table 6-1 (on previous page): Values for LV anterior wall conduction delay, action 
potential duration (APD) 90, APD75, APD50, rise time, dF/dtmax and AP amplitude for 
control, AAP10 and carbenoxolone (CBX) hearts, at baseline, after 8 minutes of LAD 
ischaemia and at 3 minutes post-reperfusion (n=6 in each group). Values shown as mean ± 
S.E.M. ANOVA P values are shown for comparison between the three groups, asterisks 
denotes P<0.05 for post-hoc Tukey’s test. 
 
6.4 Discussion 
The main findings from this chapter were: (1) Both AAP10, a peptide that improved gap 
junction coupling, and carbenoxolone (CBX), a gap junction uncoupler, improved survival 
from reperfusion VF. (2) Ischaemia produced progressive slowing of conduction, 
shortening of action potential duration and slowing of action potential upstroke, all of 
which recovered rapidly upon reperfusion. (3) AAP10 and CBX, through different 
mechanisms, resulted in smaller magnitudes of recovery of conduction velocities 
immediately following reperfusion, which may underlie their anti-arrhythmic effect. (4) 
AAP10, by maintaining gap junctional intercellular communication, also reduced the 
dispersion of action potential durations immediately prior to reperfusion. 
 
6.4.1 Abrupt recovery of myocardial conduction in the setting of reperfusion is pro-
arrhythmic  
It has previously been established that the rapid recovery of action potentials immediately 
following reperfusion is pro-arrhythmic because the spatially-distributed restoration of 
action potentials is not equally rapid in the first few seconds (Kaplinsky et al., 1981). The 
initial unequal recovery may in part be due to spatial heterogeneities in coronary blood 
flow (Conway & Weiss, 1985; Aldea et al., 1990; Austin et al., 1990), as well as 
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heterogeneities in cellular injury prior to reperfusion due to heterogeneities in cellular 
metabolism (Decking & Schrader, 1998), resulting in some regions of ischaemic 
myocardium recovering before others. This leads to heterogeneities of action potentials in 
the reperfused myocardium, which predisposes to re-entrant arrhythmias (Manning & 
Hearse, 1984; Wit, 2001). 
 
The data above suggest that rapid recovery of myocardial conduction also contributes to 
the arrhythmic substrate post-reperfusion, with evidence suggesting that gap junction 
modulators, through the action of attenuating the magnitude and the rate of recovery of 
conduction velocity immediately following reperfusion, can protect against reperfusion 
arrhythmias. It is possible that, as the restoration of electrophysiological properties in 
ischaemic myocardium tends to be initially heterogeneous for reasons described above, 
greater magnitudes of recovery of conduction will create greater heterogeneities of local 
conduction velocities in the first few seconds post-reperfusion. This increased dispersion 
of local conduction velocities is known to increase susceptibility to re-entry (van Rijen et 
al., 2004; Wiegerinck et al., 2008). 
 
Further support for the hypothesis that rapid recovery of conduction and action potentials 
during reperfusion is pro-arrhythmic comes from studies looking at the effects of slow 
reperfusion, where reducing the rate of reperfusion was shown to reduce the incidence of 
reperfusion arrhythmias (Petropuolos & Meijne, 1964). In a study where dogs were 
reperfused following 30 minutes of circumflex artery ligation, the Sheehan et al found an 
inverse relationship between survival during reperfusion and peak rate at which blood 
flow returned to the ischaemic myocardium (Sheehan & Epstein, 1982). 
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These data, in conjunction with the results demonstrating the protective effects of gap 
junction modulation against reperfusion arrhythmias, suggest that the speed and 
magnitude of recovery following reperfusion are important determinants of reperfusion 
arrhythmias. It follows that any other pharmacological or biological intervention that 
dampens or reduces the rate or magnitude of recovery of conduction or action potentials 
may also reduce the incidence of reperfusion arrhythmias. 
 
There are also other possible mechanisms, not specifically assessed in these studies, by 
which gap junction modulation may protect against reperfusion arrhythmias. Some 
reperfusion arrhythmias are non-reentrant and are due to triggered arrhythmias. The 
likelihood of these triggered arrhythmias can be increased by calcium overload or the 
formation of reactive oxygen species (ROS) during reperfusion (Manning et al., 1984). It 
is possible that the enhancement of gap junction coupling may increase the sink available 
for calcium and ROS to diffuse out of the ischaemic myocardium, thus reducing the 
likelihood of triggered arrhythmia. Altering gap junction coupling may also create current 
source-sink mismatches to prevent the propagation of triggered action potentials (Xie et 
al., 2010). Enhancement of coupling may create a current sink that is greater than the 
current source provided by the cells with triggered action potentials, resulting in a 
reduction in safety factor, conduction block and failure of propagation of those action 
potentials (Rohr et al., 1997). 
 
6.4.2 Gap junction uncoupling after brief periods of ischaemia 
In the studies described above, the left anterior descending artery was occluded for 6 or 8 
minutes before reperfusion. These durations are at the steep part of the bell-shaped 
relationship between ischaemia duration and reperfusion arrhythmia incidence (Bernier et 
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al., 1989; Penny & Sheridan, 1983). Previous studies measuring extracellular resistance in 
arterially-perfused rabbit papillary muscle have shown that gap junction uncoupling only 
occurs 10-15 minutes after the onset of ischaemia (Kléber et al., 1987). Beardslee et al 
also showed that uncoupling occurs after approximately 15 minutes after onset of global 
ischaemia in the isolated, perfused rat heart, coinciding with the onset of Cx43 
dephosphorylation (Beardslee et al., 2000). 
 
However, there are studies that suggest that gap junction uncoupling can occur within 
several minutes of onset of ischaemia. It has been demonstrated that acute ischaemia 
causes a rapid decrease in pH to approximately 6.4 after 5 minutes (Garlick et al., 1979), 
which would be expected to lead to significant uncoupling of Cx43 channels (Liu et al., 
1993). Furthermore, it has been shown that Cx32-expressing mouse, which are less 
sensitive to pH-induced uncoupling and therefore have preserved gap junction coupling 
during acute iscahemia-reperfusion, have reduced arrhythmia incidence in a 5-minute 
ischaemia-reperfusion protocol, suggesting that gap junction uncoupling occurs within the 
first few minutes of ischaemia (Anyukhovsky et al., 2010).  
 
The data in this chapter suggest that, in this ex vivo rat model of ischaemia-reperfusion, 
gap junction uncoupling occurs within several minutes of ischaemia onset. Over the 8 
minutes of ischaemia, it was shown using optical mapping that there was significant 
conduction slowing across the epicardial surface of the ischaemic left ventricle. Some of 
this conduction slowing can be explained by inactivation of sodium channels and reduced 
membrane excitability (Kléber, 1987). However, the observation that AAP10, a specific 
gap junction channel opening agent (Muller et al., 1997a), can attenuate conduction 
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slowing suggests that a significant proportion of this conduction slowing is due to gap 
junction uncoupling.  
 
One possible explanation for the differences in the timing of onset of gap junction 
coupling between the studies by Kleber et al and Beardslee et al with the studies in this 
thesis and those by Anyukhovsky et al is the difference in experimental models. The 
studies that showed gap junction uncoupling occurred 15 minutes after ischaemia onset 
were performed in global ischaemia experiments (Kléber et al., 1987; Beardslee et al., 
2000), whereas studies supporting an earlier onset of gap junction uncoupling were in 
regional ischaemia experiments (Anyukhovsky et al., 2010). As demonstrated earlier in 
Chapter 3, global no-flow ischaemia rapidly led to a cessation of sinus node activity and 
hearts were essentially electrically quiescent at 3-5 minutes after ischaemia onset. 
However, as shown in Chapter 4 and in this chapter, hearts subjected to regional 
ischaemia retained sinus node activity and had heart rates of over 200 beats per minute 
throughout the duration of ischaemia. The heart rate during ischaemia was shown to be a 
crucial factor in determining the rate of onset of ischaemia-induced electrophysiological 
changes in Chapter 3. Therefore, because the heart rates are significantly greater in 
regional ischaemia experiments compared with global no-flow ischaemia experiments, it 
would be expected that gap junction uncoupling would be observed significantly earlier in 
regional ischaemia studies. 
 
6.4.3 Specificity of pharmacological gap junction modulators 
Previous studies have shown that gap junction channel opening peptides such as AAP10 
and rotigaptide (Muller et al., 1997a; Kjolbye et al., 2003), and the gap junction uncoupler 
carbenoxolone (de Groot et al., 2003; Kojodjojo et al., 2006), have relatively specific 
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effects on gap junctions and no discernable effects on action potential morphology. 
Although ion channel activity was not directly studies, optical action potentials were 
recorded over the course of ischaemia and reperfusion. These results also showed that 
AAP10 and carbenoxolone did not significantly alter action potential morphology 
compared to control in the context of acute ischaemia and reperfusion, thus supporting 
earlier findings about the specificity of these agents. Although there were no differences in 
mean action potential duration, a reduction in dispersion of APDs for AAP10 hearts was 
observed, which is consistent with previous reports of AAP10 reducing activation-
recovery intervals (Dhein et al., 1994). AAP10 is thought to reduce repolarisation 
heterogeneities by allowing the passive equalisation of charge between cells by increasing 
gap junction intercellular communication. 
 
6.4.4 Gap junction modulation as a therapeutic strategy 
Modulation of gap junction coupling has received much interest in recent years as a 
possible novel anti-arrhythmic strategy (Wit & Duffy, 2008; Dhein et al., 2010). The 
results above suggest that modulating gap junction coupling can protect against 
reperfusion arrhythmias by attenuating the abrupt recovery of myocardial conduction 
following reperfusion, and may be of use in clinical practice. The duration of ischaemia in 
this model was relatively short, therefore the results would suggest that gap junction 
modulation may be protective against reperfusion arrhythmias following brief periods of 
coronary vasospasm lasting several minutes (Tzivoni et al., 1983; Miller et al., 1982). It is 
unclear whether these results can be extrapolated to settings of reperfusion following 
hours of ischaemia such as the primary angioplasty setting. 
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However, these results on the anti-arrhythmic effects of gap junction modulation relate to 
the very specific setting of reperfusion arrhythmias and must be interpreted with care. 
Reperfusion is part of a wider spectrum that includes acute ischaemia-infarction-
reperfusion and should not be viewed in isolation. The effects of gap junction modulation 
are situation-specific and modulating gap junction coupling in one direction may be 
beneficial in some settings but detrimental in others. 
 
The strategy of uncoupling gap junctions with carbenoxolone may be protective in the 
narrow setting of reperfusion, but may actually be pro-arrhythmic in the event of longer 
durations of ischaemia, as the conduction slowing and increased repolarisation dispersion 
brought about by progressive uncoupling would be expected to predispose to ischaemic 
ventricular arrhythmias (de Groot, 2002; de Groot & Coronel, 2004). The strategy of 
improving gap junctional communication, for example with AAP10 or rotigaptide, may 
protect against ischaemic and reperfusion arrhythmias (Haugan et al., 2006b), but 
concerns exist that facilitating intercellular communication during acute 
ischaemia/infarction may facilitate the spread of infarction and lead to larger infarct sizes 
(Prestia et al., 2011).  
 
6.4.5 Study limitations 
A limitation of the above studies is the lack of reliable optical mapping data from the first 
few seconds immediately following reperfusion, due to technical issues of movement 
artefact and altering depth of focus upon releasing the occluder tube and suture to cause 
reperfusion. The first reliable recordings were 60 seconds after reperfusion, by which time 
conduction had recovered and stabilised to that of pre-ischaemic levels. This limited the 
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ability to draw firm conclusions about the heterogeneities of conduction that occur 
immediately following reperfusion. 
 
A further limitation was that, using optical mapping, it was only possible to map 
transmembrane voltage transients from the epicardial surface of the heart (Efimov et al., 
2004). With epicardial mapping, it was not possible to determine with certainty whether 
the reperfusion arrhythmias in this model were re-entrant or non-reentrant in nature. Some 
of the arguments presented above were based on the assumption that the majority of 
reperfusion arrhythmias in this model are due to re-entry, though arrhythmias in this 
setting could also be due to triggered activity or enhanced automaticity (Manning et al., 
1984). The observation that modifying conduction changes can alter arrhythmia incidence 
supports the assumption that these arrhythmias are predominantly re-entrant. Furthermore, 
studies looking at calcium accumulation kinetics in ischaemia have shown that short 
durations of ischaemia of up to 10 minutes were not associated with excess calcium 
accumulation (Shen & Jennings, 1972). Similarly, Allen et al, using aequorin to monitor 
intracellular calcium in ferret papillary muscle subjected to ischaemia, showed that 
intracellular calcium started to rise within 10 minutes of onset of ischaemia and reached a 
peak at 20-30 minute after ischaemia (Allen et al., 1989). These data suggest that calcium-
induced triggered arrhythmias were less likely in the model above, where hearts were only 
subjected to 8 minutes of ischaemia before reperfusion. 
 
6.5 Summary 
Increasing gap junction coupling with AAP10 or uncoupling gap junctions with 
carbenoxolone protected against reperfusion arrhythmias in a model of acute ischaemia-
reperfusion. Both AAP10 and carbenoxolone attenuated the magnitude and rate of 
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recovery of conduction velocities immediately following reperfusion, which may underlie 
their protective effects. In addition, AAP10 also reduced the dispersion of action potential 
durations at peak ischaemia and immediately after reperfusion, which may contribute to 
its observed anti-arrhythmic effect. 
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Chapter 7: 
Effects of acute gap junction modulation 
on the healed infarct morphology 
and post-MI arrhythmogenesis 
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7.1 Introduction 
7.1.1 Infarct morphology as a determinant of post-MI arrhythmias 
Ventricular arrhythmias are responsible for the majority of sudden cardiac deaths (Morgan 
et al., 2006; Zheng et al., 2001), with myocardial infarction (MI) being the principal 
underlying cause for these lethal tachyarrhythmias (Huikuri et al., 2001). The majority of 
sudden cardiac deaths in patients with myocardial infarction occur months to years after 
their index event (Adabag et al., 2008). For ventricular arrhythmias that occur in the 
chronic MI setting, infarct morphology has been demonstrated to be a determinant of 
arrhythmia susceptibility.  
 
Larger infarcts are known to be more susceptible to post-MI arrhythmias, and infarct 
surface area and mass, as measured by cardiac MRI, have been shown to identify patients 
who have a substrate for monomorphic VT (Bello et al., 2005). Heterogeneity of infarct 
scarring has also been identified as a determinant of late post-MI arrhythmias, with 
increased heterogeneity of fibrosis being associated with increased arrhythmic risk 
(Schmidt et al., 2007). Inhomogeneous scarring leads to bundles of surviving myocardium 
within areas of dense scar and creates complex interactions between fibrotic tissue and 
surviving myocardium at the infarct borders, both of which are thought to play a role in 
the anatomical re-entry circuits in post-MI ventricular tachycardia (VT) (de Bakker et al., 
1988; de Bakker et al., 1993). Structural discontinuities due to inhomogeneous scarring 
are also thought promote arrhythmogenesis by promoting wavebreak (Derksen et al., 
2003) and amplifying discordant alternans (Engelman et al., 2010). 
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7.1.2 Gap junction modulation to modify infarct spread and healing during acute MI 
Gap junctions play an important role in mediating electrical coupling between cells and in 
reducing inhomogeneties of action potentials and repolarisation across ventricular 
myocardium (Eloff et al., 2003; Quan et al., 2007). Another less discussed function of gap 
junctions is their potential to modulate the spread of infarction during acute MI. Studies 
have shown that modulating gap junction coupling can, by altering communication 
between adjacent cardiomyocytes, modify infarct spread and alter the size of the healed 
infarct (Garcia-Dorado et al., 1997; Kanno et al., 2003; Saltman et al., 2002; Haugan, 
Marcussen, et al., 2006b; Hennan et al., 2006). This raises the possibility that modulating 
gap junction coupling acutely can also modify the morphology of the healed infarct with 
profound effects on late post-MI arrhythmia susceptibility.  
 
Conceptually, there are reasons to expect why either increasing or reducing gap junction 
coupling during acute MI can beneficially modify the healed infarct substrate to reduce 
post-MI susceptibility. Analagous to the concept of reducing inhomogeneities of action 
potentials described above, enhancement of gap junctional intercellular communication 
during acute MI may produce more homogeneous cell necrosis during myocardial 
infarction and reduce inhomogeneities in the healed infarct, thus producing a less 
arrhythmic substrate. Reducing coupling during acute MI may reduce the spread of the 
infarct, thus producing smaller infarcts and reducing post-MI arrhythmia susceptibility. 
 
The hypothesis for the following studies described in this chapter was that the modulation 
of gap junction coupling acutely during MI could modulate the spread of infarction and 
infarct healing, thus modifying the healed MI substrate and altering post-MI arrhythmia 
susceptibility. To test this hypothesis, gap junction modulators were given acutely to rats 
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undergoing MI and the healed infarct was studied at 4 weeks post-MI. Rotigaptide was 
used to enhance gap junction coupling whilst carbenoxolone was used to reduce gap 
junction coupling. 
 
7.2 Methods  
7.2.1 Chronic Myocardial Infarction Protocol 
Forty male Sprague-Dawley rats (250g) were subjected to surgical myocardial infarction 
as described in Section 2.3.3. Rats were randomly allocated to one of 3 groups: (1) 
treatment with rotigaptide to enhance gap junction coupling (n=13), (2) treatment with 
carbenoxolone to reduce gap junction coupling (n=13) or (3) phosphate-buffered saline 
(PBS) as control group (n=14). Rats were pre-treated with a bolus of gap junction 
modulator or vehicle subcutaneously immediately before LAD artery ligation (2.5nmol/kg 
rotigaptide, 5mg/kg carbenoxolone or 0.5ml PBS). Gap junction modulators or vehicle 
were then delivered for 7 days post-myocardial infarction using osmotic minipumps 
(Azlet 2ML1), which were placed in the peritoneal cavity at the time of the myocardial 
infarction surgery (Infusion dose: Rotigaptide 0.11nmol/kg/min, Carbenoxolone 
100mg/kg/day, or PBS 2ml/week).  
 
Doses were selected based on the existing literature. The rotigaptide doses were based on 
the doses used in the study by Haugan et al, who measured plasma concentrations in rats 
after administration of rotigaptide (Haugan et al., 2006b). They showed that the 
administration of the above doses of rotigaptide in rats produced plasma concentrations of 
16 ± 4.5 nM, which was within its therapeutic range of 10nM to 50nM, and also 
demonstrated enhancement of gap junction coupling with these doses. The carbenoxolone 
doses were based on a number of in vivo studies in rat. The doses used in this chapter have 
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previously been shown to produce gap junction uncoupling effects in vivo in rats 
(Bostanci & Bagirici, 2007; Gareri et al., 2005; Gareri et al., 2004; Hosseinzadeh et al., 
2005). The carbenoxolone dose of 100mg/kg/day was also shown to produce in vivo ECG 
changes in preliminary dose-response studies. 
 
For the animals that survived the initial MI surgery, a second surgical procedure was 
performed at 2 weeks post-myocardial infarction to remove the osmotic minipump and to 
implant ECG-telemetry devices as described in Section 2.4.3. At four weeks post-
myocardial infarction, rats had 24 hours of continuous ECG-telemetry recording to 
document in vivo arrhythmia burden. The incidence of spontaneous arrhythmia burden 
were compared between groups. Analysis was performed blinded to treatment groups. 
 
7.2.2 Ex vivo optical mapping and arrhythmia provocation protocols 
At 4 weeks post-MI, after ECG-telemetry recording as described above, rats were 
sacrificed, and hearts were perfused ex vivo for optical mapping as described in Section 
2.6.3. Hearts were subjected to transmembrane voltage (Vm) mapping followed by 
arrhythmia provocation protocols to induce ventricular arrhythmias. Programmed 
Electrical Stimulation (PES) and isoprenaline pulse protocols were performed as described 
in Sections 2.7.2 and 2.7.3 respectively. For PES protocols, each heart was then assigned 
an Arrhythmia Inducibility Score depending on ease of arrhythmia inducibility, as 
described in Section 2.7.2. Both arrhythmia provocation protocols were performed blinded 
to the treatment group. 
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7.2.3 Histology and Immunohistochemistry 
Following the ex vivo experiments described above, hearts were flash frozen for 
histological and immunohistochemistry experiments. The histology and 
immunohistochemistry experiments described in this chapter were performed by Jeremy 
Kalindjian, a 4th year Imperial College London medical student, under my supervision.  
 
Cryostat sections (10 µm) of flash frozen hearts were stained with Masson’s trichrome as 
described in Section 2.10.2. Using these Masson’s Trichrome-stained images, infarct size 
was quantified as described in Section 2.10.3, and histomorphometry was performed as 
described in Section 2.10.4 to quantify the heterogeneity of fibrosis at the infarct border 
zone. Cryostat sections were also immunolabelled for Cx43 as described in Section 2.8.3, 
and the degree of Cx43 maldistribution was quantified using the Cx43 Lateralisation 
Score described in Section 2.8.4. All analyses were performed blinded to treatment group. 
 
7.3 Results 
7.3.1 Acute mortality rates were not different between groups 
A total of 40 rats were subjected to surgical myocardial infarction: rotigaptide (ROT) 
n=13, carbenoxolone (CBX) n=13, control/vehicle (CON) n=14. Treatment was given as a 
bolus immediately before MI surgery, and was continued post-MI by drug delivery 
through an osmotic minipump. Of the 40 animals, 27 survived the procedure acutely 
(ROT n=9, CBX n=8, CON n=10). Acute mortality was not different between treatment 
groups (ROT 31%, CBX 38%, CON 33%, P=NS). This was similar to the acute mortality 
rate for the cohort of animals that underwent MI surgery, described in Chapter 4, which 
was 33%. The majority of these acute deaths occurred within the first 30 minutes after 
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ligation of the left anterior descending artery and were due to ventricular 
tachyarrhythmias, which were witnessed during the surgical procedure. 
 
7.3.2 Rotigaptide-treated hearts had reduced arrhythmia susceptibility on PES at 4 
weeks post-MI 
After 7 days of treatment with gap junction modulator or vehicle, the infarcts were 
allowed to heal and the animals were next studied at 4 weeks post-MI. Studies were 
performed to assess for any differences in substrates and susceptibility to arrhythmias as a 
result of acute gap junction modulation. Extrastimulus programmed electrical stimulation 
protocols, performed to induce re-entrant arrhythmias, revealed differences in arrhythmia 
susceptibility at 4 weeks post-MI, as shown in Figure 7-1. Animals previously treated with 
rotigaptide had reduced arrhythmia inducibility at Programmed Electrical Stimulation 
(PES) compared to CBX and control, with VT or VF induced in fewer animals for any 
given number of extrastimuli (Figure 7-2A). This equated to a significantly reduced 
arrhythmia inducibility score for rotigaptide hearts compared to CBX and control 
(P<0.05). These results suggest that short-term treatment with rotigaptide altered the 
healed infarct substrate to render it more resistant to arrhythmias on PES. 
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Figure 7-1: Arrhythmia susceptibility with Programmed Electrical Stimulation (PES). (A) 
Representative ECG trace showing VT and VF successfully induced during an 
extrastimulus PES protocol in an MI heart. (B) Proportion of hearts positive for PES-
induced arrhythmias (VT/VF >1s) depending on number of extrastimuli. (C) Arrhythmia 
inducibility score at PES. Rotigaptide treated-hearts were significantly less inducible for 
VT/VF at 4 weeks post-infarction (*P<0.05). (CON: control, n=10; ROT: rotigaptide, 
n=9; CBX: carbenoxolone, n=8). 
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Figure 7-2: (A) Representative ECG trace of ventricular arrhythmias induced by 
isoprenaline (ISO) challenge. (B) Representative ECG trace of spontaneous ventricular 
ectopics documented in vivo during ECG-telemetry recording. Closed circles denote 
ventricular arrhythmias. (C) No differences between groups in arrhythmia susceptibility 
during ISO challenge. (D) No differences between groups in spontaneous in vivo 
arrhythmia burden. (CON: control, n=10; ROT: rotigaptide, n=9; CBX: carbenoxolone, 
n=8). 
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7.3.3 No difference in arrhythmia susceptibility on ISO challenge or on ECG-
telemetry 
In addition to using programmed electrical stimulation (PES) to induce re-entrant 
arrhythmias, differences in arrhythmia susceptibility were also assessed using isoprenaline 
pulse protocols to provoke catecholamine-induced arrhythmias, and using ECG-telemetry 
to document spontaneous in vivo arrhythmia burden (Figure 7-2). Isoprenaline challenge 
over 20 minutes increased heart rate in all hearts studied and induced ventricular 
arrhythmias in all but one heart, with an example shown in Figure 7-2B. Arrhythmia 
incidences were not different between groups with isoprenaline challenge (Ventricular 
ectopics during ISO challenge: ROT 42 ± 13, CBX 41 ± 14, CON 76 ± 41, P=NS) (Figure 
7-2C). There were also no significant differences detected between groups for 
spontaneous in vivo arrhythmia burden as assessed by 24 hours of continuous ECG-
telemetry recording (Log10 ventricular ectopics/day: ROT 2.0 ± 0.6, CBX 1.8 ± 0.7, CON 
2.4 ± 0.5, P=NS) (Figure 7-2D). The incidence of sustained arrhythmias was also not 
different between groups. These results suggest that, although rotigaptide hearts were 
more resistant to extrastimulus PES-induced arrhythmias, they were equally susceptible to 
catecholamine-induced arrhythmias and to spontaneous in vivo arrhythmias. 
 
7.3.4 Improvement in border zone conduction velocity with rotigaptide-treated 
hearts  
Optical mapping of transmembrane voltage was performed to assess the effects of acute 
gap junction modulation on the electrophysiology of the healed infarct border zone, and to 
determine if altered border zone electrophysiology accounted for the observed differences 
in arrhythmia susceptibility between groups. There was significant slowing of epicardial 
conduction across the infarct border zone compared to remote non-infarcted myocardium 
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for all three groups, and this was consistent with the optical mapping studies on the 
chronic MI cohort described in Chapter 4. Comparison of IBZ conduction velocities 
between groups showed a trend towards improved conduction velocities for rotigaptide 
hearts. Conduction velocity across the infarct border zone was 20% faster compared with 
control hearts, although this difference did not reach statistical significance (Border zone 
conduction velocity: rotigaptide 43.1 ± 3.4 cm/s, carbenoxolone 37.9 ± 3.1 cm/s, control 
35.7 ± 1.7, P=NS) (Figure 7-3A). The improvement in conduction velocity at the infarct 
border zone may be one of the factors underlying the increased resistance to PES-induced 
arrhythmias in rotigaptide hearts. These conduction velocities at the IBZ for all three 
groups were still significantly slower compared with conduction velocities in normal, non-
infarcted hearts, which were usually between 60cm/s and 80 cm/s. 
 
Gap junction modulation during acute MI did not alter optical action potential 
characteristics at the infarct border zone. Optical AP rise time, amplitude and duration 
were similar between gap junction modulator and control groups as shown in Figure 7-3B 
to 7-3F. 
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Figure 7-3: Optical mapping of chronic MI hearts (CON: control, n=10; ROT: 
rotigaptide, n=9; CBX: carbenoxolone, n=8). Infarct border zone conduction velocity (A), 
action potential rise time (B), action potential amplitude (C), and action potential 
durations (D, E & F) were not different between groups. 
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7.3.5 Infarct size was not different between groups 
Infarct size analyses were performed to determine if differences in infarct size accounted 
for the differential susceptibility to arrhythmias on PES. Analyses were performed by 
planimetry of Masson’s Trichrome stained heart slices. As shown in Figure 7-4A, surgical 
LAD artery ligation produced transmural infarcts (stained blue on Masson’s Trichrome) 
with compensatory hypertrophy of non-infarcted myocardium (stained red/pink). Infarct 
size, calculated as the percentage of endocardial and epicardial circumferences bounded 
by the infarct, was not significantly different groups (control 21.0% ± 3.6%, rotigaptide 
20.5% ± 1.7%, carbenoxolone 23.6% ± 1.8%; P=NS) (Figure 7-4B). Therefore, although 
infarct size is a known determinant of post-MI arrhythmia susceptibility, this was not the 
cause of the observed reduction in arrhythmia susceptibility on PES for rotigaptide hearts. 
 
7.3.6 Rotigaptide reduced heterogeneity of fibrosis at the infarct border zone 
Histomorphometric analyses were performed to describe and quantify the degree of 
complexity and heterogeneity of fibrosis and scarring at the infarct border zone, and to 
determine if differences in infarct border zone morphology accounted for differences in 
arrhythmia susceptibility and border zone conduction. The Interface Complexity Ratio, as 
described in Section 2.10.4, was calculated for multiple microscopic fields of infarct 
border zone per slice, and for 6 biventricular slices per heart. The ratio was used as a 
measure of fibrosis complexity at the border zone, with greater ratios representing more 
complex morphologies. 
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Figure 7-4: (A) Representative biventricular sections through the mid-ventricle stained 
with Masson’s Trichrome showing the healed mature infarct in blue and the surviving 
myocardium in red/pink. (B) Infarct size at 4 weeks post-MI was not different between 
groups (n=5 hearts from each group studied). 
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Figure 7-5: (A) Sample microscopic images of the infarct border zone of chronic MI heart 
slices stained with Masson’s Trichrome, showing interface between fibrotic scar tissue 
(blue) and surviving myocardium (red/pink). (B) Mean IBZ Interface Complexity Ratio 
was not different between groups (n=5 hearts from each group studied). (C) Significantly 
reduced dispersion (standard deviation) of Interface Complexity Ratio for rotigaptide-
treated hearts (*P<0.05).  
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Figure 7-5A shows sample microscopic images for the infarct border zones of MI hearts 
from control, rotigaptide and carbenoxolone groups, illustrating the complex interface 
between fibrotic scar (blue) and surviving myocardium (red/pink). The complexity of this 
interface, as quantified using the Interface Complexity Ratio, was not significantly 
different between groups (mean Interface Complexity Ratio: control 3.2 ± 0.2, rotigaptide 
3.3 ± 0.2, carbenoxolone 3.2 ± 0.2, P=NS).  
 
However, there were greater variations of infarct border zone complexity in control hearts 
compared to rotigaptide hearts. The dispersion of the Interface Complexity Ratio, 
quantified as the standard deviation of values for each heart segment, was compared 
between groups as a measure of heterogeneity of fibrosis and scarring throughout each 
heart. Rotigaptide-treated hearts had reduced heterogeneity of fibrosis at the infarct border 
zone compared to control (S.D. of Interface complexity ratio: control 1.4 ± 0.1, rotigaptide 
1.1 ± 0.1, carbenoxolone 1.2 ± 0.1, P<0.05 for Control vs. Rotigaptide) (Figure 7-5C). The 
alteration of infarct border zone morphology may be a possible mechanism by which 
short-term treatment with rotigaptide produced infarct substrates that are more resistant to 
PES-induced arrhythmias. This alteration may also explain the trend towards improved 
border zone conduction velocities in rotigaptide hearts. 
 
7.3.7 Cx43 distribution was not different between groups 
The amount of Cx43 maldistribution in viable myocardium was quantified using the Cx43 
lateralisation score (Figure 7-6). Six immunolabelled slices were analysed for each heart. 
There were no differences between treatment groups (control 1.3 ± 0.1, rotigaptide 1.3 ± 
0.1, carbenoxolone 1.3 ± 0.1). There were also no differences in the standard deviation of 
the Cx43 lateralisation scores for each heart, suggesting a lack of spatial heterogeneity in 
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Cx43 distribution (S.D. of Cx43 lateralisation score: control 0.5 ± 0.1, rotigaptide 0.5 ± 
0.1 and carbenoxolone 0.6 ± 0.2, P=NS). 
 
 
Figure 7-6: (A) Sample images showing the extremes of the Cx43 Lateralisation score. 
Left: A microscopic field with <10% cells containing lateralised Cx43 (Score = 1). Right: 
Significant lateralisation of Cx43 as shown by arrows, with lateralisation found in >40% 
of cells in that microscopic field (Score = 5). (B) Cx43 lateralisation scores were not 
different between groups (n=5 hearts from each group studied). 
 
7.4 Discussion 
The studies described in the chapter provided evidence showing that a novel strategy of 
enhancing gap junction coupling during acute myocardial infarction with rotigaptide 
reduced inhomogeneities of fibrosis and scarring at the healed infarct border zone. This 
reduction of heterogeneity of scarring was associated with a reduction in late post-MI 
arrhythmia susceptibility at PES and a trend towards an improvement in conduction 
velocity across the infarct border zone in rotigaptide-treated hearts.  
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7.4.1 Heterogeneity of scarring is a determinant of post-infarction ventricular 
arrhythmias 
Heterogeneity of fibrosis has been shown to be a determinant of post-MI ventricular 
arrhythmias. Schmidt and colleagues quantified the heterogeneity of the infarct periphery 
using delayed-enhanced MRI imaging in post-infarction patients, and found that increased 
heterogeneity strongly correlated with inducibilty of monomorphic ventricular 
tachycardias (Schmidt et al., 2007). Similarly, Yan et al demonstrated using cardiac MRI 
that, in patients with prior MI, the extent of the heterogeneous peri-infarct zone provided 
incremental prognostic value beyond left ventricular systolic volume index or ejection 
fraction for predicting post-MI mortality (Yan et al., 2006). 
 
Greater tissue heterogeneity would likely increase the tortuosity and path length of 
impulse propagation across the infarct border zone, which then manifests as macroscopic 
conduction slowing across the border zone (de Bakker et al., 1993). This increase in path 
length, in conjunction with microscopic changes that slow conduction at the border zone 
(Peters et al., 1997; Cabo et al., 2006), would be expected to predispose to re-entrant 
ventricular tachycardias. Tissue discontinuities created by heterogeneous scarring and 
fibrosis have also been shown to alter conduction velocity restitution and promote 
wavebreak in cultured neonatal rat cardiomyocytes, which may be another mechanism by 
which heterogeneous scarring promotes arrhythmogenesis (Derksen et al., 2003). 
Modelling and computer simulation studies have also shown that structural discontinuities 
can amplify discordant alternans and provide a rate-dependent substrate for re-entry 
(Engelman et al., 2010). 
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7.4.2 Enhancement of gap junction coupling reduced inhomogeneities of scarring and 
fibrosis 
The studies described above provide evidence for a novel approach to arrhythmia 
substrate modification. They showed that administering a short course treatment of 
rotigaptide to enhance gap junctional intercellular communication at the time of infarction 
reduced the heterogeneity of fibrosis at the healed infarct border zone. Studies using 
pharmacological agents that enhance gap junction coupling have previously shown that 
improving communication between cardiomyocytes can reduce repolarisation 
heterogeneities between different regions of the heart through passive equalisation of 
charge (Eloff et al., 2001; Quan et al., 2007; Dhein et al., 1994). However, gap junction 
channels do not merely allow the spread of action potentials and charge between cells, but 
also mediate the spread of small molecules, including the passage of necrotic factors and 
mediators of cell death (Decrock et al., 2009a; Decrock  et al., 2009b).  
 
During acute ischaemia, the closure of gap junction channels occurs (de Groot & Coronel, 
2004), thus preventing passage of these mediators of cell death between cells. Due 
perhaps to heterogeneities of vascular supply and coronary blood flow (Polansky & 
Weiss, 1993; Ghaleh et al., 1996), as well as heterogeneities in metabolism (Decking & 
Schrader, 1998), cells at the borders of the ischaemic zone have varying degrees of 
ischaemic stress and insult. The natural closure of gap junction channels would be 
expected to further exacerbate heterogeneities of ischaemic stress, thus leading to 
inhomogeneous cell death and a more heterogenous healed infarct, which is more prone to 
arrhythmias. The data above, showing a reduction in infarct border zone fibrosis 
heterogeneity, as assessed by histomorphometry, in rotigaptide-treated animals suggest 
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that enhancing coupling between cells during acute MI may lead to more homogeneous 
cell death and scarring. 
 
The specific mediators of cell death and cell survival that pass through gap junction 
channels during infarction are still unclear, and were not the subject of investigation of 
this thesis. It has been proposed that both necrotic and apoptotic factors that promote cell 
death and anti-apoptotic factors that promote cell survival can pass through gap junctions 
(Decrock et al., 2009b; Andrade-Rozental et al., 2000). The so-called “kiss-of-death” or 
bystander effect has been observed in in vitro studies on the effects of ganciclovir (GCV) 
on neoplastic cells, where the process of cell death can spread from GCV-sensitive to 
GCV-insensitive cells through gap junction channels (Elshami et al., 1996). The opposite 
“kiss-of-life” or “metabolic cooperation” effect has also been observed whereby adequate 
gap junction communication to neighbouring cells could protect a GCV-sensitive cell 
from GCV-mediated apoptosis (Pitts, 1998). It is possible that the enhancement of gap 
junction coupling during myocardial infarction allows greater transfer and exchange of 
both necrotic/apoptotic and anti-apoptotic mediators between neighbouring cells, leading 
to a more homogeneous cell death process, and creating a more homogeneous infarct scar. 
 
7.4.3 Enhancement of gap junction coupling reduced late post-MI arrhythmia 
susceptibility 
The studies above also demonstrated that enhancement of gap junction coupling during 
acute myocardial infarction with rotigaptide reduced late susceptibility to ventricular 
arrhythmias. This is possibly due to the effect of enhancement of coupling on creating a 
more homogeneous healed infarct scar, which is less susceptible to substrate-based re-
entrant arrhythmias. The clinical parallel of this approach of reducing inhomogeneities is 
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that of catheter ablation as a potentially curative therapeutic strategy for post-MI 
ventricular tachycardia (Stevenson & Soejima, 2007). Using a substrate ablation approach, 
Marchlinski and colleagues demonstrated that an extensive set of ablation lesions in or 
around areas of scar during sinus rhythm can ablate multiple and unstable VTs 
(Marchlinski et al., 2000). Although there are different approaches to catheter ablation, the 
effect of delivering multiple lesions to destroy myocardium in and around the scar is 
possibly to homogenise the scar to some extent in the short-term. The strategy of 
enhancement of gap junction coupling during acute MI may represent an alternative 
approach to substrate modification to reduce inhomogeneities in the healed infarct and 
reduce post-MI arrhythmia susceptibility. 
 
7.4.4 Alterations in post-MI arrhythmic substrate detected using Programmed 
Electrical Stimulation (PES) 
It is important to note that although there was a reduction in arrhythmia inducibility at 
Programmed Electrical Stimulation (PES) for rotigaptide-treated hearts, there were no 
significant differences between groups when isoprenaline challenge or in vivo arrhythmia 
burden on ECG-telemetry were used as measures of arrhythmogenicity. This is perhaps 
not an entirely surprising finding. PES extrastimuli protocols are designed to induce 
substrate-dependent re-entrant arrhythmias, whereas isoprenaline challenges and in vivo 
ECG-telemetry record arrhythmias of both re-entrant and non-reentrant mechanisms. 
Therefore, if the mechanism by which short-term rotigaptide treatment protected against 
late arrhythmias was through modification of the arrhythmic substrate, PES protocols 
would be the most sensitive test to identify differences between groups in their 
susceptibility to substrate-dependent re-entrant arrhythmias.  
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However, as PES only induces re-entrant arrhythmias, it is known to be a weak predictor 
for sudden cardiac death in general in post-MI patients (Buxton et al., 2000; Goldberger, 
2010). This is because sudden cardiac death post-MI is a syndrome with a variety of 
causes, including new-onset acute ischaemia, primary VF, non-reentrant VT and 
bradyarrhythmias, for which re-entrant VT accounts for only a proportion of cases (Bloch 
Thomsen et al., 2010). Therefore, whether the proposed strategy of substrate modification 
alone, which reduces the risk of substrate-based re-entrant VT, can significantly affect 
overall rates of sudden cardiac death in the post-MI population is unclear.    
 
7.4.5 Acute gap junction modulation did not significantly alter infarct size 
No significant differences in infarct size between control hearts and hearts treated with 
gap junction modulators were detected. Studies looking at the effects of gap junction 
modulation on infarct size have so far produced conflicting results. Previous studies using 
rotigaptide to enhance coupling during myocardial infarction have shown a reduction in 
infarct size (Haugan et al., 2006b), yet studies where gap junction coupling was preserved 
through the introduction of Cx32, a liver connexin which is less pH-sensitive than 
myocardial connexins, showed an increase in infarct size in response to enhancement of 
coupling (Prestia et al., 2011). 
  
Studies using Cx43 knockout mice have also shown that reduced coupling during MI can 
reduce infarct size (Kanno et al., 2003), which appears to contradict the findings of the 
previous rotigaptide studies (Haugan et al., 2006b). These disparities may reflect 
differences in animal models and of timing and duration of enhancement of coupling, as 
well as differences in methods of measuring infarct size. The results above would suggest 
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that although modifying gap junction coupling can affect infarct spread, these effects on 
infarct size and presumably left ventricular function may be small.  
 
7.4.6 Study Limitations 
A limitation was that, although it was shown that short-term enhancement of gap junction 
coupling with rotigaptide reduced inhomogeneities of scarring at the healed border zone 
and reduced late susceptibility to re-entry ventricular arrhythmias, there was no clear 
evidence of changes to the electrophysiology of infarct border zone. There was a 20% 
increase in border zone conduction velocity in rotigaptide-treated hearts compared with 
control, but these differences failed to reach statistical significance. This may merely 
reflect underpowering of the study and that further experiments are required. 
 
Another limitation was that the experiments were carried out in a chronic non-reperfused 
infarct model. Increasing numbers of patients in the UK and USA now receive reperfusion 
therapy within the first few hours of acute MI, and there is evidence to suggest that 
arrhythmias in the reperfused MI heart are different to those in non-reperfused chronic MI 
hearts (Wijnmaalen et al., 2010). Further studies are required to assess if the proposed 
strategy of substrate modification with acute gap junction modulation is also beneficial in 
the setting of reperfused myocardial infarction. 
 
7.5 Summary  
The studies in this chapter provide proof-of-concept evidence for a novel approach to 
substrate modification, by demonstrating that short-term enhancement of gap junction 
coupling with rotigaptide early during myocardial infarction can reduce inhomogeneities 
of fibrosis in the healed infarct border zone and reduce late susceptibility to ventricular 
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tachyarrhythmias on programmed electrical stimulation at 4 weeks post-MI. Gap junction 
modulation did not significantly alter the size of the chronic infarct. 
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Chapter 8: 
Conclusions 
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8.1 Summary of findings 
The work in this thesis set out to explore the effects of gap junction modulation on 
ventricular arrhythmogenesis. Specifically, ventricular arrhythmias in the acute 
reperfusion and the chronic post-myocardial infarction settings were studied. In order to 
assess the hypothesis that gap junction modulation can alter reperfusion arrhythmogenesis 
by altering conduction velocities and repolarisation heterogeneities, an ex vivo model of 
acute ischaemia-reperfusion was developed and characterised. The effects of gap junction 
modulators on conduction, action potentials and Cx43 phosphorylation were also 
characterised in ex vivo isolated, perfused heart models. In order to assess the effects of 
gap junction modulation on infarct morphology and post-infarction arrhythmia 
susceptibility, a four-week post-MI model was developed and characterised.  
 
The key findings relating to the two main hypotheses were: 
(1) Gap junction modulation reduced the incidence of reperfusion arrhythmias, 
possibly resulting from attenuating the magnitude of changes in conduction 
velocity during reperfusion and reducing heterogeneities in conduction velocities. 
(2) Enhancement of gap junction coupling during acute MI altered the morphology of 
the healed infarct scar by reducing the heterogeneities in infarct border zone 
scarring, which was associated with a reduction in post-MI inducible arrhythmia 
susceptibility. Gap junction modulation did not significantly alter infarct size or 
spontaneous in vivo arrhythmias. 
 
Other findings were: 
(1) Gap junction modulators, AAP10, rotigaptide and carbenoxolone, altered 
conduction velocity without affecting action potential morphology. 
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(2) Infarct border zone conduction velocity was a determinant of post-infarction 
arrhythmias susceptibility. 
(3) Heart rate during acute ischaemia, but not heart rate at reperfusion, was a 
determinant of reperfusion arrhythmia susceptibility 
 
These key findings are discussed in more detail below. 
 
8.1.1 Effects of gap junction modulation on reperfusion arrhythmogenesis 
The set of studies performed to assess the effects of AAP10 and carbenoxolone on 
reperfusion arrhythmia incidence revealed that gap junction modulation, with either 
AAP10 or carbenoxolone, reduced the incidence of reperfusion VF. When the studies 
were performed with concurrent optical mapping, it was shown that both AAP10 and 
carbenoxolone reduced the magnitude of recovery of conduction velocity with 
reperfusion, through different mechanisms. AAP10 attenuated conduction slowing during 
ischaemia whilst carbenoxolone attenuated the recovery of conduction velocity, with the 
net effect of reducing the magnitude of change at reperfusion. 
 
These studies provide further insight into the mechanisms of reperfusion arrhythmias. 
Firstly, they support the view that reperfusion arrhythmias are quite distinct from 
ischaemia-induced arrhythmias, and are the result of the combination of abrupt 
electrophysiological and biochemical changes triggered by reperfusion (Manning & 
Hearse, 1984). These results suggest that interventions that slow the rate of recovery or 
attenuate the magnitude of recovery of action potentials or conduction veolocity during 
the process of reperfusion may have an anti-arrhythmic effect. This is in line with other 
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studies that have shown that graded or slow reperfusion can reduce the incidence of 
reperfusion arrhythmias (Petropuolos & Meijne, 1964).  
 
Immediately following reperfusion, some regions of ischaemic myocardium recover 
electrophysiologically before others (Kaplinsky et al., 1981; Murdock et al., 1980). This 
initial unequal recovery in the first few seconds following reperfusion may in part be due 
to spatial heterogeneities in coronary blood flow (Conway & Weiss, 1985; Aldea et al., 
1990; Austin et al., 1990), as well as heterogeneities in cellular injury prior to reperfusion 
due to heterogeneities in cellular metabolism (Decking & Schrader, 1998). Given that the 
recovery of action potentials and conduction velocity are unequal immediately following 
reperfusion, it follows that greater magnitudes of recovery would produce greater 
electrophysiological heterogeneities following the reintroduction of blood flow, and 
therefore be associated with greater propensities to reperfusion arrhythmias. 
 
Secondly, these data support a role for gap junction coupling in reperfusion 
arrhythmogenesis. Up until the past decade, it had been thought that gap junction 
uncoupling in the context of acute ischaemia was irreversible once it was established 
(Kléber et al., 1987). This was in line with the view that gap junction uncoupling played a 
protective role in acute ischaemia-infarction to prevent the spread of cell death. However, 
recent studies have shown that gap junction uncoupling can be reversed by reperfusion 
(Cascio et al., 2001), and indeed may contribute to reperfusion arrhythmogenesis. The 
acute ischaemia-reperfusion studies described in this thesis support that view. Although 
gap junction coupling was not specifically measured, the recovery of conduction velocity 
with reperfusion supports the reversibility of gap junction uncoupling, and the ability of 
gap junction modulators to alter reperfusion arrhythmia incidence supports a role for gap 
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junctions in reperfusion arrhythmogenesis. It needs to be stated that the results in this 
thesis only provide evidence supporting a role for gap junctions in reperfusion 
arrhythmogenesis in cases of reperfusion after short durations of ischaemia lasting several 
minutes. Whether gap junction uncoupling can be reversed after longer periods of 
ischaemia and whether gap junctions play a role in arrhythmogenesis under those 
circumstances is unclear. 
 
As described above, gap junction modulation may have produced their anti-arrhythmic 
effects by reducing heterogeneities in conduction velocities and thus reducing the 
likelihood of re-entry. However, it is also possible that gap junction modulation may have 
prevented non-reentrant arrhythmias via mechanisms not studied in this thesis. 
Enhancement of gap junction coupling may have increased the sink available for calcium 
and reactive oxygen species to diffuse out of the ischaemic myocardium, thus reducing the 
likelihood of triggered arrhythmias, or may have created current source-sink mismatches 
to prevent the propagation of triggered action potentials (Rohr et al., 1997). 
 
8.1.2 Effects of gap junction modulation during acute MI on the morphology of the 
healed infarct and on post-MI arrhythmia susceptibility 
The studies performed to assess the effect of acute gap junction modulation on the healed 
infarct morphology and post-infarction arrhythmia susceptibility provide evidence for a 
novel approach to arrhythmia substrate modification. They showed that rotigaptide 
administration as a bolus immediately before coronary artery ligation and then by osmotic 
minipump for 7 days post-MI altered the healed infarct morphology and modified 
arrhythmia susceptibility at 4 weeks post-MI. Specifically, there was less heterogeneous 
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scarring at the infarct border zone, which was associated with increased resistance to 
ventricular arrhythmias on programmed electrical stimulation.  
 
By demonstrating an alteration in infarct morphology with gap junction modulation, these 
data support the findings of in vitro studies showing that gap junction coupling is 
important in the process of the spread of acute necrosis between neighbouring cells 
(Andrade-Rozental et al., 2000). The specific mediators of cell death that pass through gap 
junction channels during infarction are still unclear, but may involve both pro-cell death 
mediators such as calcium ions and reactive oxygen species as well as pro-cell survival 
mediators (Decrock et al., 2011; Decrock et al., 2009b; Kung et al., 2011). 
 
Two opposing hypotheses have been proposed to explain the role of gap junctions in 
modulating infarct spread. The so-called “kiss-of-death” or bystander effect states that 
infarction will spread from a dying cell to its neighbour through gap junction channels 
(Elshami et al., 1996). This hypothesis may explain why gap junctions normally uncouple 
during acute ischaemia as a protective mechanism to reduced infarct size (de Groot & 
Coronel, 2004). The opposite “kiss-of-life” or “metabolic cooperation” effect states that 
the process of cell death may be prevented if a dying cell is in communication with 
healthy neighbouring cells (Pitts, 1998). The literature on the effects of gap junction 
modulation surrounding this debate has been conflicting. There are in vivo data to suggest 
that enhanced coupling during infarction is detrimental and can increase infarct size 
(Prestia et al., 2011; Kanno et al., 2003), whilst there are other studies that suggest 
enhancing coupling is protective and can reduce infarct size (Hennan et al., 2006; Haugan 
et al., 2006b). 
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The data from the studies in this thesis suggest that it may not be as straightforward as 
suggesting that one of these two mechanisms is predominant. The infarct size at four 
weeks post-MI were not different between animals treated with carbenoxolone or 
rotigaptide compared with control animals in the permanent ligation chronic MI model. 
Although the infarct sizes were similar, infarct morphology was different, and rotigaptide-
treated hearts have less heterogeneities in scarring. It is possible that both the “kiss-of-
life” and “kiss-of-death” effects are equally important, and the enhancement of gap 
junction coupling during acute infarction alters the distribution of cell death without 
significantly altering the amount of infarcted myocardium. Enhancement of gap junction 
coupling may allow for greater exchange and transfer of pro- and anti-apoptotic mediators 
between cells in and around the ischaemic myocardium, thus leading to more 
homogeneous cell death, but without altering infarct size. This may be akin to the effects 
of enhancing gap junction coupling on action potential inhomogeneities, where the passive 
exchange of charge between cells through gap junction channels serve to reduce the 
dispersion of action potential duration between different regions of myocardium, but 
without any effect on the overall mean action potential duration (Eloff et al., 2003). 
 
The increased homogeneity of scarring in rotigaptide-treated hearts was associated with 
increased stability at programmed electrical stimulation. This was not a surprising finding 
as infarct scar heterogeneity has previously been established as a determinant for post-
infarction arrhythmias (Schmidt et al., 2007; Yan et al., 2006). The increased homogeneity 
may protect against arrhythmias by increasing macroscopic conduction velocity across the 
infarct border zone (de Bakker et al., 1993), or may produce a substrate that is more 
resistant to wavebreak and to action potential alternans (Derksen et al., 2003; Engelman et 
al., 2010). 
	   284 
8.1.3 Specificity of gap junction modulators 
The data from this thesis provide evidence to support the specificity of actions of gap 
junction modulators. Results from the various optical mapping experiments in normal 
hearts, in states of global metabolic stress, and in acute regional ischaemia-reperfusion, all 
suggest that AAP10, rotigaptide and carbenoxolone act on gap junctions without any gross 
effects on action potential morphology. Although gap junction coupling was not 
specifically measured, nor were the activity of individual ionic currents quantified, these 
optical mapping experiments showed that AAP10 and rotigaptide, in the context of the 
intact heart, improved conduction velocity and reduced APD dispersion without 
significant effects on optical AP duration and upstroke. Similarly, carbenoxolone was 
shown to slow conduction without significant effects on optical action potential 
morphology. 
 
These results are in agreement with the majority of previous studies on gap junction 
modulators. Studies in isolated cells, muscle strips and whole hearts all support the 
specific gap junction enhancing actions of both AAP10 (Muller et al., 1997a; Jozwiak & 
Dhein, 2008; Hagen et al., 2009), and for rotigaptide (Eloff et al., 2003; Haugan et al., 
2006a). They are also in line with both preclinical studies in isolated cells and intact 
myocardium, as well as clinical human studies, showing the specific gap junction 
uncoupling effects of carbenoxolone (de Groot et al., 2003; Kojodjojo et al., 2006). 
However, there are isolated studies that have shown effects of these gap junction 
modulators on ionic currents on action potentials, including descriptions of shortening of 
refractory periods with rotigaptide (Macia et al., 2011), and inhibition of calcium channels 
in neural tissue with carbenoxolone (Vessey et al., 2004). The reasons for these 
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discrepancies are unclear but may be attributed to differences in experimental models and 
conditions.  
 
8.1.4 Infarct border zone conduction velocity is a determinant of post-MI arrhythmia 
susceptibility 
Studies on the four-week chronic MI model revealed that infarct border zone conduction 
velocity is a determinant of post-MI arrhythmia susceptibility. Comparison of PES(+) with 
PES(-) hearts showed that PES(+) hearts had significantly slower macroscopic conduction 
across the infarct border zone on optical mapping. These data confirm the important role 
of the infarct border zone in post-infarction ventricular arrhythmogenesis. 
 
The infarct border zone has long been thought to be a critical part of re-entrant VT circuits 
in post-infarction hearts. This has been supported by the results of ventricular mapping 
studies, which have indicated that re-entrant VTs often arise from these areas adjacent to 
dense scar (Josephson et al., 1978; Josephson et al., 1980; Fenoglio et al., 1983). The 
importance of the infarct border zone in post-MI VT was further supported by clinical 
cathether ablation studies, which showed that ablation performed at the infarct border zone 
can abolish previously inducible VTs (Marchlinski et al., 2000; Soejima et al., 2001). At 
the molecular level, remodelling of connexins and ion channels have been shown to occur 
at the infarct border zone. Redistribution of connexins (Peters et al., 1997), slowing of the 
action potential upstoke (Lue & Boyden, 1992), and the reduction in the inward sodium 
current (INa) and altered INa kinetics (Pu & Boyden, 1997), have all been shown to occur at 
the infarct border zone of a 5-day canine post-infarction model. These changes at the 
infarct border zone are associated with conduction slowing (Cabo et al., 2006), and are 
thought to contribute to post-MI arrhythmogenesis. 
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The greater degrees of conduction slowing seen in PES(+) hearts in the 4-week post-MI 
model is consistent with the fact that conduction slowing predisposes to re-entry, as first 
proposed by Mines (Mines, 1913). The specific causes of the slower conduction in these 
arrhythmic hearts in this model were not specifically studied. The conduction slowing 
seen in those PES(+) hearts may be a combination of slowed macroscopic and 
microscopic conduction. Macroscopic conduction slowing in these hearts may be the 
result of increased heterogeneity of scarring in the border zone causing to a more tortuous 
path for impulse propagation across the border zone, whereas microscopic conduction 
slowing may be due to greater degrees of remodelling of gap junctions and sodium 
channels in those hearts. 
 
8.1.5 Heart rate during acute ischaemia is a determinant of susceptibility to 
reperfusion arrhythmias  
The ischaemia-reperfusion experiments with ivabradine and atrial pacing showed that 
heart rate is a determinant of reperfusion arrhythmia susceptibility. It had previously been 
demonstrated that atrial pacing during ischaemia-reperfusion led to a rate-dependent 
increase in the incidence of reperfusion-induced ventricular fibrillation (Bernier et al., 
1989). However, it was not clear if it was the heart rate during ischaemia or the heart rate 
during reperfusion that was more important in determining reperfusion arrhythmia 
susceptibility. 
 
There were plausible explanations as to why either may have been the case. Heart rate 
during ischaemia can influence the rate of development of ischaemia, with greater heart 
rates leading to greater degrees of ischaemic injury, and increased arrhythmic 
susceptibility. The heart rate at reperfusion may also be important as increased heart rates 
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can increase the slope of the APD restitution curve, leading to greater likelihood of 
alternans, wavebreak and fibrillation (Nolasco & Dahlen, 1968). Increased heart rates at 
reperfusion may also increase cytosolic calcium concentrations and increase propensity to 
delayed afterdepolarisations and triggered arrhythmias. 
 
Ivabradine, a specific If current blocker with heart rate lowering effects (Borer et al., 
2003), together with atrial pacing were used in varying combinations to determine the 
relative importance of heart rates during ischaemia and reperfusion in reperfusion 
arrhythmogenesis. Those results revealed that the mean heart rate during ischaemia, but 
not heart rate at reperfusion, was a determinant of reperfusion arrhythmia susceptibility. 
The optical mapping experiments suggested that increased heart rates during ischaemia 
increased arrhythmia susceptibility in the ischaemia-reperfusion model by means of 
accelerating the rate of development of ischaemia and the rate of onset of the ischaemia-
related electrophysiological changes. 
 
8.2 Clinical relevance 
The findings of the work in this thesis are clinically relevant as they not only provide 
insights into mechanisms of ventricular arrhythmogenesis, but also demonstrate the 
potential anti-arrhythmic effects of gap junction modulators. Modulation of gap junction 
coupling has received much interest in recent years as a possible novel anti-arrhythmic 
strategy in acute ischaemia-infarction (Wit & Duffy, 2008; Dhein et al., 2010), but the 
results from this thesis also provide evidence for their beneficial effects on reperfusion 
arrhythmias and post-MI arrhythmias. Rotigaptide and carbenoxolone, two of the agents 
studied in this thesis, have already been safely administered in vivo in man, and can 
therefore easily be moved onto clinical trails if required. Rotigaptide has previously been 
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administered to healthy volunteers without any adverse effects (Lang et al., 2008; Udata 
2006a; Udata 2006b), whilst carbenoxolone has been used for decades in clinical practice 
as a gastroprotective agent (Pinder et al., 1976). 
 
8.2.1 Gap junction modulation to prevent reperfusion arrhythmias 
The results of the acute ischaemia-reperfusion studies suggest that modulating gap 
junction coupling can protect against reperfusion arrhythmias. Their protective mechanism 
may be via the attenuation of the abrupt recovery of myocardial conduction following 
reperfusion. The duration of ischaemia in the ischaemia-reperfusion model was relatively 
short, therefore the results would suggest that gap junction modulation may be protective 
against reperfusion arrhythmias following brief periods of ischaemia. A clinically relevant 
scenario would be in episodes of coronary vasospasm lasting several minutes (Tzivoni et 
al., 1983; Miller et al., 1982) or in cases of unstable angina. It is unclear whether these 
results can be extrapolated to settings of reperfusion following hours of ischaemia such as 
the primary percutaneous coronary intervention (PCI) setting, and further studies are 
required to address this question. 
 
In the acute ischaemia-reperfusion studies, both enhancing and reducing coupling were 
found to be anti-arrhythmic through different mechanisms. However, it must be noted that 
these results apply specifically to myocardial reperfusion. The effects of gap junction 
modulation are situation-specific and modulating gap junction coupling in one direction 
may be beneficial in some settings but detrimental in others. The strategy of uncoupling 
gap junctions, although potentially protective against reperfusion arrythmias, may actually 
be pro-arrhythmic in the event of longer durations of acute myocardial ischaemia.  
Progressive gap junction uncoupling during ischaemia would be expected to slow 
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conduction, increase repolarisation dispersion and predispose to ischaemic ventricular 
arrhythmias (de Groot, 2002; de Groot & Coronel, 2004), thus making further uncoupling 
of gap junctions a risky strategy in acute ischaemia-reperfusion. Therefore, although both 
enhancing and reducing coupling were protective against reperfusion arrhythmias, perhaps 
only the earlier is a viable option for clinical translation. 
 
8.2.2 Gap junction modulation to modify infarct morphology and prevent post-MI 
arrhythmias 
The studies using the in vivo MI model demonstrated that enhancement of gap junction 
coupling during acute myocardial infarction with rotigaptide reduced late susceptibility to 
ventricular arrhythmias on programmed electrical stimulation at 4 weeks post-MI. This is 
possibly due to the effect of enhancement of coupling creating a more homogeneous 
healed infarct scar, which is less susceptible to substrate-based re-entrant arrhythmias. 
These studies raise the possibility that a short-term treatment at the time of myocardial 
infarction can modify the process of infarct spread and healing to beneficially alter the 
infarct morphology and create a substrate that is more resistant to arrhythmias.  
 
This approach has parallels with contemporary clinical strategies that use catheter ablation 
to modify the infarct scar to render it less arrhythmic (Stevenson & Soejima, 2007). One 
of the current catheter ablation approaches for post-MI VT is the substrate ablation 
approach, whereby an extensive set of ablation lesions are created in or around areas of 
scar (Marchlinski et al., 2000). This destroys surviving myocardium in and around the 
scar, with the effect of homogenising the scar to stabilise the substrate. The proposed 
therapeutic strategy of acute gap junction modulation during myocardial infarction seeks 
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to achieve the same effect as these substrate ablation procedures through the modification 
of infarct scar morphology and reducing inhomogeneities of scarring. 
 
However, there are two important differences between the experimental model and the 
clinical scenario of acute MI. Firstly, the experiments were designed as proof-of-concept 
studies to demonstrate that modification of gap junction coupling during acute MI can 
alter infarct morphology. To prove this concept in rat, which has poor collateral blood 
supply to the myocardium (Curtis et al., 1987), gap junction modulators were given as a 
bolus immediately before coronary artery ligation to ensure therapeutic levels in the 
circulation before ligation. This is not a clinical model as it would not be possible to 
administer gap junction modulators in patients just before myocardial infarction. It is 
unclear whether the administration of gap junction modulators solely after the onset of 
myocardial infarction will have similar beneficial effects on infarct morphology, and must 
be the subject of further studies. 
 
The second difference to current clinical practice is that these experiments were carried 
out in the chronic non-reperfused MI model. There is evidence to suggest that reperfused 
and non-reperfused MIs are different in several aspects. Reperfused infarcts have more 
patchy and heterogeneous scarring and ventricular tachycardias (VTs) of shorter cycle 
lengths (Wijnmaalen et al., 2010). The mechanism of cell injury and cell death are also 
different in non-reperfused and reperfused myocardial infarction (Yellon & Hausenloy, 
2007). Further studies are required to assess if the proposed strategy of substrate 
modification with acute gap junction modulation is also beneficial in the setting of 
reperfused myocardial infarction. 
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8.2.3 Importance of infarct border zone in risk stratification of post-MI patients 
The studies on the four-week chronic MI model demonstrated that infarct border zone 
conduction velocity was an important factor in determining arrhythmia susceptibility. As 
discussed earlier in this thesis, risk stratification of post-MI patients for therapies such as 
ICDs is currently unsatisfactory (Goldberger et al., 2011). Clinical tests currently used to 
risk stratify patients into high- and low-risk groups such as left ventricular ejection 
fraction (LVEF) and programmed electrical stimulation (PES) have poor specificities and 
sensitivities (Goldberger, 2010).  
 
Risk stratification may be improved if assessment of the infarct border zone is a 
component of the risk stratification process. Although measurement of conduction 
velocity across the infarct border zone may be difficult clinically, there may be surrogate 
markers for slowed conduction that are more easily measured. For example, it been 
suggested that slowing of conduction can manifest as fractionation of the contact 
electrogram (Jacquemet & Henriquez, 2009). It may be possible to use markers of slowed 
conduction measured in the cardiac catheter laboratory to risk stratify post-MI patients 
into high- and low-risk for arrhythmias.  
 
Another alternative is to use imaging of the infarct border zone to identify patients at 
greater risk of post-MI VTs. One of the structural correlates of slowed conduction across 
the infarct border zone is increased patchiness of scarring at the border zone. There are 
already some preliminary studies showing that increased amounts of heterogeneous 
scarring as identified on cardiac MRI can be used to predict vulnerability of arrhythmias 
(Schmidt et al., 2007), and post-MI mortality (Yan et al., 2006). Improved resolution of 
cardiac imaging in the near future may make it possible to resolve the specific 
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morphological features of the infarct border zone that predispose to arrhythmias, and 
imaging modalities such as contrast enhanced-MRI may be used as a further risk 
stratification tool. 
 
8.3 Limitations 
8.3.1 Rat cardiac electrophysiology 
All the experiments in this thesis were carried out in the rat heart. The rat was chosen 
because of its suitability for myocardial ischaemia-infarction studies, which is due to its 
consistent coronary anatomy and the lack of collateral blood supply (Curtis et al., 1987). It 
has the advantage of producing reliable and reproducible transmural infarcts, unlike the 
guinea pig, whose extensive collateralisation of coronary blood flow makes it difficult to 
generate myocardial infarctions. A second reason for choosing the rat is that its small size 
makes it ideal for whole heart optical mapping studies to study the electrophysiological 
changes in acute ischaemia-reperfusion and post-infarction. The rat also has the advantage 
of being a cost-efficient species for experimental studies, as well as being a well-
phenotyped species, with a wealth of data available on the effects of ischaemia and 
infarction on the rat heart. 
 
However, the rat has different electrophysiological properties compared to man. The rat 
has a significantly different repolarisation pattern because of its higher baseline IKTO 
channel expression, absence of IKs channel and lower levels of NCX levels (Gussak et al., 
2000; Wettwer et al., 1993). These differences in repolarisation currents lead to 
significantly shorter APDs, without the Phase 2 plateau seen in man. The shorter APDs 
may increase vulnerability to re-entry as this reduces the pathlength of any excitation 
impulse. Although any results relating to ion channel or action potential changes in the rat 
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need to be interpreted with caution because of the above, the work described in this thesis 
focused mainly on gap junction coupling. Species differences are less relevant in studies 
on gap junction coupling because, unlike ion channel expression, the expression of 
connexins and their specific amino acid sequences are relatively preserved across 
mammalian species (Cruciani & Mikalsen, 2005).  
 
8.3.2 Optical mapping 
Optical mapping studies were performed to assess the electrophysiological changes during 
acute ischaemia-reperfusion, with gap junction modulation, and in the chronic post-MI 
heart. A limitation of the optical mapping studies was the use of excitation-contraction 
uncouplers to eliminate movement artefact. In these studies, blebbistatin, an inhibitor of 
myosin II, was used to uncouple electrical excitation from contraction. Previous studies 
have shown that blebbistatin is selective in its actions, and does not alter action potential 
morphology (Fedorov et al., 2007). Because of its selective effects, blebbistatin has 
recently been the excitation-contraction uncoupler of choice for optical mapping 
experiments. However, there are recent reports that blebbistatin prolongs monophasic 
action potential durations in isolated rabbit hearts, as well as increasing the maximum 
slope of restitution and altering fibrillation threshold (Narang et al., 2011). Therefore, 
there is the possibility that blebbistatin altered baseline electrophysiological properties 
during the optical mapping experiments. 
 
A second limitation of using an excitation-contraction uncoupler was its effect on 
myocardial energetics. The removal of myocardial contraction liberates ample ATP for 
electrophysiological processes that would otherwise have been consumed for mechanical 
contraction (Sebbag et al., 2003). As a result, pathological changes may have been less 
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evident in those optical mapping studies in the absence of potential metabolic disturbances 
that could be unmasked by mechanical work (Lou et al., 2011). 
 
Another limitation of optical mapping was that it was only possible to map 
transmembrane voltage transients from the epicardial surface of the heart (Efimov et al., 
2004). With epicardial mapping, it was not possible to determine with certainty whether 
the arrhythmias studied, both in the acute ischaemia-reperfusion and the chronic MI 
experiments, were re-entrant or focal in nature.  
 
A further limitation, specific to the ischaemia-reperfusion studies, was the lack of reliable 
optical mapping data from the first 30 seconds immediately following reperfusion, due to 
technical issues of movement artefact and altering depth of focus upon releasing the 
occluder tube and suture to cause reperfusion. This limited the ability to draw firm 
conclusions about the electrophysiological changes that occured immediately following 
reperfusion. 
 
8.3.3 Pre-treatment with gap junction modulators 
In both the acute ischaemia-reperfusion experiments and the in vivo chronic MI studies, 
gap junction modulators were administered before the onset of myocardial ischaemia. As 
discussed above, one reason for administration of gap junction modulators before 
coronary artery ligation in these proof-of-concept studies was to ensure there were 
sufficient concentrations of these compounds in the circulation and in the myocardium 
before the cessation of blood flow. This was especially important in the rat, which has 
very few collateral vessels. In the acute ischaemia-reperfusion experiments, there was a 
second reason for administering the agents before coronary artery occlusion. This was 
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because the durations of ischaemia in these studies were short, lasting several minutes, 
and therefore gap junction modulators had to be given early to ensure they had time to 
reach maximal effect by the time of reperfusion. This approach of pre-treatment before the 
onset of ischaemia or metabolic stress is in fact the norm in many preclinical gap junction 
modulator studies designed to investigate the effects of these compounds (Hennan et al., 
2006; Haugan et al., 2006b; Eloff et al., 2003; Jozwiak & Dhein, 2008; Muller et al., 
1997a). Pre-treatment may be possible in the example of a patient who has been admitted 
to hospital with increasingly unstable angina, and thus treatment may be administered 
before the occurrence of myocardial infarction. However, many individuals develop 
myocardial infarction without prior warning and pre-treatment will not be possible in such 
individuals. Therefore, further studies will be required to assess if administration of these 
agents post-coronary ligation would have similar effects. 
 
8.3.4 Ex vivo arrhythmia studies 
The acute ischaemia-reperfusion experiments and the arrhythmia provocation studies in 
chronic MI hearts were performed ex vivo, to allow for simultaneous optical mapping of 
transmembrane voltage transients. One drawback of the ex vivo isolated heart preparation 
is the lack of neuronal input into the ex vivo heart and the lack of humoral influence. It can 
be argued that the results of the experiments and the types of arrhythmias observed may 
have been altered by the lack of neurohormonal input. For example, it has been suggested 
that enhanced automaticity due to alpha-adrenergic stimulation may account for some 
reperfusion arrhythmias (Sheridan et al., 1980), and these arrhythmias may have been less 
evident in the ex vivo preparation.   
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However, the disadvantages of the ex vivo model in studying substrate-based ventricular 
arrhythmias were probably not as great as if studying arrhythmias with neuronal 
involvement such as atrial fibrillation, and were compensated by the advantage of being 
able to optically record transmembrane voltage transients during these experiments. In 
fact, the lack of neurohormonal input is also often viewed as a key advantage, as it allows 
for studies specifically into the electrophysiological substrate without any confounding 
influences. 
 
8.4 Future directions 
8.4.1 MRI imaging to characterise infarct scar morphology 
The studies on the chronic MI model showed that acute gap junction modulation with 
rotigaptide during MI altered post-MI arrhythmia susceptibility. This was thought to be 
due to alterations in infarct scar morphology based on histomorphometric analyses. The 
exact mechanism by which acute gap junction modulation modified post-MI susceptibility 
needs to be further studied.  
 
To assess the hypothesis that enhancement of gap junction coupling leads to more 
homogeneous scarring, detailed imaging studies to characterise the morphology of the 
healed infarct should be performed. Although technically challenging in the rodent heart 
because of its size, the technical advancements of both contrast-enhanced MRI and 
diffusion-tensor imaging mean that detailed characterisation of infarct morphology is now 
a possibility.  
 
It has recently been shown that late-enhancement MRI imaging of ex vivo chronic MI rat 
hearts can have resolutions at near cellular level (Schelbert et al., 2010). Images acquired 
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with a 7T scanner in the study by Schelbert et al routinely detected clefts of viable 
cardiomyocytes 2 to 4 cells thick that separated bands of fibrous tissue, and had good 
correlation with histological analyses. Diffusion-tensor imaging, with its ability to provide 
rapid and non-destructive characterisation of the three-dimensional fibre architecture of 
cardiac tissue, may also be used to resolve myocardial architecture at the infarct border 
zone (Chen et al., 2003). Recently, diffusion spectrum MRI tractography, a novel imaging 
technique, has been shown to be able to detect and resolve in the rat heart the complex 
network of residual myofibres persisting within portions of the infarcted myocardium and 
linking the infarct zone to the border zone (Sosnovik et al., 2009). The advancements in 
imaging may be used to compare infarct scars of hearts treated with rotigaptide with 
control hearts to determine if gap junction enhancement does indeed lead to more 
homogeneous scarring. With the advancement of MRI techniques, imaging studies should 
also be performed on chronic MI rodent hearts to determine if there specific 
morphological features of the infarct scar or border zone morphology that can identify 
patients at risk of post-MI ventricular tachyarrhythmias. 
 
8.4.2 High-resolution optical mapping to characterise the electrophysiology of the 
infarct border zone 
The chronic MI studies in this thesis showed a trend towards improved macroscopic 
conduction velocities in rotigaptide-treated hearts though this did not achieve statistical 
significance. One possible mechanism by which the reduction in heterogeneities of 
scarring in rotigaptide-hearts protected against arrhythmias was via an improvement in 
conduction velocities across the infarct border zone. To assess this, higher-resolution 
optical mapping of the infarct border zone should be performed to more accurately 
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measure local conduction velocities and action potentials at the infarct border zone in 
control hearts and in gap junction modulator-treated hearts (Ding et al., 2010).  
 
8.4.3 Studies to assess the effects of gap junction enhancement on infarct spread 
during acute MI  
Another hypothesis that has arisen as a result of this thesis is that gap junction 
enhancement during acute MI can spatially homogenise the process of cell death by 
allowing interchange and passage of pro-apoptotic and pro-survival mediators between 
cells in the ischaemic and border zones. Immunohistochemisty can be performed to 
determine the spatial pattern of cell death and to determine if the enhancement of gap 
junction modulation leads to more homogeneous cell death as proposed by the work in 
this thesis. Antibodies directed towards markers of apoptosis such as caspase-3, caspase-7 
and cleaved cytokeratin 18 (Duan et al., 2003; Bressenot et al., 2008), may be used on 
tissue from hearts subjected to acute regional ischaemia to assess if there are changes in 
the distribution of these markers in and around the ischaemic zone in response to gap 
junction enhancement. 
 
8.4.4 Alternative experimental models to assess effects of gap junction modulation 
As discussed above, the experimental models used in this thesis have important 
differences to the clinical setting. In both the acute ischaemia-reperfusion studies and 
chronic MI studies, gap junction modulators were administered before coronary artery 
ligation. If gap junction modulation is to be a viable therapeutic strategy to prevent 
reperfusion and post-MI arrhythmias, then an effect must be demonstrated when these 
agents are given after coronary occlusion. Studies should be repeated in species with 
greater collateral coronary blood supply, such as porcine and canine models (Patterson & 
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Kirk, 1983), to assess their effects when given after coronary occlusion.  The collateral 
blood supply will allow delivery of these agents via the patent coronary arteries to the 
ischaemic border zone to exert their effects.  
 
Studies should also be performed in a reperfused MI model. The reperfused MI model is a 
more clinically relevant model compared with the non-reperfused chronic MI model as 
increasing numbers of patients with acute MI are now receiving acute reperfusion therapy. 
There are also important differences in the mechanisms of cell injury and cell death 
between non-reperfused and reperfused MIs (Yellon & Hausenloy, 2007).  Whether gap 
junction modulation can alter the pattern of cell death in the context of myocardial 
reperfusion injury and modify post-MI arrhythmia susceptibility in this context is unclear 
and should be investigated. 
 
8.5 Conclusions 
In conclusion, the studies described in this thesis provide evidence that gap junction 
modulation during acute myocardial infarction and coronary reperfusion can alter 
myocardial structure and function, and affect ventricular arrhythmogenesis. They support 
a role for gap junction coupling in reperfusion arrhythmogenesis and in the spread of acute 
myocardial infarction. These studies provide proof-of-concept evidence that acute 
enhancement of gap junction coupling during myocardial infarction can modify the 
morphology of the healed infarct by reducing inhomogeneities of scarring, thus leading to 
reduced post-MI arrhythmia susceptibility. They also showed that gap junction 
modulation during acute ischaemia-reperfusion can protect against reperfusion 
arrhythmias, possibly by attenuating the abrupt recovery of conduction during reperfusion. 
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